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  I 
Abstract 
ON01910.Na (Rigosertib, Estybon®), a styryl benzylsulfone, is a Phase III 
stage anti-cancer agent. This non-ATP competitive kinase inhibitor has multi-
targeted activity, promoting mitotic arrest and apoptosis. Extensive Phase I/II 
studies with ON01910.Na, conducted in patients with solid tumours and 
haematological cancers demonstrate excellent efficacy. However, issues 
remain affecting its development. These include incomplete understanding of 
anti-tumour mechanisms, low oral bioavailability and unpredictable 
pharmacokinetics.  
In an attempt to improve drug-likeness and ADME properties of ON01910.Na 
analogues, a novel series of (E)-styrylsulfonyl methylpyridine derivatives was 
designed and synthesised. The SAR of this novel series is discussed. The lead 
compounds TL-68, TL-77, and AH-123 are highly potent mitotic inhibitors. 
Their selective cytotoxicity to cancer cells was identified in the screening 
cascade. Impressively, TL-77 possesses excellent pharmaceutical properties, 
with improved oral bioavailability when compared to ON01910.Na. 
The detailed cellular mechanisms of TL-77 were further investigated in 
comparison with ON01910.Na. TL-77 exhibits potent anti-proliferative activity 
against a wide range of human tumour cell lines, and demonstrated > 2 fold 
greater potency in cancer cell lines over normal cells.. Cell cycle analyses 
reveal that TL-77 evokes profound G2/M cell cycle arrest at ı 6 h in cancer 
cells, followed by the onset of apoptosis. In cell-free conditions, TL-77 as well 
as ON01910.Na potently inhibits tubulin polymerization. Mitotically arrested 
cells display multipolar spindles and misalignment of chromosomes, indicating 
  II 
TL-77 interfere mitotic spindle assembly in cancer cells. These effects are 
accompanied by induction of DNA damage, inhibition of Cdc25c (Ser198) 
phosphorylation [indicative polo-like kinase 1 (Plk1) inhibition], and 
downstream inhibition of cyclin B1. However, kinase assays failed to confirm 
the inhibition of Plk1. Non-significant effects on PI3K/AKT signal 
transduction are observed after TL-77 treatment. Analysis of apoptotic 
signalling pathways reveals that TL-77 down-regulates expression of B-cell 
lymphoma 2 (Bcl-2) family proteins [Bid (BH3 interacting-domain death 
agonist), Bcl-xl (B-cell lymphoma-extra large) and Mcl-1 (induced myeloid 
leukaemia cell differentiation protein)] and stimulates caspase activation. 
These effects are comparable to those elicited by ON01910.Na. Unlike 
ON01910.Na, however, TL-77 causes preferential toxicity in cancer cells when 
compared to normal cells and mediates rapid mitotic inhibitory effects. 
In summary, selective in vitro anti-tumour activity and multi-faceted 
mechanisms of action of a novel molecule TL-77 have been identified, 
presenting a strong rationale for further development of (E)-styrylsulfonyl 
methylpyridine derivatives as therapeutic agents for cancer. 
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Abbreviations 
ADME Absorption, distribution, metabolism and excretion 
Akt Protein Kinase B (PKB) 
AML Acute myeloid leukemia 
aPKs Atypical Protein Kinases 
ATP Adenosine triphosphate 
Bax Bcl-2-associated X 
Bcl-2 B-cell CLL/Lymphoma 2 
Bid BH3 interacting-domain death agonist 
BSA Bovine serum albumin 
CDK Cyclin-depend Kinase 
DCM Dichloromethane 
DMF N, N-dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
ECL Enzymatic chemiluminescence 
ePKs Eukaryotic Protein Kinases 
ER Oestrogen receptor 
EtOAc Ethyl acetate 
EtOH Ethanol 
FBS Foetal bovine serum 
FITC Fluorescein isothiocyanate 
G1 phase Gap phase I 
G2 phase Gap phase II, pre-mitotic phase of cell cycle 
GI50 The concentration required to achieve 50% growth inhibition 
H2AX H2A histone family, member X 
  V 
HCl Hydrogen chloride 
HER2 Human Epidermal Growth Factor Receptor 2 
HUVEC Human umbilical cord vein endothelial cell; 
K2CO3 Potassium carbonate 
Mcl-1 Induced myeloid leukemia cell differentiation protein 
M phase Mitosis cell cycle phase 
MDS Myelodysplastic syndrome 
MeOH Methanol 
MgCl2 Magnesium chloride 
m.p. Melting point 
MS Mass spectrometry 
mTOR Mammalian target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaOH Sodium hydroxide 
NBS N-Bromosuccinimide 
NMR Nuclear magnetic resonance 
ON01910.Na 
(E)-2-((2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)phen-yl)amino)-acetate, 
sodium salt 
PARP Poly (ADP-ribose) polymerase 
PBD Polo box domain 
PBS Phosphate Buffered Saline 
PD study Pharmacodynamic study 
PDK Phosphoinositide-dependent protein kinase 
PE Petroleum ether 
PI propidium iodide 
PI3K PI 3-Kinase, phosphatidylinositide 3-kinases 
PK Protein kinase 
  VI 
PK study Pharmacokinetic study 
Plk Polo-like kinase 
PRAS40 Proline-rich Akt substrate of 40 kDa 
PTEN Phosphatase and tensin homolog 
Rb Retinoblastoma protein 
RNA Ribonucleic acid 
RNAi RNA interference 
r.t. Room temperature 
SAR Structure-activity relationship 
Ser Serine 
TBS Tris Buffered Saline 
THF Tetrahydrofuran 
TL-77 
(E)-N-(2-methoxy-5-((2,4,6- 
trimethoxystyrylsulfonyl)methyl)pyridin-3-
yl)methanesulfonamide. 
TLC Thin layer chromatography 
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1 Introduction 
 Cancer 
Cancer is a global concern. In 2012, about 14.1 million people were diagnosed 
with cancer worldwide, leading to 8.2 million deaths from cancer in the same 
year. (WTO media report, 2014) According to the latest statistics from Cancer 
Research UK, cancer has been and still is the major cause of death in England 
and Wales.1  
Cancer is a genetic disease that occurs when the information in cellular DNA is 
altered and subsequently leads to aberrant patterns of gene expression.2 The 
process of cancer development, carcinogenesis, generally involves three 
essential stages: initiation, promotion, and progression. Initial changes in 
carcinogenesis are irreversible genetic changes. By generating a DNA adduct 
formation, initiators cause either activation of proto-oncogenes or loss of 
tumour-suppressor genes, giving proliferative advantage. In the next stage, 
tumour promotion is induced by tumour promoters that enhance the selective 
clonal expansion of initiated cells. Tumour promoters are generally non-
mutagenic; however, they can reduce the latency period for tumour formation, 
enhance proliferation or improve the sensitivity of cells to an initiator. During 
the third stage, progression, further genetic and epigenetic mutations selecting 
for increasingly aggressive disease occur due to the malignant conversion. 
Cells progress to malignant tumour with further degrees of independence, 
invasiveness, eventually invade adjacent tissue / vessels, and metastasis to 
distant sites seeding secondary tumours and metastatic disease.3 
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 Hallmarks of Cancer 
The major goal of cancer research is to understand the causation of malignancy, 
and translate this knowledge into the development and improvement of cancer 
treatments.4, 5 ,QWZRODQGPDUNUHYLHZV³7KH+DOOPDUNVRI&DQFHU´LQDQG
2011, Douglas Hanahan and Robert A. Weinberg summarized the essence of 
several biological capabilities acquired during the multistep development of 
human malignancies.6, 7 The hallmarks of cancer provide a solid foundation for 
understanding the biology of cancer and are described in turn below. 
 
)LJXUH7KHVL[KDOOPDUNVRIFDQFHU 
 Sustaining Proliferative Signalling 
Mitogenic growth signals (GS) stimulate cell proliferation by directly 
controlling the initiation of cell cycle. In normal tissues, the production and 
release of growth-promoting signals are strictly controlled to maintain a 
homeostasis of cell population and functions.7 However, the growth signalling 
pathways are suspected to suffer deregulation in all human tumours.6 Cancer 
cells can sustain proliferative signalling by mimicking normal growth 
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signalling. They deregulate these signals and achieve autonomy through 
several molecular strategies;6, 7 
i producing growth factor ligands themselves, resulting in autocrine 
proliferative stimulation; 
i stimulating signals normal cells within the tissue to induce expression of 
growth factors; 
i increasing cellV¶ sensitivity to growth factors by overexpressing or 
structurally altering surface receptor proteins; 
i activating components of intracellular circuits operating downstream of 
these receptors. 
 Evading Growth Suppressors 
In normal cells, cell proliferation is a highly regulated process wherein multiple 
anti-proliferation signals operate to maintain cellular quiescence and tissue 
homeostasis. These anti-proliferation signals can block proliferation in two 
ways; by forcing a proliferative cell out of cycle into quiescence (G0) phase, or 
by entering into a post-mitotic state, which usually involves terminally 
differentiation of the cell.6 (For cell cycle, please refer to Figure 1.2) 
Most cancer cells circumvent normal growth suppressors in order to sustain 
their proliferative capacity. p53 and retinoblastoma protein (pRb) operate the 
two key complementary tumour-suppressor pathways that control cellular 
responses of apoptosis and cellular senescence, and are most commonly 
dysregulated in cancer cells.7, 8 The Rb protein is a critical gatekeeper of the 
cell cycle, maintaining cell division at a healthy pace. Stress signals such as 
oncogenes induced INK4 (Inhibitors of CDK 4) and Cip/Kip (CDK interacting 
protein/Kinase inhibitory protein) family proteins, which specifically inhibit 
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the activity of CDKs (Cyclin-Dependent Kinases) and thereby prevent the 
phosphorylation of Rb.8, 9 When in a hypophosphorylated state,, Rb blocks 
entry of cells into S phase by sequestering and altering the function of the 
eukaryotic transcription factors (E2Fs), which regulate the transcription of 
many genes essential for progression from G1 to S transition.8 Cancer cells 
evade the anti-proliferative signals by disrupting the pRb pathway. 
While the Rb pathway receives antigrowth signals, mainly from outside of the 
cell, p53 is activated by intracellular operating systems. In response to DNA 
damage and cellular stresses, p53 functions as a central regulator causing cell-
cycle arrest, and triggers apoptosis.7 Loss of p53 allows propagation of 
damaged DNA and aberrant cell cycle progression. 
 Resisting Cell Death 
The population expansion of cancer is determined by the rate of both cell 
proliferation and cell attrition. Apoptosis, autophagy and necroptosis are the 
three main types of programmed cell death. Apoptosis, as a major source of 
cell attrition, becomes a critical barrier to cancer development.7 
Apoptosis is triggered and regulated through at least two principal pathways at 
many levels. The intrinsic pathway (mitochondrial pathway) is primarily 
regulated by Bcl-2 family proteins in response to the signals of survival factors, 
cell stress and injury. In the Bcl-2 family, a balance is established between two 
kinds of regulators, the anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, A1 and 
Mcl-1,), which prevent programmed cell death by guarding mitochondrial 
integrity and regulating the activation of several caspases, and the pro-
apoptotic proteins (Bax family and BH3-only family), which block the 
protective effect of apoptosis inhibitors and initiate apoptosis. This balance 
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arbitrate the life-or-death decision.10 Apoptosis is triggered when the protective 
buffer of anti-apoptotic proteins and pro-apoptotic proteins is breached. The 
mitochondria are permeabilized and damaged, causing the release of pro-
apoptotic factors. The most important factor, cytochrome c, interacts with the 
cell-death adaptor Apaf-1 (apoptotic protease-activating factor 1), subsequently 
activate caspase-9. 
The extrinsic pathway (death receptor pathways), on the other hand, is induced 
by receiving and processing extracellular death-inducing signals. For instance, 
the death receptors on the cell surface, such as Fas ligand, are ligated with their 
FRJQDWHOLJDQGV)DVUHFHSWRUIRUPLQJWKHµGHDWK-LQGXFLQJVLJQDOOLQJFRPSOH[¶
(DISC). This complex subsequently activates caspase-8. 
%\DFWLYDWLQJWZR³JDWHNHHSHU´FDVSDVHVFDVSDVH-9 and -8, respectively), each 
pathway initiates a cascade of downstream effector caspases (caspase-3, and -7) 
to induce the multiple cellular changes associated with the apoptotic 
programme.7, 11, 12 
Cancer cells can evade apoptosis through various strategies. Mutation and the 
consequent inactivation of p53 is one of the most common and occurs in more 
than 50 % of human tumours. For instance, the PI3K-AKT/PKB pathway, 
which transmits anti-apoptotic signals, is hyper-stimulated in a substantial 
fraction of cancers.6 In addition, it is found that all the Bcl2 pro-survival 
proteins can promote tumorigenesis, and certain pro-apoptotic members can act 
as tumour suppressors.10 The multiple apoptosis-avoiding mechanisms that 
found in tumour cells include: over-expression of pro-survival family members 
or down-regulation of pro-apoptotic factors to increase expression of survival 
signals and evade the extrinsic ligand-induced pathway.11 
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 Enabling Replicative Immortality 
The concept of the Hayflick limit has been widely accepted. It indicates normal 
cells have a finite replicative capacity in vivo, after which they reach the state 
of senescence or crisis.7, 13 Cancer cell, on the other hand, acquires unlimited 
replicative potential giving rise to macroscopic tumours.7 
It has been indicated that telomeres and telomerase are centrally involved in the 
capability for unlimited proliferation and tumorigenesis.7, 14 Telomeres are 
composed of tandem hexanucleotide repeats and protect the end of the 
chromosome from recombination and degradation activities.15 Due to the end-
replication problem, telomeres progressively lose telomeric DNA sequences 
coupling to cell division in non-immortalized cells. This shortening eventually 
results in the eventual loss of telomere protection and leads to chromosomal 
instability, after which cells progress into senescence.7, 15 
Telomerase is an enzyme that adds repetitive nucleotide sequences to the ends 
of DNA strands in telomere regions. Many observations indicate that the 
expression of telomerase is an essential requirement for cellular 
immortalization and unlimited proliferation characteristic of cancer cells.14 
Almost all human tumours (approximately 90%) have detectable telomerase 
activity, which is sufficient for the escape of proliferation barriers.16 By 
aberrantly up-regulating telomerase, tumour cells can prevent telomere loss and 
maintain the replicative immortality. 
 Inducing Angiogenesis 
The formation of new blood vessels helps tumour tissues to obtain essential 
nutrients and oxygen, as well as evacuate metabolic wastes. Therefore, this 
progress is critical for sustained tumour growth and metastasis. Tumour 
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angiogenesis is induced by a continually DFWLYDWHG ³DQJLRJHQLF VZLWFK´ LQ
tumour cells, which is regulated by the balance of the anti- and the pro-
angiogenic factors.17 Vascular endothelial growth factors (VEGF), pro-
angiogenic factors, are generally overexpressed by oncogene signals during an 
early stage of the development of invasive cancers.7 
 Activating invasion and metastasis 
Tissue invasion and metastasis represent a multistage process of cancer cells 
escaping from the primary site and disseminating into distant organs. Pioneer 
cancer cells from an aggressive primary mass acquire the ability to penetrate 
the walls of lymphatic and/or blood vessels, circulate through the bloodstream, 
seed at distant sites by forming small nodules of cancer cells, continue to 
multiply, and eventually colonize to generate macroscopic tumour.7, 18, 19 The 
process of tissue invasion and metastasis is not fully understood. Up to now, E-
cadherin, a key cell-to-cell adhesion molecule, is the best characterized 
antagonist of invasion and metastasis. Down-regulation and mutation of E-
cadherin are frequently detected in human carcinomas.7 
 Emerging hallmarks and characteristics 
The continuous conceptual progress for understanding the biology of cancer 
has presented two emerging hallmarks: reprogramming of energy metabolism 
and evasion of immune destruction. 
The anomalous characteristic of cancer cell energy metabolism was first 
observed by Otto Warburg.7 Glycolysis is a major metabolic program for 
cancer cells. By increasing uptake and utilization of glucose (even in the 
SUHVHQFH RI R[\JHQ OHDGLQJ WR µµDHURELF JO\FRO\VLV¶¶ FDQFHU FHOOV FDQ
reprogram their glucose metabolism, and thus their energy production to 
  Introduction 
 8 
support tumour growth more effectively.20 The second emerging hallmark 
describes the ability of cancer cells to evade immunological destruction by T/B 
lymphocytes, macrophages or natural killer cells. However, these two 
emerging hallmarks still need to be fully generalized and validated.7 
In addition, genome instability and tumour-promoting inflammation facilitate 
the acquisition of both main and emerging hallmarks and thus are endowed 
with two enabling characteristics.7 
 Targeting cell cycle progression 
As reviewed in the previous session, aberrant regulation of the cell cycle 
leading to uncontrolled proliferation is one of the hallmarks of cancer. Over the 
decades, considerable effort has been expended to understand the molecular 
mechanisms driving the cell cycle, thereby aiding identification of potential 
targets for cancer therapeutics.21 
 The mammalian cell cycle 
Maintaining genetic integrity, as the most important condition for the survival 
of species, is tightly controlled during the cell cycle. Orchestration of cell cycle 
progression involves a critical network that governs the DNA division and 
duplication (replication) to produce daughter cells, as well as integration of 
external and cellular pro- and anti-proliferative signals.22, 23 
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)LJXUH7KHPDPPDOLDQFHOOF\FOHZLWKF\FOLQVDQGFKHFNSRLQWV 
3URJUHVVLQWKHHXNDU\RWLFFHOOF\FOHLVGULYHQE\SHULRGLFDFWLYDWLRQRI&'.V7KHPDPPDOLDQ
FHOOF\FOHFRQVLVWVRIIRXUSKDVHV6-SKDVH0-SKDVH*DQG*SKDVH7KHGLIIHUHQWF\FOLQV
VSHFLILF IRU WKH*-6-RU0-SKDVHVRI WKHFHOO F\FOH DFFXPXODWHDQGDFWLYDWH&'.VDW WKH
DSSURSULDWHWLPHVGXULQJWKHFHOOF\FOHDQGWKHQDUHGHJUDGHGFDXVLQJNLQDVHLQDFWLYDWLRQ7KH
LOOXVWUDWLRQ LV DGDSWHG IURP :LNLPHGLD &RPPRQV ³ &HOO &\FOH :LWK &\FOLQV DQG
&KHFNSRLQWV´ 
There are four phases in the mammalian cell cycle (Figure 1.2): DNA-synthesis 
(S) phase, during which the genome is duplicated; mitosis (M) phase, a highly 
complex multi-stage process that segregates the chromosomes into two new 
nuclei in preparation for cell division or cytokinesis. These two phases are 
separated by WZR ³*DS´ SKDVHV, called G1 and G2. In G1 phase, cells are 
prepared to ensure proper intracellular changes and DNA replication 
occurrence for entering into S phase, while G2 phase is a period for protein 
synthesis and rapid cell growth before the entry of M phase. G0 denotes the 
quiescent state in which cells have withdrawn from the active cell cycle. 
The cell cycle is controlled temporally by discrete transcriptional programs. 
Cyclins and CDKs are the key drivers of the cell cycle. Different cyclins, 
specific for the G1-, S-, G2- or M-phases of the cell cycle, bind to and activate 
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the subunits of CDKs at the appropriate times. Therefore, activated cyclin-
CDK complexes drive the cell forward through the cell cycle (Figure 1.2).22, 23 
The surveillance mechanisms that ensure the proper spatial and temporal order 
of cell cycle events are termed cell cycle checkpoints.24 Like in all signalling 
pathways, the regulation of cell division is achieved through reversible 
phosphorylation of regulatory components by protein kinases and 
phosphatases.22 To date, several families of protein kinases that control the cell 
cycle regulation have been characterized, including CDKs, polo-like kinases 
(Plks), and Aurora kinases. 
Considering the high relevance to this project, the G2/M DNA damage 
checkpoint and spindle assembly checkpoint will be reviewed in detail here. 
1.1.2.1.1 G2/M checkpoint (DNA damage checkpoint) 
 
)LJXUH&HOOF\FOH*0'1$GDPDJHVLJQDOOLQJSDWKZD\ 
,OOXVWUDWLRQ LV DGDSWHG IURP RI &HOO 6LJQDOLQJ 7HFKQRORJ\ ,QF ZZZFHOOVLJQDOFRP ZLWK
SHUPLVVLRQ 
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The G2/M DNA damage checkpoint prevents cells containing damaged DNA 
from entering mitosis by inducing several cellular responses. In general, the 
entry into mitosis is promoted by activated CDK1(Cdc2) bound to cyclin B or 
by accumulation of the CDK1/cyclin B complex in the nucleus.25  
CDK activity is regulated by phosphorylation on the catalytic subunit. This 
involves phosphorylation at Thr 161 by Cyclin Activating Kinase (CAK, or 
CDK7) and removing two inhibitory phosphate groups at Thr14 and Tyr15, 
which are added by Wee1 and Myt1 and removed by Cdc25 phosphatases (Cdc 
refers to cell division cycle).26 Therefore, CDK1 activity is competitively 
regulated by Wee1 and Myt1 (negatively) and Cdc25c phosphatase (positively). 
As cells approach the G2/M boundary, Bora and the aurora kinase A 
cooperatively activate polo-like kinase 1 (Plk1).27 Plk1 in turn activates the 
Cdc25c, down-regulates Wee1 and Myt1, and subsequently activates 
CDK1/cyclin B. Alternatively Plk1 can directly phosphorylate cyclin B to 
block export of cyclin B1 from the nucleus. Hence, Plk1, Cdc25c, and 
CDK1/cyclin B form a feedback loop to positively regulate each other's 
activity and drive the cell into mitosis.28, 29 
DNA damage signals activate the sensory DNA-PKcs / ATM / ATR kinases, 
which initiate G2/M DNA damage checkpoint signalling and relay two parallel 
cascades. In the first cascade, the key checkpoint kinases CHK1 and CHK2 are 
rapidly activated, which in turn phosphorylate and deactivate Cdc25 
phosphatases through phosphorylation at Ser216. Once phosphorylated by 
CHKs, Cdc25c is stimulated to bind to 14-3-3 proteins, and the resulting 
complex is sequestered in the cytoplasm, which prevent Cdc25c to 
dephosphorylate Cdc2, leading to the G2 arrest. In the slower second parallel 
cascade, phosphorylation of p53 promotes the dissociation between p53 and 
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MDM2, resulting in p53 stabilization. Activation of p53 leads to cell cycle 
arrest and apoptosis, in part through the CDK inhibition via p21Waf1, and the 
induction of several pro-apoptotic proteins, including Bax, PUMA (p53 
upregulated modulator of apoptosis), PIG3 (proapoptotic human p53-inducible 
quinone oxidoreductase), and NOXA (Phorbol-12-myristate-13-acetate-
induced protein 1).22, 28, 30 
1.1.2.1.2 Mitosis and spindle assembly checkpoint 
The spindle assembly checkpoint (SAC) delays the metaphase-anaphase 
transition until each chromosome is properly attached to the spindle apparatus. 
Generally, SAC is activated and maintained through two steps. Firstly, SAC 
negatively regulates Cdc20, thereby preventing polyubiquitylation mediated by 
anaphase-promoting complex/cyclosome (APC/C) on two key substrates, 
cyclin B and securin, which delays mitotic exit. A mitotic checkpoint complex 
(MCC) that contains a series of proteins has been proved to be a SAC 
effector.31 Prior to anaphase, SAC proteins bind unattached kinetochores, 
which facilitate the creation of MCC and production of inhibitory complexes to 
maintain the SAC activity. The proper attachment of all kinetochore and 
chromosome congression negatively regulates the SAC signal and promotes 
the mitotic exit.22, 31  
Several kinases have key roles in regulating SAC. Centrosome maturation is 
critical for cell division to occur and is regulated by several kinases including 
Plk and aurora kinase.23 Kinases such as MPS1, BUB1, BUBR1, Plk1, NEK2, 
MAPK and aurora-B kinases play the key role in recruiting SAC proteins to 
kinetochores and maintaining SAC activity.31 Deregulation of these kinases are 
found in a wide spectrum of cancers in humans. 
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 Targeting the cell cycle for cancer therapy 
Perturbations in the cell cycle are described commonly in carcinogenesis and 
are mainly caused by genetic alterations of tumour suppressor genes 
(inactivation), such as pRb and p53, and proto-oncogenes (mutation).23, 25 This 
dysregulation occurs through mutations of genes, which encode proteins at 
different phases of cell cycle, including CDK, cyclins, CDK-activating 
enzymes, CKI, CDK substrates, and checkpoint proteins, such as CHKs, WEE 
kinases, aurora kinases and Plks.22, 25, 32 Therefore, the enzymes that mediate 
reversible phosphorylation of cell cycle regulation, especially kinases, are 
currently being pursued as drug targets.22 
The rationale for targeting the cell cycle for cancer therapy is based on the 
frequency of perturbations in cell cycle in human malignancy and the 
observation that cell cycle arrest could induce apoptosis. This rationale led to 
the development of CDK inhibitors (CDKI) as novel antitumor agents. These 
compounds can inhibit CDKs by directly inhibit the catalytic subunit of CDK, 
or by indirectly target regulatory pathways to govern the CDK activity. To date, 
the most successful strategy is the direct inhibition of CDK.23 About 25 of 
them have reached clinical trial, such as AT7519, CYC202 (R-roscovitine), 
and Flavopiridol, and all of which interact with the catalytic active site of Cdk 
and are ATP-competitive inhibitor.23, 33 Strategies for developing the indirect 
CDKI include overexpression of cyclin-dependent kinase inhibitor (CKI), 
decrease of cyclin levels and using small peptides mimicking the effects of 
endogenous CKI.25, 34 
In addition, targeting the deregulation of cell cycle checkpoint machinery 
presents another attractive therapeutic strategy. Cell cycle checkpoints regulate 
the quality and rate of cell division. Mutations of checkpoint proteins are 
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frequent in all types of cancer.25 In contrast to healthy cells, tumour cells are 
unable to stop at predetermined points of the cell cycle because of loss of 
checkpoint integrity.23 Therefore, this rationale led to the development of 
agents that destruct the cell-cycle checkpoints. Candidates currently under the 
development either abrogate or arrest the checkpoints.35 Abrogation of G2/M 
DNA damage checkpoint allow damaged cells enter mitosis and thus undergo 
apoptosis. A number of reported compounds override G2/M checkpoint and 
have shown enhanced cytotoxicity.36, 37 On the other side, increasing G2/M 
DNA damage arrest have also been associated with enhanced cytotoxicity and 
apoptosis. This has been proven by many agents, such as flavopiridol and 
silibinin.35, 38 
 Protein kinases as an important class of cancer 
drug targets 
In 1954, Krebs and Fischer first discovered the key role protein kinases play in 
regulating diverse biochemical signalling pathways.39 Since then, the protein 
kinases have come to be recognised as critical catalysts in cellular energy 
supply and regulators activating almost all cellular processes. 
 The structure and regulation of protein kinases 
Protein kinases are one of the largest gene families in eukaryotes. They 
catalyse the transfer of ATP Ȗ-phosphate to specific hydroxyl groups of serine/ 
threonine or tyrosine residues of protein substrates.39 Hence, they are broadly 
divided into serine/threonine kinases and tyrosine kinases. To date, 518 human 
genes encoding protein kinases have been identified, of which 478 are human 
eukaryotic protein kinases (ePKs) and 40 are atypical protein kinases (aPKs). 
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Based on the various gene sequences and structure, they are classified into 10 
subsets as shown in Figure 1.4.40-42 
 
)LJXUH&ODVVLILFDWLRQRIKXPDQNLQDVHV 
'LIIHUHQW SURWHLQ NLQDVH VXEVHWV DUH GHQRWHG LQ YDULRXV FRORXUV ZLWK WKH QXPEHU RI SURWHLQ
NLQDVHV LQ HDFK VXEVHW LQSDUHQWKHVH $*&3.$3.*DQG3.&&$0.&DFDOPRGXOLQ-
GHSHQGHQWSURWHLQ NLQDVH &. FDVHLQNLQDVH&0*&&'.V 0$3.V*6.VDQG &/.V
5*& UHFHSWRU JXDQ\ODWH F\FODVH 67( KRPRORJXHV RI VWHULOH   DQG  NLQDVHV 7.
W\URVLQHNLQDVH 7./ W\URVLQHNLQDVH-OLNH RWKHUV NLQDVHV KDYH QR VXIILFLHQW FORVH VHTXHQFH
VLPLODULW\ 
Due to conservation in sequence, protein kinases share a homologous catalytic 
core (Figure 1.5). The catalytic domain of protein kinases is formed as two 
lobes, which consists of a small N-terminal lobe (mainly RIȕ-sheets and long 
D-helix) and a larger C-terminal lobe of predominantly Į-helices. At the 
junction of the two lobes, an activation cleft is formed, which is a key element 
of the ATP nucleotide binding site.43, 44 A short polypeptide chain named the 
hinge region is located in this cleft.44 All kinases have a conserved activation 
loop, which is important in regulating kinase activity. When the activation loop 
folds back and exhibits as a substrate mimic, the active site is disrupted and the 
kinase remains inactive.45 
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)LJXUH*OREDOIHDWXUHVRIDSURWHLQNLQDVHFDWDO\WLFGRPDLQEDVHGRQWKH
VWUXFWXUHRILQVXOLQUHFHSWRUNLQDVH,5. 
7KH1-OREH LVFRORXUHG LQJUHHQ WKH&-OREH LV LQSXUSOHDQG WKHDFWLYDWLRQ ORRS LV VKRZQ LQ
\HOORZ$Q$73LQEODFNELQGVDWWKHMXQFWLRQEHWZHHQWKHWZROREHV7KHĮKHOL[-&FRQWDLQV
UHVLGXHVFULWLFDOIRUFDWDO\VLVDQGWKHĮKHOL[-*LVLQYROYHGLQGRFNLQJSURWHLQVXEVWUDWHV 
Protein kinases are involved in almost all cellular processes. In human cells, 
the accumulation of signalling molecules is a key feature of biochemical 
signalling cascades. In these clusters with high concentration of signalling 
effectors, diverse protein-protein interactions are promoted by utilizing 
specialized domains. Through reversible phosphorylation, protein kinases 
activate themselves and other proteins, therefore, mediating the whole cellular 
processes.45 Most protein kinases are involved in multiple regulatory 
mechanisms, playing diverse biological roles with individual properties 
relating to various residues, loops or insertions in different families.46-47  
 Targeting cancer with kinase inhibitors 
Given that protein kinases mediate most of cellular processes, it is apparent 
that mutations and dysregulation of protein kinases play causal roles in human 
diseases, especially cancer.39, 42 Thus, protein kinases have attracted significant 
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attention as important targets for cancer drug discovery. Several outstanding 
small molecule inhibitors have been approved for the treatment of cancer and 
more are currently undergoing clinical evaluation. 
 ATP-competitive inhibitors 
The majority of kinase inhibitors to date interact with the ATP binding pocket 
of target kinases. These kinase inhibitors, named as type I kinase inhibitors, 
directly bind to the adenine region of ATP binding site and do not require a 
three-residue motif, Asp-Phe-Gly (DFG), in the activation loop, generating a 
ĀDFG-LQ´ FRQIRUPDWLRQ (Table 1.1). These inhibitors usually form 1-3 
hydrogen bonds with the hinge region of the kinase, thus mimicking the 
hydrogen bonds formed by the adenine ring of ATP.48, 49 
However, several challenges have arisen along with the development of second 
generation type I kinase inhibitors. Due to the highly conserved ATP binding 
site in protein kinase family, it is difficult for inhibitors to specifically identify 
the target kinase.40 This has been demonstrated by a recent study, which 
evaluated the selectivity of previously characterized 38 kinase inhibitors 
against a panel of 317 kinases.50 Additionally, it is challenging for inhibitors to 
target with high-affinity to the kinase competing with high intracellular ATP 
concentrations (typically 1±10 mM). The low selectivity ATP-competitive 
inhibitors have exhibited undesirable toxicities (lack of selectivity, e.g. CDK 
inhibitors) and drug resistance (due to the mutations in the ATP binding site, 
e.g. imatinib), which have limited their clinical use as drugs.51 
 Non-ATP-competitive inhibitors 
Accumulating efforts are focusing on developing new types of non-ATP-
competitive inhibitors, which could be an alternative strategy to overcome the 
  Introduction 
 18 
cross-reactivity of ATP-competitive inhibitors. As presented in Table 1.1, there 
are three types of non-ATP-competitive reversible kinase inhibitors based on 
their mechanism of action. 
7DEOH&RPSDULVRQEHWZHHQWKHGLIIHUHQWW\SHVRIreversibleNLQDVHLQKLELWRUV 
.LQDVH,QKLELWRUV Type I Type II Type III Type IV 
Binding site ATP site 
ATP site and 
DFG pocket 
Allosteric (by 
ATP pocket) 
Allosteric (substrate 
binding domain) 
ATP-competitive Yes Yes, indirectly No No 
Selectivity 
Usually low, but very selective 
inhibitors have been identified 
High Very high Very high 
5HSUHVHQWDWLYH
LQKLELWRUV *HILWLQLE(UORWLQLE6XQLWLQLE 
,PDWLQLE
%,5% 
*1)-*1)-
VHOXPHWLQLE 
21
211D 
1.2.2.2.1 Type II kinase inhibitors 
Type II kinase inhibitors occupy a hydrophobic site that is directly adjacent to 
the ATP binding pocket. This site is made by the DFG motif of the activation 
loop being moved away from the kinase active conformation (form³')*-RXW´
conformation).48, 49 Type II inhibitors typically have more potent cellular 
activity and a higher degree of selectivity compared with type I kinase 
inhibitors, this is benefit from their lipophilic interactions with the DFG pocket. 
However, on the other hand, binding to the hydrophobic DFG pocket leads to 
the production of compounds with undesired properties for druggability, such 
as high MW and clogP.52 Although the allosteric site provides Type II kinase 
inhibitors another handle for improving kinase selectivity, drug resistance issue 
due to their high sensitivity to the mutations in the ATP binding site as well as 
mutations located in regions that affect the kinase conformation is still a 
disadvantage affecting their development (e.g. imatinib).48, 49 
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1.2.2.2.2 Allosteric Inhibitors 
Type III kinase inhibitors, also named as allosteric inhibitors, bind in the 
regulatory regions modulating the activity of the kinase in an allosteric manner. 
Inhibitors belonging to this class tend to show relatively high kinase selectivity 
because they bind sites that are unique to a particular kinase family.52 
1.2.2.2.3 Substrate Directed Inhibitors 
Substrate directed inhibitors, or the fourth type of kinase inhibitor, are small 
molecules that present a reversible interaction at the substrate binding site in an 
ATP-independent manner.52 To ensure signalling fidelity, protein kinase must 
recognize and act only on a defined subset of cellular targets. Due to this 
exquisite specificity in the interactions between kinase and substrate, a high 
degree of selectivity could be achieved by targeting substrate binding regions 
of kinases with substrate competitive inhibitors. 
ON01910.Na is a Phase III clinical non-ATP competitive inhibitor with multi-
targeted activity. It inhibits Plk1 (9 - 10 nM) by binding to the substrate 
binding sites of Plk1. At higher concentrations (20 - 260 nM), the activities of 
several kinases, such as BCR-ABL, PDGFR, FLT-1, PI3K, Fyn and Plk2 as 
well as CDK1, are influenced by ON01910.Na.53 Whether the efficacy of 
ON01910.Na in inhibiting tumour growth is the direct result of inhibiting Plk1 
or other protein kinases remains a controversial issue that requires further 
investigation. Due to its broad spectrum of anti-cancer activity, excellent 
efficacy and safety profile, ON01910.Na has become a promising compound 
for the treatment of cancer. 
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 Preclinical cancer drug discovery, design and 
development 
 Integrated preclinical cancer drug development 
The discovery of modern anti-cancer agents is a time-consuming and expensive 
process, which consists of preclinical discovery and clinical development. 
Success in discovering a drug requires a creative interplay between the 
essential disciplines of biology/pharmacology and medicinal chemistry.54 A 
typical preclinical cancer drug discovery and development with biological test 
cascade is shown in Figure 1.6. 
 
)LJXUH6WDJHVRIGUXJGLVFRYHU\DQGGHYHORSPHQWZLWKELRORJLFDOWHVWFDVFDGH 
$EEUHYLDWLRQV 6$5 VWUXFWXUH DFWLYLW\ UHODWLRQVKLS $'0( DEVRUSWLRQ GLVWULEXWLRQ
PHWDEROLVP DQG H[FUHWLRQ $'0(7 DEVRUSWLRQ GLVWULEXWLRQ PHWDEROLVP DQG H[FUHWLRQ -
WR[LFLW\ LQ SKDUPDFRNLQHWLFV 3.3' VWXGLHV 3KDUPDFRNLQHWLFV DQG SKDUPDFRG\QDPLFV
VWXGLHV 
Selecting the right molecular target is crucial to success in developing a new 
drug. A good target should be µGUXJJDEOH¶, while a good drug should be 
efficacious, safe, meet clinical and commercial needs. The best approach to 
develop anti-cancer drugs is acting upon the hallmark traits of cancer (refer to 
Figure 1.1). In support of this notion, most drugs that have been approved for 
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clinical use throughout the past century target one of the six classic 
hallmarks.55 Targeting the cell cycle, by inhibiting key regulatory kinases, and 
interfering with mitotic spindle assembly, is observed after exposure of cancer 
cells to TL-77 described in this project. This may address the proliferative 
dysregulation and induce apoptosis in cancer cells. 
2QFH D WDUJHW LV FKRVHQ RQH RU PRUH ³KLW´ PROHFXOHV ZLWK SUHOLPLQDU\
biological activity against the target must be generated.56 Several hit generation 
approaches have successfully been developed and can be used either 
individually or in combination. These approaches include, but are not limited 
to high-throughput screening, fragment screening, focused screening, virtual 
screening, physiological screening, NMR screening, structural aided drug 
design and knowledge-based design.57, 58 
Once a number of hits have been identified, the next job is to define which 
compounds justify future investigation. Intensive structure±activity relationship 
(SAR) studies and primary assays to generate target dose±response curves will 
compare activity and selectivity of each compound. For compounds with 
similar core structure hitting specific classes of targets (such as kinases), 
focused or knowledge-based screening is a cheaper and effective method.58 In 
chapter three, SAR and cell-based screenings are described, which are able to 
identify compounds with improved potency and drug-like properties compared 
to reported compounds. 
The hit-to-lead and optimization processes are iterative cycles of chemical 
synthesis and biological evaluation. Extensive modification of compounds is 
required. Optimizations in key parameters include: potency and understanding 
molecular mechanism(s) of action, pharmaceutical properties (absorption, 
distribution, metabolism, and excretion), tolerability and efficacy against 
  Introduction 
 22 
cancer tumour in vivo. Each cycle provides feedback to allow further 
optimization of new compounds to improve properties.56 In formulation and 
toxicology studies, if successful, one or more candidates are nominated for 
clinical development, clinical evaluation and ultimately be a marketed drug. 
 Analogue-based drug design 
In addition to ligand-based and structure-based drug design, analogue-based 
drug design, which is the process of using existing drugs as leads, has been an 
efficient and reliable strategy to synthesize new drugs. 
Analogue-based drug design possesses considerable advantages. Firstly, 
developing a pioneer drug can be extraordinarily unpredictable and risky, 
because the therapeutic use has not yet been validated clinically. One may 
argue that this would be an attractive challenge of drug discovery, but it is true 
that one can avoid a major uncertainty from the overall risk of success by 
starting with an established drug with proven therapeutic use. Secondly, 
developing a pioneer drug can be extraordinarily costly and time-consuming. 
An existing drug may have been developed with validated target and well-
established biomedical assays. Research team can shorten the research cycle 
and expenses by directly focusing on the iterative improvements of compounds. 
Moreover, ongoing improvement in understanding of the drugs mechanism of 
action and in vivo behaviour provide opportunities for improved drug 
analogues. 
Analogue-based drug design is based on the improvement and optimization of 
existing drugs, for example reducing the side effects, improving the target 
selectivity, or developing a better dosage form. It is important to identify an 
analogue with expected clinical advantage over the established drug. The aim, 
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therefore, must be to prove the improvement of new compounds compared 
with the lead drug.56 
Lovastatin is a convincing example to illustrate the success of analogue-based 
approaches on improvement of drug-likeness properties. Lovastatin (Mevinolin, 
Merck) is potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase for hypercholesterolemia treatment. The disclosure of 
biological efficacy of Lovastatin opened opportunities for the discovery of 
therapeutic analogues. This led to the success of Rosuvastatin, which is the 
most recent approved HMG-CoA reductase inhibitor. By replacing a 
pyrimidine to lower ring system of statins and introducing the 
methanesulfonamide to optimize physical properties, Rosuvastatin shows 
greater potency and superior efficacy.56, 59 
 
)LJXUH6WUXFWXUHVRIVHOHFWHG+0*-&R$UHGXFWDVHLQKLELWRUV 
 Discovery and development of ON01910.Na 
 ON01910.Na 
ON01910.Na (also referred to as Estybon, Rigosertib) is a novel anti-cancer 
agent currently undergoing clinical trials for various solid tumours and 
hematologic malignancies. This compound is selected from a class of (E)-
VW\U\OEHQ]\OVXOIRQHV GHYHORSHG E\ 'U ( 3 5HGG\¶V UHVHDUFK WHDP DQG
currently supported by Onconova Therapeutics®, Inc.60 The chemical 
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composition of ON01910.Na is C21H24NNaO8S (MW= 473.47 Da), sodium 
(E)-2-((2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate (Figure 1.8).  
 
)LJXUH6WUXFWXUHRI211D 
 Pre-clinical studies 
ON01910.Na exhibits a broad spectrum of anti-cancer activity with an IC50 
value range from 50 to 250 nM against more than 100 cell lines, including 
numerous drug-resistant cell lines.53 Statistical comparison using the NCI 
algorithm COMPARE confirmed that ON01910.Na is a mitotic blocker of 
cancer cells. The finding that such a large range of cancer cell lines are 
sensitive to this compound suggests that its targets are essential for cancer cell 
proliferation and survival.61 Meanwhile, strong synergistic effects were 
observed when ON01910.Na therapy was combined with other anti-cancer 
agents including oxaliplatin, doxorubicin, and gemcitabine.62 
The pharmacokinetic profile (PK) of ON01910.Na was evaluated across 
several species such as mice, rats and dogs. This compound exhibited extensive 
plasma protein binding and displayed a rapid distribution with a prolonged 
elimination phase. 63, 64 Half-lives (t1/2) less than 2 hours were observed in rat, 
dog, and human plasma following single dose administration.62 Because of the 
short half-life and the rapid clearance, ON01910.Na was suggested to be 
administered as a continuous intravenous (IV) infusion for cancer treatment.62 
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There has been limited evidence of drug metabolism in in vitro and in vivo 
experiments, and studies in mice and rats so far identified that ON01910.Na 
exhibited extensive liver uptake, and is mainly eliminated through biliary 
excretion.62 In a steady-state study in orthotopic U87 glioma xenograft model, 
ON01910.Na exhibited low brain (5%) and brain tumour (14%) distribution. 
The limited access of ON01910.Na to the brain is perhaps attributed to its low 
lipophilicity (predicted logD value RI í DQG LQIOXHQFHd by high plasma 
protein binding (93±95%).62, 63 Toxicology studies using rats and dogs by 
Gumireddy et al showed a very desirable safety profile for ON01910.Na; no 
evidence for hamatologic, hepatocellular or neurotoxicity was detected and 
only slight toxicity was observed until drug levels were as high as 1200mg/m2 
in rats.53 
 Clinical Studies 
On the basis of the encouraging results from the preclinical stage, ON01910.Na 
is currently under clinical assessment as a single agent (oral and parenteral 
formulations) and in combination with conventional chemotherapy (Figure 1.9). 
In advanced Phase I and Phase II clinical trials, the compound has been tested 
in patients with both solid tumours and haematological cancers.  
Clinical studies of ON01910.Na in patients with solid tumours showed good 
tolerability across a range of dosing schedules by IV infusion.65 In the clinical 
WULDOVZLWK0'6SDWLHQWV21ZDV LQIXVHG ,9DWíPJP2, and 
the maximum tolerated dose (MTD) was 800 mg/ (kg·m2·d) infused for 5 days 
every other week.66 A patient with refractory ovarian cancer had an objective 
response after four cycles and remained progression-free for 24 months.64 
Recent phase I studies with B-cell chronic lymphocytic leukaemia 
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demonstrated that ON01910.Na selectively induced apoptosis and reduced 
Plk1 activity in the leukaemia cells.65 
 
)LJXUH&OLQLFDOGHYHORSPHQWRI211D5LJRVHUWLE 
7KH ILJXUH LV DGDSWHG IURP 2QFRQRYD 7KHUDSHXWLFV ,QF KRPHSDJH
KWWSZZZRQFRQRYDFRP 
ON01910.Na is also being investigated for the treatment of myelodysplasia 
(MDS) due to its inhibitory effect on cyclin D1 accumulation and selective 
toxicity towards trisomy 8 cells and is currently in Phase I/II/III trial in MDS 
patients with refractory anamia. (Figure 1.9)63 Four Phase I/II clinical studies 
were conducted to assess the efficacy and safety of intravenous ON01910.Na 
in 48 higher risk MDS/AML patients, and increased overall survival after the 
treatment of ON01910.Na was reported.68-70 ON01910.Na appeared to be well-
tolerated and no significant myelosuppression, hamatologic toxicities or drug 
accumulation (repeatedly treated) was noted. Most common drug-related side 
effects included fatigue, anorexia, nausea, dysuria and abdominal pain.71 These 
encouraging results led to the initiation of a pivotal Phase III ONTIME trial of 
intravenous rigosertib (ON01910.Na) in patients with secondary MDS who 
have failed prior therapy with hypomethylating agents. On 19th Feb. 2014, 
however, Onconova announced that the Phase III ONTIME trial failed to meet 
the primary endpoint of overall survival.72 
Oral formulation of ON01910.Na has entered phase II to treat patients with 
MDS and advanced solid malignancies.73, 74 The recommended MTD of oral 
rigosertib is 560 mg (1120 mg/d) twice daily given continuously. The 
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permeability studies found ON01910.Na displayed medium permeability with 
absolute bioavailability of 10±15%.in rats (10 and 20 mg/kg, 1h infusion).75 
More recently, a new oral formulation of ON01910.Na (in PEG400 and 
PEG4000) showed a modest improvement in oral bioavailability (F=׽34.9% 
fasting vs ׽13.8% fed) at MTD levels.73 However, only at a higher dose of 700 
mg did ON01910.Na achieve a Cmax value of 3-4 ȝM, while the minimum 
pharmacodynamically relevant level required for its biological activity is 4-7 
ȝM (by measuring cyclin B1, p-CDK1, and p-H3 in plasma). The poor and 
variable oral availability of ON01910.Na is further complicated by its efflux by 
P-gP and MRP membrane transporters.75, 76 Clearly, the pharmacological 
properties of ON01910.Na are not satisfactory. 
 Cellular mechanism of action of ON01910.Na 
ON01910.Na is a multi-targeted kinase inhibitor promoting selective mitotic 
arrest and apoptosis in cancer cells. According to studies to date, ON01910.Na 
causes three major abnormalities leading to the loss of cancer cell viability: (a) 
abnormal cell division by interfering chromosomal segregation and 
cytokinesis;64 (b) irregular centrosome and spindle localization, subsequently 
followed by G2/M arrest and apoptosis; and (c) decreased expression of 
phosphatase Cdc25c.77 
211D¶V FRPSOH[ PHFKDQLVP RI DFWLRQ LQYROYHV VXSSUHVVLRQ RI WZR
important cellular signalling pathways, Plk and phosphatidylinositide 3-kinase 
(PI3K), both of which are frequently overexpressed in cancer cells. In HeLa 
cells, ON01910.Na inhibited the Plk1 activity, creating spindle abnormalities 
and mitosis dysregulation.53 Recent studies indicated ON01910.Na modulates 
the PI3-K/Akt pathway to promote apoptosis in cancer cells.78 This multi-
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targeted mechanism of action makes ON01910.Na effective in killing cancer 
cells with various anti-apoptotic and drug-resistance mutations. 
 ON01910.Na targets Plk1 
1.4.2.1.1 What is Polo and what are Plks? 
Plks belong to the family of serine/threonine kinases and play key roles during 
multiple stages of cell cycle progression.79 In the 1980s, polo, the founding 
member of the Polo kinase family, was first discovered in Drosophila 
melanogaster to encode a protein kinase whose mutation resulted in abnormal 
spindle poles.80 Since then, five mammalian Plk family members have been 
identified so far, Plk1(STPK13, serine-threonine kinase 13), Plk2 (SNK, serum 
inducible kinase), Plk3 (CNK, connector enhancer of KSR; FNK, FGF-
inducible kinase; and PRK, proliferation-related kinase), Plk4 (SAK, Snk/Plk-
akin kinase; and STK18, serine-threonine kinase 18) and Plk5.81 
All Plks share the similar topology with a catalytic kinase domain at the N-
terminus and a regulatory C-terminal region, known as Polo-box domain 
(PBD). PBD is unique to the Plk family. Plk1, Plk2, Plk3 and Plk5 have a PBD 
consisting of two polo boxes, while Plk4 possesses only one polo box.29 The 
general structure of Plk families is depicted as in Figure 1.10.The kinase 
domains are very highly conserved among all Plks, and most closely resemble 
those in aurora kinases and calcium/ calmodulin-dependent kinases. 
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)LJXUH*HQHUDOVWUXFWXUHRI3ONSURWHLQV 
7KHNLQDVHGRPDLQLVVKRZQLQWKHOHIWUHJLRQZKLOHWKH3%'LVVKRZQWRULJKW7KHQXPEHURI
SURWHLQUHVLGXHLQHDFK3ONPHPEHULVDOVRSUHVHQWHG 
 
)LJXUH'RPDLQVWUXFWXUHDQGNH\IHDWXUHVRI3ON 
The key structural features of Plks are shown in Figure 1.11. The kinase 
domain holds the regulatory phosphorylation site, the activation loop (T-loop) 
and an ATP-binding site, and is responsible for phosphorylation. 
Phosphorylation of Thr-210, which located in the T-loop is required for the 
activation of Plk1.81 The polo-box domain functions as a protein-protein 
interaction motifs containing three binding sites (Trp414, His538 and 
Lys540).29 Localization of Plks is governed by docking of the PBD to specific 
motifs (phosphothreonine/phosphoserine)-(proline/X) that have been primed by 
phosphorylation.82 Early reports indicated that Plks activity is negatively 
regulated by the PBD.83 In the absence of phosphorylated ligands, the PBD 
blocks WKHNLQDVHGRPDLQ¶s substrate docking sites, thereby inactivating Plks. 
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Once the PBD is bound by the phosphopeptide to its ligands, the catalytic 
domain is released and activates Plks. Simultaneously Plks localize to specific 
subcellular structures and initiate subsequent downstream effects.65, 79 
1.4.2.1.2 The multiple functions of Plk1 in cell cycle 
 
)LJXUH)XQFWLRQVDQGORFDOL]DWLRQRI3ONLQWKHFHOOF\FOH 
Among all family members, Plk1 is best characterized. In human cells, it is 
expressed primarily during G2/M phases and controls critical steps in the cell 
cycle.84 (Figure 1.12) 
In human cells, Plk1 positively triggers the entry and progression of mitosis 
and, therefore, is suggested as a marker for proliferation.84 As reviewed in 
previous session, Plk1 controls the rate of mitotic entry by phosphorylating 
Cdc25c, which in turn activates CDK1/cyclinB. When cells enter mitosis, Plk1 
is involved in recruiting Ȗ-tubublin and facilitates the centrosome's microtubule 
nucleating activity.23 Mutation or depletion of Plk1 results in aberrations in 
mitotic spindle formation and unstable chromosome alignments.29, 85 Sister-
chromatid separation and mitotic exit are coordinated through the anaphase-
promoting complex/cyclosome(APC/C)-dependent ubiquitylation.29 By 
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activating certain functions of APC, which in turn triggers the proteolysis of 
cyclin B, Plk1 allows mitotic exit.53 
1.4.2.1.3 Plk1--- An attractive drug target for cancer treatment 
As with the important role in cell proliferation, Plk1 is found to be a major 
driving force in oncogenesis of many cancers.86 Cancer is regarded as a 
proliferative disorder; targeting the cell cycle, therefore, has become a potent 
strategy for new anti-cancer agents.87 
Substantial evidence supports Plk1 is an attractive candidate molecule for anti-
cancer therapy. Firstly, about 80% of human tumours with diverse origins 
overexpress Plk1 transcripts, which correlate with a poor outcome.65 Plk1 
overexpression leads to enhanced proliferation and induce genetic instability 
(chromosomal instability (CIN), DNA aneuploidy and centrosome 
amplification), thus promoting oncogenic transformation.88 Secondly, 
constitutive expression of Plk1 is able to transform mouse NIH-3T3 cells and 
induces tumour growth in nude mice.89 Many studies have identified that 
targeted interference of Plk1 activity using antibodies or small interfering RNA 
results in mitotic arrest with subsequent induction of apoptosis in numerous 
cancer cell lines.53, 90-93 Notably, interference with Plk1 function was reported 
to selectively induce apoptosis in tumour cells but not in non-transformed cells. 
A series of Plk1 hypomorphs were generated by the lentivirus-based RNAi 
approach. Hela cells with strong Plk1 hypomorph underwent serious mitotic 
catastrophe, exhibiting significant delayed mitotic entry and complete mitotic 
block. In contrast, non-transformed hTERT-RPE1 and MCF10A cells with 
Plk1 depletion exhibited no apparent cell proliferation defect or cell cycle 
arrest.93 Moreover, Plk1 possesses two regions as potential targets, the kinase 
domain and the polo-box domain. Interfering with Plk1 function could be not 
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only via targeting the kinase domain, but also by interfering with PBD binding 
to docking proteins, which increase the potential for discovery and design of 
selective and specific inhibitors. Several small-molecule Plk1 inhibitors, such 
as BI2536, GSK-461364, are presently in clinical trials and exhibit potent and 
specific effect in cancer.39, 65 
1.4.2.1.4 ON01910.Na affects microtubule dynamics by inhibiting Plk1 
Among the Plk1 inhibitors, ON01910.Na increasingly gains attention in view 
of its potent inhibitory activity. Studies of the inhibitory effects of 
ON01910.Na on a panel of 29 serine/threonine and tyrosine kinases showed 
that Plk¶VDFWLYLW\ZDVLQIOXHQFHGPRVWZLWKDQ,&50 of 9 - 10 nM, suggesting 
it might be one of the primary targets (Table 1.2).53 Steady-state analysis on the 
effects of increasing concentrations of ATP or substrate (recombinant casein 
and Cdc25c) on the Plk1 (recombinant) inhibitory activity of the compound 
revealed that ON01910.Na targets Plk1 activity in an ATP-independent and 
substrate-dependent manner: the velocity of substrate phosphorylation was 
unaltered in the presence of increasing concentrations of ATP, while increasing 
the concentration of the substrate resulted in increased substrate 
phosphorylation.53 
The mitotic microtubule abnormalities induced by this agent activate apoptotic 
pathways leading to cancer cell death and have been clarified by many 
comparative analyses.94 ON01910.Na treated cells exhibited profound 
abnormalities in spindle formation in G2/M. The multipolar spindles then led 
to misalignment of chromosomes, which was similar to the appearance 
observed in Plk1-depleted cells.95 Moreover, Plk1 siRNA as well as 
ON01910.Na treatment exhibited growth inhibitory effects on HS766T cells, 
while mild additive effects were observed when Plk
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were given together.96 This indicates that Plk1 knockdown- and ON01910.Na-
mediated effects may impinge on both parallel and connected pathways in 
mitotic progression. Phosphorylation of Cdc25c at Ser198 was suggested to 
serve as a reliable marker to monitor Plk1 activity.24 ON01910.Na has been 
shown to induce stark G2/M arrest and suppress cell cycle effectors 
downstream of Plk1, including phospho-Cdc25c (Ser198) and cyclin B1.53, 64 
To date, the molecular modelling of ON01910.Na in complex with Plk1 has 
not been resolved, thus the exact binding mode is still undefined. It has been 
reported that a range of kinases without PBDs are also inhibited by 
ON01910.Na. Meanwhile, ON01910.Na shows inhibition of tyrosine kinases 
as well as CDK1 (Table 1.2).53 These clues suggest that ON01910.Na may 
interfere with the kinase domains by binding to the peptide binding sites, rather 
than target the polo-box domain of Plk1.95 
7DEOH.LQDVHLQKLELWRU\DFWLYLW\RI211D 
,QKLELWRU\ DFWLYLW\ RI 211D DJDLQVW D SDQHO RI VHULQHWKUHRQLQH DQG W\URVLQH NLQDVHV
UHSRUWHGE\*XPLUHGG\HWD5HSRUWHGH[SHULPHQWDOSURFHGXUHVLVGLVFULEHGLQ$SSHQGL[, 
Protein Kinase IC50 (nM) 
$NW3.%Į >10,000 
Aurora A >10,000 
Aurora B >10,000 
BCR-ABL 32 
BTK >10,000 
Cdk1 260 
Cdk2 >10,000 
Cdk4 >10,000 
Cdk5 >10,000 
Cdk6 >10,000 
Cdk9 >10,000 
Chk1 >10,000 
Chk2 >10,000 
ErbB-2 >10,000 
EGFR >10.000 
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ERK >10,000 
Flt1 42 
Fyn 182 
FGFR >10,000 
IGFR >10,000 
JNK >10,000 
Lyn B >10,000 
MEK1 >10,000 
Plk1 9 
Plk2 260 
Plk3 >10,000 
PDGFR 18 
ROS >10,000 
Src 155 
Although the antimitotic activity of ON01910.Na was deemed as the 
consequence of Plk1 inhibition, continuative studies did not support a direct 
effect on Plk1. However, previous kinase inhibitory results of ON01910.Na on 
Plk1 could not be reproduced by other scientists.97, 98 Several lines of 
experimental evidence suggested that ON01910.Na is an inhibitor of tubulin 
polymerization rather than a Plk1 inhibitor. The compound effectively blocks 
cell proliferation, however, cellular effects caused by this compound resembled 
the phenotype that is caused by treatment with microtubule depolymerizing 
agents rather than Plk1 RNAi.97, 99 When treated with higher doses (2.5PM) 
of ON01910.Na, depolymerisation of microtubules was visible in interphase 
cells. Moreover, in vitro kinase assays indicated that ON01910.Na does not 
show obvious Plk1 inhibition in until concentrations of  ȝ0 have been 
reached.97 Overall, it seems that the mechanism for ON01910.Na on Plk1 
activity has not yet been completely established. Improved understanding of 
the specific interactions between ON01910.Na and Plk1 are critical. 
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 ON01910.Na targets PI3K/Akt pathway 
Since its discovery in the 1980s, Phosphatidylinositol 3-kinases (PI3 kinases, 
PI3Ks) have been found to be play key roles in regulating many cellular 
processes.33 The PI3K/Akt pathway is a key signal transduction system linking 
multiple receptors, as well as oncogenes, to essential cellular processes and is 
activated in cancers.100 Thus, this pathway presents both an opportunity and a 
challenge for cancer drug disoverers.33 Recent studies reported that the 
PI3K/Akt pathway was affected by ON01910.Na. 
1.4.2.2.1 Structure and function of PI 3-kinases 
1.4.2.2.1.1Structure of PI 3-kinases 
PI 3-kinases are a lipid kinase family characterized by their capability to 
phosphorylate inositol lipids on the 3-position of the inositol phospholipids.101 
To date, eight PI3K isoforms have been identified in mammals and are 
subdivided into three classes (Class I, Class II, and Class III). (Figure 1.13 A)  
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)LJXUH7KHPHPEHUVRIWKH3,.IDPLO\ 
$3,.VKDYHEHHQGLYLGHGLQWRWKUHHFODVVHVDFFRUGLQJWRWKHLUVWUXFWXUDOFKDUDFWHULVWLFVDQG
VXEVWUDWH VSHFLILFLW\ % 7KH OHYHO RI SKRVSKDWLG\OLQRVLWRO--WULSKRVSKDWH 3,3 LV
UHJXODWHGE\&ODVV,3,.DQG37(1 
Among major classes of 3,.FODVV,3,.VQDPHGDV3,.Į3,.ȕ3,.Ȗ
DQG 3,.į KDYH shown to be involved in cancers, and so have drawn the 
majority of attention in research.102 Class I PI3Ks are heterodimers consisting 
of a regulatory subunit and a 110 kDa catalytic subunit. Based on different 
mechanisms of activation, this class is further divided into two subgroups: class 
Ia SĮ Sȕ DQG Sį DQG FODVV ,b SȖ 7KHy phosphorylate the 
inositol lipids to generate the same lipid product phosphatidylinositol-3,4,5-
triphosphate (PtdIns(3,4,5)P3) (Figure 1.13 B).33, 103 Interestingly, class I PI3K 
could also function as serine/threonine protein kinases.104 
A 
B 
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1.4.2.2.1.2PI3K/Akt signalling pathway 
The signalling network defined by PI3K, Akt and mTOR controls most 
hallmarks of cancer, including cell cycle, survival, metabolism, motility and 
genomic instability.103 The PI3K/Akt signalling pathway is depicted in Figure 
1.14. 
Activated by receptor tyrosine kinases (RTKs) and Ras at the membrane, PI3K 
generates phospholipids (second messengers) and initiates a series of 
intracellular signalling pathways. The production of key second messenger 
phosphatidylinositol-3, 4, 5-trisphosphate (PtdIns(3,4,5)P3) from the substrate 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P3) is tightly regulated by 
the opposing activity of PI3K and PtdIns(4,5)P2 phosphatases (PTEN).101, 105, 
106
 PTEN (Phosphatase and tensin homolog) is an important tumour suppressor, 
and acts as a major negative regulator of PI3K/Akt signalling. Loss of PTEN 
activity leads to unrestrained PI3K/Akt pathway activation leading to cancer.33 
Through providing docking sites for signalling proteins with pleckstrin-
homology (PH) domains, PtdIns(3,4,5)P3 then recruits a subset of signalling 
proteins to the plasma membrane, including Akt and its activator PDK1 (3-
phosphoinositide-dependent kinase 1).101 Akt, also known as protein kinase B, 
is a serine/threonine kinase phosphorylated by both PDK1 (on Thr308) and 
mTOR2 (on Ser473). It is the primary receptor of PI3K-initiated signalling and 
controls essential cellular activities through phosphorylation of a number of 
downstream effectors.102, 107 
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)LJXUH7KHFODVV,3,.VLJQDOOLQJSDWKZD\ 
One of the key downstream effector of Akt is mTOR. The serine/threonine 
protein kinase mTOR belongs to a group of the PI3K family referred to as class 
IV PI3Ks. It functions at two distinct nodes in the pathway: mTOR complex 2 
(mTORC2) phosphorylates key residues to activate Akt and other kinases, 
while mTORC1 is a central regulator of cellular metabolism and 
biosynthesis.103 Akt activate mTOR by phosphorylating both PRAS40 and 
TSC2 (tuberous sclerosis complex) to release their inhibitory effects on 
mTORC1. The best characterized downstream targets of mTORC1 are S6K1 
(p70S6 kinase) and 4E-BP1 (4E-binding protein), both of which are critically 
involved in the regulation of protein synthesis.33 
1.4.2.2.1.3PI3K/Akt signalling on cell cycle and apoptosis 
PI3K/Akt pathway regulates cell growth signalling pathways and determines 
the rate of cell cycle progression. PI3K and its downstream effector Akt control 
cell cycle entry by inactivating the FOXO (Forkhead Box, subgroup O) 
transcription factors. PI3K/FOXO work as a complementary switch: when 
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PI3K is active, FOXO transcription factors are inactive. The switch is turned 
on and off at different phases of the cell cycle, thus regulating cell cycle 
progression.108 During the G1/S cell cycle progression, Akt inactivates GSK-ȕ
leading to increased cyclin D1 and P21Cip1 phosphorylation.107 Meanwhile, it 
inhibits tumour suppressor tuberin (TSC2), leading to the reduction of 
p27(Kip1).109 Thus, Akt positively regulates G1/S cell cycle progression and 
prolongs cell survival. Recent studies have also shown that constitutive 
activation of PI3K pathway induced by DNA damage led to a substantial 
decrease in Chk1 kinase activity.110 Inactivation of Chk1 therefore mediated 
Cdc25c phosphorylation and prevent the inhibition of cyclin B1/Cdc2 leading 
to resistance to DNA damage mediated G2/M arrest. 
PI3K/Akt pathway is one of the major anti-apoptotic pathways operating in 
cells and Akt mediates PI3K-dependent survival. Anti-apoptotic effects 
mediated by Akt include modulating the activity of Bcl-2 family members, 
down-regulation of death receptors, and enhancement of the glycolytic rate.109 
Akt phosphorylates pro-apoptotic Bad, which in turn dissociates from Bcl-2, 
consequently inducing cell survival and preventing apoptosis.107 
1.4.2.2.1.4Linking the PI3K pathway to human cancers 
The discovery that the tumour suppressor PTEN worked by antagonizing PI3K 
established the first direct link between PI3K activation and human cancer.33 
Recent human cancer genomic studies suggest that the PIK3CA gene 
HQFRGLQJ WKH 3,. FDWDO\WLF LVRIRUP SĮ LV WKH VHFRQG PRVW IUHTXHQWO\
mutated oncogene and multiple components of the PI3K pathway are 
frequently mutated or altered in common human cancers.33, 103 As described 
above, activation of the PI3K signalling pathway contributes to cellular 
processes responsible for all important aspects of tumourigenesis. 
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For these reasons, PI3 kinase and other key components in this pathway 
become one of the most attractive targets for therapeutic intervention in cancer. 
Gradually deepening understanding about the PI3K/Akt signalling pathways is 
emerging and helping to provide a platform for novel drug discovery. From the 
first-generation inhibitors (LY294002 and Wortmannin) to the latest clinical 
candidate (GDC-0941), numerous PI3K inhibitors have shown promising 
results in cancer therapy.100, 107 
1.4.2.2.2 ON01910.Na inhibits the PI3K/Akt pathway 
A recent study by Prasad et al reported the molecular mechanism of 
ON01910.Na in mantle cell lymphoma (MCL) cell lines.78 ON01910.Na down-
regulates cyclin D1 by suppressing cyclin D1 mRNA translation through 
inhibiting PI-3K/Akt/mTOR/eIF4E-BP signalling pathway, and induces 
apoptosis via the mitochondrial pathway. 
1.4.2.2.2.1ON01910.Na down-regulates cyclin D1 
MCL is a subtype of B-cell lymphoma. Uncontrolled over-expression of cyclin 
D1 is the main characteristic of MCL. Many studies with ON01910.Na 
treatment both in vitro and in vivo have indicated that ON01910.Na may affect 
the translation of cyclin D1 through the PI3K/Akt/mTOR/eIF4E-BP signalling 
pathways.74, 78, 111 
ON01910.Na modulates post-transcriptional regulation of cyclin D1, which is 
supported by the observation in cells that expression of cyclin D1 was 
significantly inhibited, while the mRNA levels of cyclin D1 were minimally 
affected. 
In cancer cells, activated Akt phosphorylates and activates mTOR protein on 
Ser2448, which in turn phosphorylates eIF4E-BP (eIF4E-binding protein). The 
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phosphorylated eIF4E-BP releases eukaryotic translation initiation factor 4E 
(eIF4E), which simultaneously binds to the mRNA 7-methyl-guanosine cap 
and initiates translation of cyclin D1.112 It has been shown that eIF-4E 
overexpression leads to an increase in cyclin D1 protein through both 
transcriptional and post-transcriptional regulatory pathways.113 eIF4E enhances 
the transport of the cyclin D1 mRNA from the nucleus.114 
ON01910.Na inhibited phosphorylation of Akt (Ser473), mTOR, eIF4E-BP 
and reduced the cap binding activity of eIF4E, indicating ON01910.Na 
negatively regulates the Akt/mTOR/eIF4E-BP/eIF4E pathway. However, the 
expression of PTEN was not affected, suggesting that PI3K was the direct 
target of ON01910.Na. This is confirmed by in vitro kinase inhibition assays 
using the recombinant PI-3KD, E, J and Gisoforms. ON01910.Na inhibited the 
kinase activity of PI-3KD and E isoforms between concentrations of 1 and 10 
mM in vitro.78 The proposed mechanism of ON01910.Na blocking the 
PI3K/Akt/mTOR pathway is shown in Figure 1.15. 
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)LJXUH3URSRVHGPHFKDQLVPRIDFWLRQRI211DRQEORFNLQJWKH
3,.$NWP725H,)(-%3SDWKZD\DQGLQGXFLQJDSRSWRVLV 
6WLPXODWRU\UHGDQGLQKLELWRU\EODFNLQWHUDFWLRQVZLWK211DDUHVKRZQ 
1.4.2.2.3 ON01910.Na induces mitochondrial apoptosis 
ON01910.Na was reported to induce apoptosis through mitochondrial 
pathways.78 Analysis of the Bcl-2 family revealed that ON01910.Na down-
regulate the expression of Bid, Bcl-xL and Mcl-1, while Bax and Bad are not 
affected. Recently ON01910.Na was found to inhibit another anti-apoptotic 
factor, BIM, which is targeted and phosphorylated by Akt.115 Bid plays the key 
role in releasing cytochrome c from mitochondria.116 Existing as an inactive 
precursor in the cytosol, Bid is activated following cleavage by caspase-8. 
Subsequently, Bid translocates to the mitochondria and induces cytochrome c 
release, followed by mitochondrial damage.117 
The caspase-8 independent cleavage of Bid involves JNKs (c-Jun N-terminal 
kinases), members of MAP-kinases which play important roles in both death 
receptor (DR) and mitochondrial-mediated apoptotic pathways.118 
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ON01910.Na increases the phosphorylation of JNKs. Afterwards, JNKs induce 
cleavage of Bid and release cytochrome c to form the apoptosomes.118 Studies 
show that after ON01910.Na treatment caspase-3 and -7 also generate the 
cleaved product and lead to apoptosis.78 
 Other possible targets of ON01910.Na 
ON01910.Na has also been reported to target other signalling pathways. A 
study demonstrated that ON01910.Na induced apoptosis in chronic 
lymphocytic leukaemia B-cells without significant toxicity against T-cells or 
normal B-cells.119 Gene expression profiling revealed two main mechanisms of 
action: inhibition of PI3K/Akt and induction of an oxidative stress response 
through AP-1 (activator protein 1), JNK and ATF3 (Cyclic AMP-dependent 
transcription factor) that culminated in the up-regulation of NOXA. Induction 
of cell cycle arrest by ON01910.Na has also been shown to correlate with the 
level of hyper-phosphorylation of Ran GTPase-activating protein.119 
 ,VVXHV DIIHFWLQJ 211D¶V GHYHORSPHQW DV DQ DQWL-
cancer agent 
Despite ON01910.Na presenting efficacious activity against a wide range of 
cancers together with an attractive safety profile, a number of key issues 
remain that are affecting its development; these include an incomplete 
understanding of its anti-tumour mechanisms, its low oral bioavailability and 
unsatisfactory pharmacological properties. 
 Incomplete understanding of anti-cancer mechanisms 
ON01910.Na is regarded as a multi-target kinases inhibitor. To date, although 
hypotheses regarding mechanism of action have been put forward, limited 
  Introduction 
 44 
findings have been reported and the precise mechanisms still need to be 
established. Besides, the crystal structure or molecule modelling for 
ON01910.Na in complex with any target kinase is not available yet, therefore 
the precise binding mode is difficult to predict, which holds back lead 
optimization of molecules with improved druggable properties. 
 Unsatisfactory pharmacological properties 
In preclinical data, the plasma half-life of ON01910.Na was less than 2 hours 
in rat, dog, and human plasma.120 Due to its short plasma half-life and rapid 
clearance, a continuous IV infusion is recommended. This issue will limit the 
option for dosage forms and schedule, and more importantly, will increase 
unwanted toxicities. 
Both oral and parenteral formulations of ON01910.Na are under clinical 
investigation. However, low lipophilicity of ON01910.Na was observed with 
LogDpH 7.4 = 0.83. This would reduce the extent of drug absorption as well as 
limiting its administration. Moreover, failure to broadly metabolize 
ON01910.Na in vivo limits the drug exposure and must be compensated by 
higher drug concentrations.62 It is a fact that ON01910.Na exhibits extensive 
protein binding which impairs drug distribution to the tissue, further resulting 
low drug bioavailability (10±15%.in rats).75  
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2 Aims and objectives 
(E)-Styrylbenzylsulfones exhibit broad spectrum of anti-tumour activity in 
vitro while exhibiting relatively mild toxicity to normal human cells.68 In view 
of the limitations identified during the development of ON01910.Na, the 
styrylbenzylsulfones pharmacophore was intended to be optimized by 
implementing an analogue-based design approach and develop a novel series of 
anti-cancer agents. The aim of the research project described hereinafter is to 
design, synthesise and biologically evaluate a novel class of 5-
((styrylsulfonyl)methyl)pyridin-3-amine with improved efficacy and drug-like 
properties using ON0910.Na as a lead compound. 
To achieve this major aim, the research project was undertaken with the 
following specific objectives: 
1) Design and synthesis of a class of 5-((styrylsulfonyl)methyl)pyridin-3-
amine as novel anti-cancer agents. A synthesis strategy will be developed 
for 5-((styrylsulfonyl)methyl)pyridin-3-amine and its derivatives. 
2) Understand the SAR of new compounds, based on their effects on 
proliferation. The new SAR will enrich previously reported SAR and help 
to verify the variation of certain features, including efficacy, selectivity 
and drug like properties of the molecule. Furthermore, these SAR 
relationships in turn may guide to predict the activity of new analogues.  
3) Develop a cell-based screening cascade for evaluating biological activities 
of new compounds, including the effects on proliferation, cell cycle 
regulation and apoptosis. This cascade could then be used to identify 
favoured compounds to go forward to in vitro and in vivo testing, such as 
assessment of drug like properties. 
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4) Investigate the detailed cellular mechanism of action of favoured 
compounds in comparison with ON01910.Na.  
During the middle-stage of the project, TL-77 as well as ON01910.Na was 
subjected to the kinase activity test. Although ON01910.Na was originally 
considered to be a novel Plk1 inhibitor, lacking Plk1 kinase inhibitory 
activity was observed in both compounds treatment. Thus, it became one 
of the major goals of this project to identify the mechanism of action and 
could be addressed through the following strategy:  
x In-depth analysis the effects of lead compound TL-77 on cell cycle 
regulation. Effect of TL-77 on DNA damage signalling regulators will be 
primarily identified. 
x Probe the potential target molecules on PI3K/AKT signal transductive 
pathway.  
x Examine the effect of TL-77 on tubulin polymerization and inducing 
microtubule abnormalities. 
x Identify the molecule mechanism of TL-77-induced apoptosis. 
This project involves the synthesis phase, in vitro biological evaluation and 
preliminary mechanistic study of these small molecule inhibitors. Broad 
spectra of biological and chemical techniques are employed, which are critical 
in the early stages of drug discovery. 
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3 Synthetic Chemistry 
 Introduction and rationale of design 
'H¿QLWLRQV RI ³GUXJ-OLNHQHVV´ KDYH EHHQ ZLOGO\ SXEOLVKHG EDVHG RQ WKH
analysis of molecular properties of successful drugs. These rules correlate 
simple molecular properties with successful drug development.121 The 
optimization of drug-like properties, such as absorption, distribution, 
metabolism, excretion, and toxicity (ADME/Tox) properties is an integral 
element of drug discovery studies.122 The primary guide to this approach is 
SLRQHHUHGE\/LSLQVNL¶V5XOHRI)LYH 
Based on an extensive analysis of the structures of orally active drugs 
candidates, Lipinski and colleagues set up an absorption - permeability alert 
procedure to guide the development of an orally active compound.123 
According to the Rule of Five, good absorption or permeation is more viable 
IRUDFKHPLFDOZKHQK\GURJHQERQGGRQRUVDUHK\GURJHQERQGDFFHSWRUV
 PROHFXODU ZHLJKW   DQG /RJ 3   RFWDQRO-water partition 
coefficient).123 /LSLQVNL¶V5XOHRI)LYHSURYLGHGWKHRULJLQDOIUDPHZRUNIRUWKH
development of orally bioavailable drug candidates and it has been widely used 
for the assessment of drug-likeness.124, 125 In addition to the molecular 
properties discussed by Lipinski, other properties have been proposed as oral 
bioavailability parameters, such as the number of rotatable bonds (NROT), 
lipophilicity, polar surface area, and number of aromatic rings.126-128 An 
example of those extensions of the rule is the adjustment of the optimal 
molecular lipophilicity. Lipophilicity significantly influences ADME/Tox 
properties and can be valued by partition or distribution coefficient (Log P or 
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Log D). Compounds with moderate lipophilicity (Log D 0-3, optimal Log D ~2) 
generally possess good balance between solubility and permeability, and is 
optimal for drug development.129 Moreover, in an attempt to improve the 
predictions of drug-likeness, the rule of five has also been extended to the rule 
RI WKUHH EDVHG RQ WKH µIUDJPHQW-EDVHG¶ GLVFRYHU\ WR GHILQH OHDG-like 
compounds.124 
Reddy et al. have pioneered the development of a novel group of anti-tumour 
agents with general structure of (E)-Styrylbenzylsulfones to inhibit the cell 
cycle progression and induce apoptosis in cancer cells (Figure 3.1).61 A 
molecule with the amino group in third position on benzene ring, ON01500 
(Figure 3.1), showed the highest potency; however, it has very low solubility. 
In order to enhance the drug-likeness and the hydrophilicity, the amino group 
in third position was converted to glycine as ON01910, which was further 
made into its water-soluble sodium ON01910.Na (Figure 3.1). The presence of 
sodium glycine in ON01910.Na did not affect the potency against cancer cell 
lines, but improved aqueous solubility, which is critical for intravenous 
administration.61  
ON013100 (Figure 3.1), a structural analogue of ON01910.Na, is another 
potent anti-tumour candidate and was selected by in silico and in vitro 
screening for evaluation in a preclinical brain tumour model. Given the 
lipophilic nature of ON013100 (predicted logD=2.53), its structure was further 
modified to achieve favourable lipophilicity values and facilitate intravascular 
administration. An aqueous soluble form, ON013105 (Figure 3.1) was then 
developed by introducing a disodium phosphate group at 3-hydroxyl position 
on the benzene ring.63 
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)LJXUH7KHVW\U\OS\ULGLQ\OVXOIRQHSKDUPDFRSKRUHDQGGUXJ-OLNHFDQGLGDWHV 
Introduction of an ionized moiety into (E)-Styrylbenzylsulfones improved 
aqueous solubility of drug candidates ON01910.Na and ON013105. However, 
failing to keep the balance between solubility and permeability, low 
OLSRSKLOLFLW\RIERWK211DSUHGLFWHGORJ' í63; logDpH 7.4 = 0.83 
125DQG21SUHGLFWHGORJ' í63) were observed. The solubility 
of ON01910.Na is 95 mg/mL (200 mM) in vitro and 30 mg/mL (Saline) in 
vivo.130 Such hydrophilic compounds are not expected to show desirable drug-
like properties or oral bioavailability. Poor permeability, low BBB penetration 
for CNS drug and high renal clearance - shortening the half-life - are big 
concerns with such compounds. The preclinical in vivo pharmacokinetics study 
of ON01910.Na confirmed this issue and recommended the administration of 
ON01910.Na by continuous IV infusion due to its short half-life and rapid 
clearance.120 Meanwhile, low bioavailability with 10-15% of ON01910.Na (10 
DQG(?PJNJKLQIXVLRQLQUDWVZDVREVHUYHG75 
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In an attempt to improve drug-likeness and ADME properties of ON01910.Na 
analogues, two novel series of (E)-styrylsulfonyl methylpyridine derivatives 
was designed (class I and II, Figure 3.2). 
 
)LJXUH7KHVWUXFWXUHVRI(-VW\U\OVXOIRQ\OPHWK\OS\ULGLQHGHULYDWLYHV 
SAR studies have identified that the styrylbenzylsulfonyl moiety is essential 
for anti-mitotic activity.68, 131 However, the main scaffold of 
styrylbenzylsulfone pharmacophore exhibits high lipophilicity (cLog P > 3, 
PSA < 40, calculated by Chem Office Ultra 13.0), which may lead to non-
specific binding, low solubility causing formulation problems, and poor oral 
absorption. Reddy group intend to increase the drug likeness and the water 
solubility by introducing ionized functional groups at the 3-position of the 
benzyl ring for intravenous administration, but the pioneer compounds 
exhibited undesirable drug likeness properties (high PSA, poor permeability), 
which have been described previously. Therefore, we intend to modify this 
pharmacophore to achieve derivatives with improved pharmaceutical 
properties. 
Pyridine replacement from benzene was proposed due to its expected impact 
on physicochemical characteristics.132 Pyridine-containing compounds 
exhibited intermediate solubility and low protein binding.133 Many examples of 
bioisosteric replacement of benzene rings with pyridine rings have been 
described.134, 135 Preferred compounds demonstrate desirable properties, 
including improved metabolic stability, aqueous solubility, as well as similar 
mechanism of action.134 In this case, by introduction of a polar pyridinyl ring, 
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two novel chemical classes were generated, which were expected to possess 
improved pharmaceutical properties (moderate lipophilicity with logD7.4 values 
~2, desirable aqueous solubility and improved oral bioavailability) when 
compared to the benzylstyrylsulfonyl series. (Figure 3.2)  
Cytotoxic activity of the styrylbenzylsulfones was found to be greatly 
dependent on the nature and position of the substituents on the two aromatic 
rings. Substitutions on the styryl ring system were generally found to be 
tolerated, but a 2,4,6-trimethoxystyryl moiety is important for optimum 
potency. A recent study has also indicated that the (E)-isomers of 
styrylbenzylsulfonyl derivatives have superior biological efficacy compared to 
the respective (Z)-isomers.136 For these reasons, the 2, 4, 6-trimethoxystyryl 
section and (E)-configuration was retained. 
Meanwhile, structure±function studies have also shown that substitutions at the 
3-position of the benzyl ring help to enhance anti-proliferative activity.68 
Therefore, diverse drug-like groups were selected that would modify the 3-
positon of the benzyl ring.   
 Synthetic strategy 
A synthetic strategy to prepare ON01910.Na was reported previously by Reddy 
et al.68 Two general methods of synthesizing benzyl styrylsulfone are shown in 
Scheme 3.1 and Scheme 3.2. 
 
6FKHPH0HWKRGRIV\QWKHVL]LQJEHQ]\OVW\U\OVXOIRQH 
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5HDJHQWVDQGFRQGLWLRQV D1D2+0H2+KU UWE+2&+&22+KU
UW  F 3LSHULGLQH EHQ]RLF DFLG WROXHQH R& -K  RU G &+&22+
EHQ]\ODPLQHR&-K 
In Scheme 3.1, substituted benzyl bromides 1 were initially reacted with 
thioglycollic acid in mild basic conditions to yield compound 2. Then 2 was 
further oxidized in hydrogen peroxide to give 3. The key step, Knoevenagel 
condensation between 3 and the aromatic aldehyde followed. This step can be 
carried out with (c) the aromatic aldehyde in toluene in the presence of 
catalytic piperidine and benzoic acid or (d) the aromatic aldehyde in glacial 
acetic acid in the presence of catalytic benzylamine to afford benzyl 
styrylsulfone 4.68 
 
6FKHPH0HWKRGRIV\QWKHVL]LQJEHQ]\OVW\U\OVXOIRQH 
5HDJHQWVDQGFRQGLWLRQV D1D2+0H2+KU UWE+2&+&22+KU
UW  F1D%+(W2+PLQ R& GS-WROXHQHVXOIRQLF DFLG&+ K UHIOX[
R& 
Alternatively, 4 could be prepared through method 2 in Scheme 3.2. Starting 
from coupling of benzyl mercaptans 5 DQGĮ-bromo substituted acetophenones, 
compound 6 was then oxidized to yield 7. Sodium borohydride was used to 
reduce the carbonyl group and give the corresponding alcohol, 8. Finally, 
elimination of water from 8 in refluxing solution of p-toluenesulfonic acid in 
benzene gave benzyl styrylsulfone 4.68 
  Synthetic Chemistry 
 53 
 Synthetic strategy of (E)-3-
((styrylsulfonyl)methyl)pyridine 
Method 1 was adopted in this project. The general synthetic strategy for the 
production of (E)-2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridine intermediates 9-16 is outlined in 
Scheme 3.3.  
 
6FKHPH6\QWKHVLVRI(--PHWKR[\---
WULPHWKR[\VW\U\OVXOIRQ\OPHWK\OS\ULGLQ--DPLQH 
5HDJHQWVDQGFRQGLWLRQVD1D0H2+UHIOX[KE1%6EHQ]R\OSHUR[LGH&&O
UHIOX[  K  F PHWK\O WKLRJO\FRODWH 1D&2 0H2+ UW  K  G +2 DFHWLF
DFLGR&KH1D&2+20H2+UWKI-7ULPHWKR[\EHQ]-
DOGHK\GHEHQ]RLFDFLGSLSHULGLQHWROXHQHUHIOX[KJ)HDFHWLFDFLG0H2+
R&K 
Starting from commercially available 2-chloro-5-methyl-3-nitropyridine (9), 
methyoxylation (nucleophilic substitution) was carried out with sodium in 
refluxing methanol to yield 2-methoxy-5-methyl-3-nitropyridine (10) in 92% 
yield. Bromination of 5-methylpyridine 10 with N-bromosuccinimide (NBS) in 
the presence of benzoyl peroxide obtained 11. Subsequent nucleophilic 
displacement of the bromine of 5-(bromomethyl)pryridine (11) with methyl 
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thioglycolate to afford thioether 12. 12 was then readily oxidised with 30% 
hydrogen peroxide in glacial acetic acid to give sulfone 13 in excellent yield. 
Saponification of the latter was performed using sodium carbonate in a mixture 
of methanol and water to give carboxylic acid 14 in a quantitative yield. 
The key step, Doebner - Knoevenagel condensation between 14 and 2,4,6-
trimethoxybenzaldehyde, was initially attempted using pyridine as solvent in 
the presence of piperidine. The desired (E)-2-methoxy-3-nitro-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridine 15 was isolated by flash column 
chromatography in 10% yield along with a piperidine-substituted by-product 
17. The yield of 15 was significantly improved to 41% when the reaction was 
conducted using toluene in the presence of a mixture of piperidine and benzoic 
acid. Reduction of 15 to (E)-2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridin-3-amine 16 was achieved in a high 
yield using iron powder in methanol in the presence of mild acid. 
 Synthetic strategy for (E)-3-
((styrylsulfonyl)methyl)pyridine 3C-amino derivatives 
To assess the influence of substitution at the 3-positon on the heterocyclic ring 
on the anti-proliferative activity, a series of 3C-amino derivatives of 16 were 
synthesised by the chemistry shown in Scheme 3.4. Substitution reaction of 16 
with methanesulfonyl chloride or acetyl chloride in the presence of an 
appropriate base afforded the corresponding sulfonamide 18a (R = NHSO2Me) 
or acetamide 18b (R = NHCOMe) in good to excellent yields. 18b was further 
treated with iodoethane in THF in the presence of strong base resulting in N, N-
disubstituted acetamide 18c (R = N(Et)COMe). Treatment of 16 with ethyl 2-
bromoacetate in DMF in the presence of base obtained ethyl acetate 18d (R = 
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NHCH2CO2Et). Subsequently hydrolysis of 18d in an alkaline solution 
afforded carboxylic acid 18e (R = NHCH2CO2H), while 18d was also reacted 
with ammonia to afford amide 18f (R = NHCH2CONH2) in 98% yield.  
 
6FKHPH6\QWKHVLVRI(--PHWKR[\---
WULPHWKR[\VW\U\OVXOIRQ\OPHWK\OS\ULGLQ-&-DPLQHGHULYDWLYHV 
5HDJHQWV DQG FRQGLWLRQV K D methanesulfonyl chloride S\ULGLQH  R& WR UW - K
EDFHW\OFKORULGHS\ULGLQH R&WRUWKGHWK\OEURPRDFHWDWH.&2
'0)R&RYHUQLJKWL1D+E7+)LRGRHWKDQHUWKM1D2+G
7+)+2UWKN1+1LQ0H2+G+2R&RQ 
 Discussion 
 Bromine free radical substitution of 2-methoxy-5-
methyl-3-nitropyridine 
 
6FKHPH6\QWKHVLVRI-EURPRPHWK\O--PHWKR[\--QLWURS\ULGLQH 
5HDJHQWVDQGFRQGLWLRQV1%6EHQ]R\OSHUR[LGH&&OUHIOX[K 
Benzylic brominations with NBS producing excellent yield of benzyl bromides 
were reported previously.137, 138 Most widely used conditions are refluxing a 
solution of NBS in CCl4 in the presence of a suitable initiator i.e. UV, benzoyl 
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peroxide, azo-bis-isobutyronitrile (AIBN).138 In this case, Benzoyl peroxide 
was used to effect radical initiation. 
 
6FKHPH3URSRVHGUHDFWLRQPHFKDQLVPRI-EURPRPHWK\O--PHWKR[\--QLWURS\ULGLQH 
The bromination of 10 followed free-radical chain mechanism. The proposed 
reaction mechanism is shown in the Scheme 3.6. Benzoyl peroxide ((PhCOO)2) 
JHQHUDWHV EHQ]R\OR[\O UDGLFDOV 3K&22 which attack NBS to produce the 
free bromide radicals %U. The free bromide radical attacks the 5-methyl of 
the molecule to produce the free radical intermediate and HBr. At the same 
time, the new generated HBr reacts with another molecule of NBS and 
maintains the high concentration of Br2. Therefore, the reaction is driven 
forward by the participation of the second molecule of Br2. 
During the reaction, dibromide compound would be formed as the majority 
side product. Chloroform was suggested as a possible solvent, since it is a more 
general and relatively lower toxic solvent for organic compounds. However, 
CCl4 was proved to have the optimal characteristics for this reaction, resulting 
in a lower level of dibromide production and a relatively high yield of the 
desired product. Alternatively, the generation of dibromide compound could be 
decreased by strictly controlling the equivalence of NBS: starting material to 
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1:1. Following these optimizations, the yield could be improved from 33% to 
42%. 
 Formation of pyridine-3- methyl sulfonyl acetic acid 
 
6FKHPH6\QWKHVLVRI--0HWKR[\--QLWURS\ULGLQ--\OPHWK\OVXOIRQ\ODFHWLFDFLG 
5HDJHQWVDQGFRQGLWLRQVD+2$F2+R&E1D&2+20H2+UW 
Pyridine methylsulfonyl acid 14 was prepared according to the route shown in 
the Scheme 3.7. The proposed reaction mechanism of oxidation and hydrolysis 
were detailed in Scheme 3.8 and Scheme 3.9. 
 
6FKHPH3URSRVHGUHDFWLRQPHFKDQLVPRI--PHWKR[\--QLWURS\ULGLQ--
\OPHWK\OVXOIRQ\ODFHWDWH 
The chemoselective oxidation of 12 is proposed to be a free radical reaction. 
Firstly, hydrogen peroxide is capable of forming ethaneperoxoic acid in the 
presence of acetic acid. At the same time, it can generate hydroxide radicals. 
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Then ethaneperoxoic acid promotes the formation of the sulfinyl bond to 
generate intermediate 12a, which is subsequently attacked by the hydroxide 
radical, thus forming compound 13 with the sulfonyl function group. 
 
6FKHPH  3URSRVHG UHDFWLRQ PHFKDQLVP RI --PHWKR[\--QLWURS\ULGLQ--
\OPHWK\OVXOIRQ\ODFHWLFDFLG 
As shown in Scheme 3.9, the hydrolysis is a base-catalysed hydrolysis reaction. 
In base, the hydroxide nucleophile (OH-) attacks the electrophilic C of the C=O 
bond in acetate ester, forming a tetrahedral intermediate. Subsequently, as a 
better leaving group, alkoxide picks up H+ and leaves as a methanol molecule 
to generate the acid 14. 
 
6FKHPH  $OWHUQDWLYH PHWKRG RI V\QWKHVLVLQJ --0HWKR[\--QLWURS\ULGLQ--
\OPHWK\OVXOIRQ\ODFHWLFDFLG 
5HDJHQWVDQGFRQGLWLRQVD1D&2+2UWE+2$F2+R& 
Alternatively, 2-((6-methoxy-5-nitropyridin-3-yl)methylsulfonyl)acetic acid 14 
could be prepared by hydrolysis of 12 followed by the oxidation of 2-(((6-
methoxy-5-nitropyridin-3-yl)methylthio)acetic acid 24 (Scheme 3.10). 
However, compared to the route detailed in Scheme 3.7, this method was 
proved not only hard to be monitored by Thin Layer Chromatography (TLC) 
but also brought difficulties to the purification procedure. 
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 Doebner-Knoevenagel condensation 
 
6FKHPH6\QWKHVLVRI(--PHWKR[\--QLWUR---
WULPHWKR[\VW\U\OVXOIRQ\OPHWK\OS\ULGLQH 
5HDJHQWVDQGFRQGLWLRQVEHQ]RLFDFLGSLSHULGLQHWROXHQHUHIOX[K 
A key step reaction of this project, the Doebner-Knoevenagel condensation 
between 16 and 2,4,6- trimethoxybenzaldehyde aims to introduce the styryl 
function group. This reaction is aldol condensation involving the 
monocarboxylate and the aldehyde. Weak bases are used to avoid side reaction 
of the aldehydes and ketones. After many trials investigating the reaction 
conditions, an optimum yield of 41% was achieved when the reaction was 
conducted using toluene in the presence of a mixture of piperidine and benzoic 
acid. 
Reaction occurs via the deprotonation of the alpha carbon of the methylene at 
the acetic acid moiety by the piperidine. An enolate intermediate is formed 
initially as shown below: 
 
Next, the resulting anion intermediate attacks the aromatic aldehyde, and an 
aldol is generated. The resulting anion pick up the H on previously generated 
piperidine cation, and then it undergo subsequent base-induced elimination. 
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In the final decarboxylation step, the decarboxylation and elimination of H2O 
and CO2 subsequently affords (E)-3-((styrylsulfonyl)methyl)pyridine. 
 
In this reaction, piperidine acts as organocatalyst and involves the 
corresponding iminium intermediate as an acceptor. Toluene is often used as 
solvents in these reactions because it forms azeotropes with water. The 
azeotropes can be measured quantitatively by distillation so as to monitor the 
reaction.139 The decarboxylation could give either the E or Z double bond. As 
the trans isomers are the more stable than cis isomers, you can assume that the 
elimination reaction is under thermodynamic control and the product has E 
geometry. 
Doebner - Knoevenagel condensation was initially attempted using pyridine as 
solvent in the presence of piperidine. The reaction gave a complex mixture 
with many by-products and resulted a yield as low as 10-15%. The purification 
of the mixture led to the identification of 2-methoxy-5-(1-(methylsulfonyl)-2-
(piperidin-1-yl)-2-(2,4,6-trimethoxyphenyl) ethyl)-3-nitropyridine 17 as one of 
the major by-products (in 14% yield). Its structure was confirmed by X-ray 
crystallography as shown in Figure 3.3. The proposed reaction mechanism is 
shown in Scheme 3.12.  
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6FKHPH3URSRVHGUHDFWLRQPHFKDQLVPRI-PHWKR[\---PHWK\OVXOIRQ\O--
SLSHULGLQ--\O---WULPHWKR[\SKHQ\OHWK\O--QLWURS\ULGLQH 
 Structure determination 
All compounds were characterized fully by 1H-NMR, 13C-NMR and Mass 
spectrometry as detailed in the Experimental Section. Stereochemistry of the 
styryl functional group can be signed using 1H-NMR spectroscopy. It is well 
known that the vicinal coupling constants measured for (E)-isomers are larger 
(range from 12±18 Hz; typical 15 Hz) than for (Z)-isomers (range from 0±12 
Hz; typical 8 Hz). 1H-NMR spectra of the derivatives of 2-
((styrylsulfonyl)methyl)pyridine and 3-((styrylsulfonyl)methyl)pyridine gave 
rise to the vicinal coupling constants J values in a range of 15-16 Hz, 
indicating (E)-stereochemistry.  
As representatives of the series, the molecular structure of compound 18a was 
further determined unambiguously by the x-ray diffraction. The data collection 
and structure is presented in Table 3.1 and Figure 3.3. Compound 18a 
crystallizes with a near planar solid-state conformation excepting the 
VXOIRQDPLGH JURXS RQ WKH S\ULGLQH ULQJ DQG WKH ³VWHS´ WKDW RFFXUV IRU WKH
sulfone and the sp3 methylene (Figure 3.3A).140 The bond length of C18-C19 is 
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0.134nm, which is confirmed to be a double bond of alkene. The crystal 
structure of 18a confirms that the compound is the (E)-isomers as expected 
from the synthetic approach and on the basis of 1H NMR spectroscopy.  
 
)LJXUH&U\VWDOVWUXFWXUHVRID$DQG%ZLWKDWRPLFQXPEHULQJVFKHPH 
7DEOH&U\VWDODQG;-UD\H[SHULPHQWDOGDWDIRUD 
Formula: C19 H24N2O8S2 M =  472.52 gmol-1 
Crystal System: Monoclinic T = 90(2)K 
Z = 4 Theta range: 8.16 d2Td148.68° 
Unitcell: a = 20.6703(11) Å 
b = 9.6447(5) Å 
c = 10.8382(4) Å 
Dcalc = 1.453 gcm-3 
D= 90.00, E= 91.021(4), J= 90.00° V = 2160.34(18) Å3 
 
$ 
% 
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4 Screening and biological evaluation of (E)-
styrylsulfonyl methylpyridines 
 Introduction 
In a programme to identify a novel chemical series of molecules possessing 
similar potency and modes of action, but improved pharmaceutical properties 
compared to ON01910.Na, our group have designed and synthesised a series of 
ON01910.Na analogues, including benzylstyrylsulfones, benzylstyrylsulfines 
and benzylsulfonyl-N-phenylacetamides.131  
A cell-based screening was carried out on Class I of (E)-styrylsulfonyl 
methylpyridines. The principal aims of the biological screening were to assess 
the in vitro anti-tumour activities of new compounds, as well as determine the 
effects of different substitution on the potency of the compounds against 
tumour cells. 
 Results and discussion 
 Anti-proliferation activity 
Effective anti-tumour drugs normally induce cancer cell death or inhibit 
proliferative activity, both of which decrease cancer cell viability. MTT is a 
water soluble yellow dye which can be converted to insoluble purple crystal 
formazan by mitochondrial dehydrogenases in viable cells. The anti-
proliferative activities of new synthesized (E)-styrylsulfonyl methylpyridine 
derivatives were first assessed against colorectal carcinoma HCT-116, breast 
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carcinoma MCF-7, and ovarian carcinoma A2780 using a standard 72 h MTT 
cytotoxicity assay.141  
We have chosen to focus the attention on these three cancers because they are 
among most common malignancies worldwide. These cell lines are all well 
characterised and are commonly utilized as model systems for studying cancer 
pathways and for developing new therapeutic approaches. 
HCT-116 cells are well characterised by intact DNA damage checkpoint, and 
normal p53 responses.142 According to Duldulao et al., up-regulated expression 
of seven genes responsible for DNA damage signalling was observed in HCT-
116, including Cdc25c.143 In addition, HCT-116 cells were reported to have a 
high expression and activity of Plk1.144 Both HCT-116 and A2780 cell lines 
have been validated in the scientific literature to be the mitotic spindle 
checkpoint proficient.145 Whereas, MCF-7 cells are partially defective for the 
G1 and mitotic spindle checkpoints.146 Meanwhile, A2780 is confirmed with a 
biallelic inactivation of PTEN (9bp deletion in exon 5 and 37bp deletion in 
exon 8).147 Due to PTEN deletion, PI3K pathway is deregulated in A2780 
cells.148 Since ON01910.Na targets Plk1 and PI3K by interrupting cell cycle 
division, decreasing expression of Cdc25c and producing multipolar spindles 
(refer to Chapter One), cytotoxicities of new synthesised compounds were 
accessed towards these cell lines. 
Silencing genes, such as Plk1, in HCT-116 cells in vitro and in vivo have been 
stably generated.149 Both HCT-116 and A2780 xenograft models established in 
nude mice were widely conducted to evaluate inhibitory capacity of Plk1 and 
PI3K inhibitors.148, 150, 151 In consideration of both HCT-116 and A2780 cell 
lines could be well developed as in vitro and in vivo models, these two cell 
lines were used in this study for investigation of the mechanism of action. 
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The GI50 values (concentration for 50% of maximal inhibition of cell 
proliferation) of the tested compounds are summarized in Table 4.1. The anti-
proliferative activity of the (E)-3-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridines were dramatically influenced by 
the 3C-substituent (R inTable 4.1) of pyridinyl ring. To analysis the influence 
of cell growth rates due to the different tissue origin on anti-proliferative 
activity, the population doubling time of tested cell lines were also provided in 
Table 4.1. A2780 exhibited a shortest population doubling time (13.5 h), while 
the doubling time of MCF-7 and HCT-116 are 30 h and 18 h, respectively. 
Among the tested cell lines, A2780 cell is the most sensitive to compounds 
compared with other two cell lines, showing less anti-proliferative with smaller 
value of GI50s (except ON01910.Na). On the other hand, compounds were 
generally less active in MCF-7 cells, with GI50s higher than respective GI50s in 
other two cell lines, except TL-66, TL-81 and AH-123. These differences in 
sensitivity correlated with population doubling time. For a given set of growth 
conditions, the cells with shorter population doubling time possess a higher 
population doubling level, which is more susceptible to mitotic block and 
subsequent mitotic death induced by mitotic blockers. In this study, compounds 
selectively exhibit enhanced anti-proliferative activity in cancer cells with 
higher population doubling level, indicating their potential anti-mitotic effect. 
A moderate anti-proliferative activity (GI50 ~ 5- ȝ0 ZDV REVHUYHG ZLWK
compound 15 (R = NO2) against these cell lines. Replacement of the nitro with 
an amino at 3C-position of the pyridinyl ring resulting in 16 (R = NH2) 
significantly enhanced activity, with GI50s in a range of 0.005- ȝ0
against all tested tumour cell lines, being ~10-fold more potent than 
ON01910.Na. Substitution of the 3C-amino with a methanesulfonamide as in 
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18a (R = NHSO2Me) reduced the potency, giving GI50 values around 0.5-
ȝ0DJDLQVW WKUHHFHOO OLQHV0RGHUDWHF\FWR[LFDFWLYLW\ZDV VHHQZLWK 18b 
(R = NHCOMe) and 18f (R = NHCH2CONH2). However its ethyl 2-
aminoacetate derivative 18d (R = NHCH2CO2Et) and 2-aminoacetic acid 
analogue 18e (R = NHCH2CO2H) significantly enhanced cytotoxic with GI50 in 
D UDQJH í ȝ0 DJDLQVW WKH WXPRU FHOO OLQHV 7R YDOLGDWH WKH FULWLFDO
requirement of secondary amine at the 3C-position of pyridine, the acetamide 
18b (R = NHCOMe) was replaced by an ethylacetamide (18c, R = 
N(Et)COMe). The substitution was not tolerated, resulting in significantly loss 
of activity. Compound 17 was also tested, but it showed low cytotoxicity. 
Overall, ON01910.Na has potent cytotoxicity with GI50s in a range of 0.031-
0.ȝ0 
In similar experiments, a compound synthesised by my group colleague Mr. 
Anran Hu and coded as AH-123, was also included. As a representative of 
Class II of (E)-styrylsulfonyl methylpyridines, AH-123 (R = NH2, X1 = C, X2 
= N) exhibited potent anti-proliferative activity, resulting in nanomolar GI50 
YDOXHVíQ0DJDLQVWDOOcancer cell lines. 
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7DEOH6XPPDU\RIVWUXFWXUHDQGELRORJLFDODFWLYLW\ 
 
Code 
Structure 72h-MTT cytotoxicity,* GI50 (Pmol/L) 
X1 X2 R 
A2780 
(PDT= 
13.5 ± 3 h152) 
MCF-7 
(PDT= 
30.2 ± 0.7 h153) 
HCT-116 
(PDT= 
18.0 ± 3 h154) 
ON01910.Na C C NHCH2CO2H 0.062 ± 0.040 0.050 ± 0.010 0.031 ± 0.003 
15 TL-66 N C NO2 7.21± 0.950 5.22 ± 0.160 7.43 ± 0.280 
16 TL-68 N C NH2 0.005 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 
18a TL-77 N C NHSO2Me 0.464 ± 0.029 0.78 ± 0.041 0.77 ±0.070 
18b TL-81 N C NHCOMe 7.095 ± 0.962 7.50 ± 1.060 8.219 ± 0.473 
18d TL-94 N C NHCH2CO2Et 0.409± 0.133 0.94 ± 0.010 0.517 ± 0.078 
18e TL-110 N C NHCH2CO2H 0.376 ± 0.093 (? 0.410 ± 0.099 
18f TL-116 N C NHCH2CON
H2 
4.66 ± 0.263 >10 6.59 ± 0.710 
18c TL-105 N C N(Et)COMe 6.28 ± 0.600 >10 >10 
(? AH-123 C N NH2 0.007 ± 0.002  0.006 ± 0.001 0.008 ± 0.001 
17 TL-107 (? (? (? 4.85 ± 0.326 6.41 ± 1.120 4.40 ± 0.220 
 'DWD H[SUHVVHG DV WKH PHDQ  VWDQGDUG GHYLDWLRQ RI WKUHH LQGHSHQGHQW H[SHULPHQWV 3'7
3RSXODWLRQGRXEOLQJWLPH 
 Structure-activity relationship (SAR) 
The established structure activity relationships (SAR) are shown schematically 
in Figure 4.1. SAR analysis suggested that the benzylstyrylsulfones moiety is 
essential for anti-proliferative activity. Substitutions on the benzyl ring system 
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were generally found to be tolerated, but the 2,4,6-trimethoxystyryl moiety is 
important for an optimum potency.68, 131 A recent study also demonstrated that 
the (E)-isomers of styrylbenzylsulfonyl derivatives have higher 
antiproliferative activity compared to the respective (Z)-isomers.136 
By introduction of a pyridinyl ring at different positions (nitrogen in X1 or X2 
in Table 4.1), two novel chemical classes of (E)-styrylsulfonyl methylpyridines 
were generated and showed equivalent activities on cytotoxicity. SAR anylysis 
of styrylbenzylsulfones analogues generated by Reddy et al. indicated that 
DPLQR JURXS DW WKH WKLUG SRVLWLRQ RI DURPDWLF ULQJ LV FULWLFDO IRU FRPSRXQGV¶
activity.61 Therefore, replacements of hydrogen atom in aromatic amine by 
various substituents are expected to be amenable to optimisation. As expected, 
the reported SAR for styrylbenzylsulfones is in harmony with the SAR of the 
(E)-3-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridines generated in house. 
So far as the compounds have been tested, substitutions on the 3C-position of 
pyridinyl ring with electron donating groups, such as amines and hydroxyl, 
afforded analogues with potent cytotoxicity. At the same time, substitutions on 
amino group were compared. Primary amine (16) possesses the best activity, 
while secondary amine with acetates (18d and 18e) exhibited superior potency 
compared with acyl and sulfonyl groups. Furthermore, tertiary amine such as 
ethylacetamide (compound 18c) resulted in significantly loss of activity. These 
observations indicate that repulsive interaction with the potential targets exists 
at this position, and smaller functional group in preferred at the substitution on 
amino group in the future structure optimization. 
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)LJXUH6XPPDU\RIVWUXFWXUHDFWLYLW\UHODWLRQVKLSVRI(-VW\U\OVXOIRQ\O
PHWK\OS\ULGLQHV 
In our study, the molecule with methanesulfonamide group at 3C position (18a, 
TL-77) exhibited desire molecular potency. Methanesulfonamide group, due to 
its low lipophilicity nature, is widely introduced to the target molecules to 
confer physical properties (i.e. logD) and improve binding affinity to the 
enzymes.155, 156 TL-77 should possess improved efficacy and oral 
bioavailability when compared to the benzylstyrylsulfonyl series. 
As the leads of the two chemical series of (E)-styrylsulfonyl methylpyridines, 
TL-68 (16) and AH-123 exhibit similar cytotoxic profiles. Therefore, TL-68, 
TL-77 and AH-123 were selected for detailed primary cellular mode of action 
studies in comparison with ON01910.Na. 
 Discussion 
In attempt to direct recognizing precise kinase inhibition, a kinase screening 
assay performed by MeUFN 0LOOLSRUH¶V .LQDVH3URILOHU ZDV FDUULHG RXW for 
both TL-77 and ON01910.Na (ON01910.Na as the positive control) on six 
potential target proteins, including Aurora-A, Aurora-B, CDK1/cyclinB, PI3 
Kinase SĮSĮ 3, .LQDVH SȕSĮ and Plk1. (Appendix I) 
However, to our surprise, in this cell-free assay, neither compound inhibited 
the activity of Plk1 or PI3K, with no inhibitory effect on tested proteins.  
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The assay format used in KinaseProfiler test in this study is very similar to that 
used in the reported kinases study by Gumireddy et al 53, which proved 
ON01910.Na is a Plk1 inhibitor with the IC50 value of 9 - 10 nM. (Appendix I)  
However, there are a couple of differences that may influence the result. Firstly, 
Gumireddy et al uses a much higher concentration of ATP (1 mM) than used in 
this study (70 uM). Although both compounds are not an ATP competitor, the 
ATP concentration may still make a difference, such as by inducing 
conformational change at the compound binding site. Secondly, Gumireddy et 
al uses a 30-minute pre-incubation of kinases with the compound, a step that is 
not included in our study. Vinyl sulfones (DE-unsaturated sulfones), as good 
electrophiles, are able to readily form covalent adducts with many nucleophiles 
via Michael-type additions. It has been widely reported that vinyl sulfones are 
selective react quicker with thiol groups than with amines or other nucleophiles 
at comparable pKa values and steric environments.157 The preference of vinyl 
sulfones for thiol groups could be utilized to selective targeting the cysteine 
residues in protein structures. Plk1 possesses three cysteines located in the 
active site (Cys 67, Cys 133, and Cys 212).158 Plk1Cys67 involves in molecular 
recognition by Plk1 inhibitors and improvement of the selectivity.159 Moreover, 
other protein kinases are more commonly contain valine at this position, 159, 160 
Therefore, benzylstyrylsulfonyl series (N01910.Na) as well as styrylsulfonyl 
methylpyridines (TL-77) with vinyl sulfones may have interactions with 
unpaired cysteine residues in Plk1. Pre-incubation of kinase with compounds 
may have a considerable effect on the apparent potency if the compound binds 
relatively slowly to the kinase. Therefore, further tests are required to 
determine the effect of compounds on kinases activity.  
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 Primary cellular mode of action 
 Time-dependent anti-proliferation activity 
Anti-proliferative activities of compounds TL-68, TL-77 and AH-123 were 
first assessed by the time-course MTT assays performed using HCT-116 and 
A2780 cells. As presented in  
Table 4.2, all tested compounds increased potency with prolonged time and 
thus demonstrated a time dependent-manner. 
Exposure of three compounds to HCT-116 and A2780 cells using the data from 
time-course MTT assays (Table 4.2) were further presented as plots in 
concentration × time vs time. As presented in Table 4.3 and Figure 4.2, 
ON01910.Na showed general consistent exposure from 24 h to 72 h in both 
cell lines, however, the product of concentration × time in A2780 (~2 Pmol·h) 
is as twice as that in HCT-116 (4.1-5.8 Pmol·h). These observations indicate 
that the anti- proliferative activity of ON01910.Na is cell line specific, and 
HCT-116 cells are more sensitive to this compound. The exposure of TL-77, 
on the other hand, reduced significantly from 91 Pmol·h at 24 h to ~50 Pmol·h 
( 48 h) in HCT-116 cells. (Table 4.3) The same situation could be observed in 
A2780 cells, suggesting drug efficacy of TL-77 in cell culture is improved with 
prolonged time. At the same time, while relatively consistent drug exposure 
(1.49 - 2.6 Pmol·h)  48 h of AH-123 were seen in both cell lines, its drug 
efficacies were largely improved (~0.5 Pmol·h) when the treatment extended to 
72h. (Table 4.3 and Figure 4.2) 
Following 24 h exposure to HCT-116 cells, TL-68, AH-123 and ON01910.Na 
exhibited comparable cytotoxicity with GI50 values ~ 0.06 ȝM, while a GI50 
value of 3.82 ȝM was observed after TL-77 treatment. Consequently, GI50 
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values of 0.06 ȝM and 4 ȝM for respective compounds in HCT 116 cells were 
adopted as agent concentrations used in subsequent assays. 
7DEOH077WLPH-FRXUVHH[SHULPHQWVDJDLQVWKXPDQ+&7-FRORQFDQFHUFHOOVDQG
$RYDULDQFDQFHUFHOOV 
&HOOOLQH &RPSRXQG 
&\WRWR[LFLW\*,PPRO/6' 
K K K 
+&7- 
211D    
7/-    
7/-    
$+-    
$ 
211D    
7/- (? (?  
7/-    
$+-    
7KHGDWDJLYHQDUHPHDQYDOXHVGHULYHGIURPDWOHDVWWKUHHUHSOLFDWHVQ SHUH[SHULPHQW
6' 
7DEOH([SRVXUHRIWKUHHFRPSRXQGVWR+&7-DQG$FHOOVXVLQJWKHGDWDIURP
WLPH-FRXUVH077DVVD\V 
Cell line Compounds 
Exposure, Concentration × Time 
(Pmol·h) 
 
 24h 48h 72h 
HCT-116 ON01910.Na 1.632 2.16 2.232 
TL-77 91.68 48.96 55.44 
AH-123 1.488 2.304 0.576 
A2780 ON01910.Na 5.808 4.128 4.464 
TL-77 41.424 41.28 33.408 
AH-123 2.664 2.16 0.504 
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)LJXUH3ORWVLQFRQFHQWUDWLRQîWLPHYVWLPHRIWKUHHFRPSRXQGVLQ+&7-$DQG
$%FHOOVXVLQJWKHGDWDIURPWLPH-FRXUVH077DVVD\V 
To identify selectivity of compounds between cancer and normal cells, TL-68, 
TL-77, AH-123 and ON01910.Na were further tested against HCT-116 cancer 
cells and human microvascular endothelial HMEC-1 cells after 72h exposure.  
As shown in Figure 4.3, despite their potent anti-proliferative activity against 
HCT-116 cancer cell lines (Figure 4.3 A), TL-68 and AH-123 showed little or 
no selectivity between cancer and normal cells, with high cytotoxicity on 
HMEC-1 cells (Figure 4.3 B). Overall, TL-77 demonstrated 4 fold greater 
potency against HCT-116 compared with normal cell line (HCT-116, GI50 = 
770 nM; HMEC-1, GI50 = 2930 nM). Moreover, no significant selectivity of 
ON01910.Na between cancer cells (HCT-116, GI50 = 31 nM) and normal cells 
(HMEC-1, GI50 = 84 nM) was observed. 
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The positive values on Y axis represent cell growth. Approximate 5% cancer 
cells could still grow after 72 h treatment of TL-77 at the highest tested 
concentration, indicating the cell-kill reached a plateau. A possibility is that 
cells that not in G2/M phase escaped from mitotic block, and entered the next 
round of cell cycle without prior cytokinesis. This could be avoid by extend the 
treatment duration, as the plateau effect could not be observed after 96 h 
exposure (Figure 5.3). Additionally, combination therapy with other mitotic 
inhibitors could also avoid the plateau effect. 
At the same time, the negative values on Y axis represent total cell death. In 
HMEC-1 cells (Figure 4.3 B), total cell death could be seen after all 
compounds treatment (from PM of TL-68 and AH-123, and PM of 
ON01910.Na), while this could not be observed until the concentration reached 
to 10 mM after TL-77 exposure. 
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)LJXUH$QWL-SUROLIHUDWLYHDFWLYLW\LQKXPDQ+&7-FDQFHUFHOOV$DQG+0(&-
FHOOV%E\077KDVVD\V 
7KHGDWDJLYHQDUHPHDQYDOXHVGHULYHGIURPDWOHDVWWKUHHUHSOLFDWHVQ SHUH[SHULPHQW
6' 
 G2/M block on cell cycle effect 
We next investigated whether the anti-proliferative effects of compounds were 
a consequence of cell cycle inhibition that caused activation of the cellular 
apoptosis program. 
Analyses by flow cytometry in HCT-116 cells exposed severe perturbation of 
cell-cycle progression for all compounds (Figure 4.4). The results suggested 
that when treated with DMSO (0.2% v/v), most of the cells accumulated in the 
G1 phase (42.9%) without loss of viability. After treated with ON01910.Na for 
-40
-20
0
20
40
60
80
100
120
140
0.001 0.01 0.1 1 10 100
C
e
ll
 g
ro
w
th
 (
%
)
Concentration (mM)
HMEC-1
ON01910.Na
TL-68
TL-77
AH-123
-20
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
C
e
ll
 g
ro
w
th
 (
%
)
Concentration (mM)
HCT-116
ON01910.Na
TL-68
TL-77
AH-123
A 
B 
  Screening and biological evaluation 
 76 
24h at GI50 and 2×GI50 ȝ0DQGȝ0UHVSHFWLYHO\!RI FHOOV
were arrested in the G2/M phase (enhanced numbers of cells with 2N DNA 
content). Similar cell-cycle profiles were observed with TL-68, TL-77 and AH-
7UHDWPHQWZLWKȝ07/-68 and AH-RUȝ07/-77 resulted in 
accumulation of a respective 49.1%, 50.6% or 55.4% of G2/M cells, 
accompanied by substantial sub-G1 peaks indicating cell death. As the 
treatment concentrations increased to 2×GI50, further G2/M phase arrests and 
increasing sub-G1 peaks were observed for TL-68, TL-77 and AH-123 in 
HCT-116 cells. 
 
)LJXUH&HOO-F\FOHHIIHFWVRI7/-7/-$+-DQG211DRQ+&7-FHOOV 
+&7-FHOOVZHUHWUHDWHGZLWKFRPSRXQGVIRUKDWWKHFRQFHQWUDWLRQVVKRZQ&HOOVZHUH
IL[HGVWDLQHGZLWKSURSLGLXPLRGLGHDQG'1$FRQWHQWZDVDQDO\VHGE\IORZF\WRPHWU\ 
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 Induction of apoptosis 
Types of cell death include apoptosis, autophagy, mitotic catastrophe, necrosis 
and senescence. Cell morphology observation and annexinV/PI double staining 
were used to prove that compounds induced apoptosis in cancer cells. 
 
)LJXUH,PDJHVRIFHOOGHDWKDIWHUWUHDWPHQWRI7/-7/-$+-DQG
211D 
+&7-FHOOVZHUH WUHDWHGZLWKFRPSRXQGVDW*, FRQFHQWUDWLRQV IRUK'062YHKLFOH
WUHDWPHQWZDVXVHGDVQHJDWLYHFRQWURO 
To investigate the morphological changes, HCT-116 cells were seeded into 6-
well plates at 5000/well. Cell images were taken after 24 h treatment with TL-
68, TL-77, AH-123, or ON01910.Na at GI50 concentrations. As illustrated in 
Figure 4.5, HCT-116 cells grew quickly after DMSO vehicle treatment (0.2% 
v/v), with nearly 60-80% confluency. However, after treatment of all 
compounds, the growth of cells was arrested with cell confluency less than 
50%. For DMSO control, cells in the field of view appeared adherent. Cells 
were exhibited in spindle shape with clear, sharp boundaries between them. In 
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contrast, after treated with four compounds, cells display typical apoptotic 
morphology. Cell retraction, dynamic plasma membrane blebbing, cell 
fragments can be clearly detected microscopically (red arrows), suggesting 
cells were undergoing apoptosis. 
To quantify the apoptosis caused by the exposure to compounds, HCT-116 
cells exposed to TL-68, TL-77, AH-123, or ON01910.Na at GI50 and 2×GI50 
for a period of 48 h were analysed by Annexin V and propidium iodide staining. 
As shown in Figure 4.6, all four compounds induced significant apoptosis. 
ON01910.Na was most effective, inducing 45.9 - 48.6% apoptotic cells 
(annexin V-positive/PI QHJDWLYH FHOOV DW FRQFHQWUDWLRQVRIȝ0DQG
ȝ0TL-77 induced apoptosis with 36.4% apoptotic cells at GI50 ȝ0, while 
a more obvious apoptotic effect were observed at 2×GI50 value (42.2%). 
Generally, TL-68 and AH-123 exhibited equivalent apoptotic profiles; 
inducing ~ 37% apoptotic cells at GI50 concentrations. As the concentration 
increase to 2×GI50, ~ 20% of necrotic population (annexin V negative/PI 
positive cells) were observed.  
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)LJXUH7/-7/-$+-DQG211DLQGXFHDSRSWRVLVLQ+&7-FHOOV 
+&7-FHOOVZHUHH[SRVHGWR7/-7/-$+-RU211DIRUKDQGVWDLQHG
XVLQJ ),7&-FRQMXJDWHG $QQH[LQ 9 DQG SURSLGLXP LRGLGH DQG VXEMHFWHG WR IORZ F\WRPHWULF
DQDO\VLV DV GHVFULEHG LQ WKH H[SHULPHQWDO SURFHGXUHV $ $QQH[LQ-QHJDWLYH DQG 3,-SRVLWLYH
GHDGFHOOV$GRXEOH-SRVLWLYHODWHDSRSWRWLFFHOOV$GRXEOHQHJDWLYHOLYHFHOOV$$QQH[LQ
9-SRVLWLYH3,-QHJDWLYHHDUO\DSRSWRWLFFHOOV$OORIWKHDERYHH[SHULPHQWVZHUHUHSHDWHGWKUHH
WLPHVDQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
 Pharmaceutical property assessment 
Biopharmaceutical properties of lead compounds, including lipophilicity and 
metabolic stability, were evaluated by colleagues in Prof :DQJ¶V UHVHDUFK
team in University of South Australia and are summarized in Table 4.4 (for 
more details please refer to the publication Lu T et. al. J Med Chem 2014). 
Compounds TL-68. TL-77 and AH-123 possess favourable physicochemical 
properties. When compared with ON01910.Na, optimal lipophilicities were 
observed in three compounds with the logD7.4 values ranging from 1.52 to 2.41. 
Metabolism was assessed using rat liver microsomal fractions. As shown in 
Table 4.4, while TL-77 exhibited excellent in vitro metabolic stability with a 
half-life of 70 min, TL-68 and AH-123 seemed more rapidly to be cleared in 
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microsomes (t1/2 = 15-20 min). All tested compounds possess excellent aqueous 
VROXELOLW\ ! ȝ0 The apparent permeability coefficients (Papp) were 
obtained from Caco-2 cell transport studies. This assay has been widely used to 
predict in vivo human intestinal absorption of the compounds across the gut 
wall by measuring the rate of transport of a compound across the Caco-2 cells. 
The cells have characteristics that resemble intestinal epithelial cells such as 
the formation of a polarized monolayer, well-defined brush border on the 
apical surface, and intercellular junctions. Assessing transport in both 
GLUHFWLRQVDSLFDOWREDVRODWHUDO$í%DQGEDVRODWHUDOWRDSLFDO%í$DFURVV
the cell monolayer enables an efflux ratio to be determined that provides an 
indicator as to whether a compound undergoes active efflux. The amino-
containing analogues TL-68 and AH-123 were found to be highly permeable 
with apparent permeability coefficients (Papp) of 42.3 × 10í6 and 33.1 × 10í6 
cm/s, respectively, suggesting the potential for high intestinal absorption. The 
efflux ratio (ER) of both compounds was less than 1, indicating that TL-68 and 
AH-123 were not subjected to active efflux that is normally indicated by an ER 
value greater than 2.161 The permeability of TL-77 was ORZHU$í% Papp = 8.9 × 
10í6 cm/s) and the efflux ratio was greater (ER = 5.29), compared to its 
respective amino-counterparts TL-68. 
7DEOH%LRSKDUPDFHXWLFDOSURSHUWLHVRI7/-7/-DQG$+- 
3DUDPHWHU 7/- 7/- $+- 
'LVVRFLDWLRQFRQVWDQW S.DD    
3DUWLWLRQFRHIILFLHQW /RJ'RFWDQROE    
0LFURVRPDOVWDELOLW\ WPLQF    
$TXHRXVVROXELOLW\ P0G ! ! ! 
3HUPHDELOLW\ 
$í%3DSSíFPVH    
%í$3DSSíFPVH    
HIIOX[UDWLRH   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D 'HWHUPLQHG XVLQJ D S+-PHWULF PHWKRG E %\ VKDNH IODVN F 0HDVXUHG E\ GLVDSSHDUDQFH RI
SDUHQW FRPSRXQG IURP D SUHSDUDWLRQ RI UDW OLYHU PLFURVRPHV G 0HDVXUHG E\ WXUELGLPHWULF
VROXELOLW\DVVD\H$SSDUHQWSHUPHDELOLW\FRHIILFLHQWPHDVXUHGE\&DFR-DVVD\(IIOX[UDWLR 
PHDQ%í$3DSSPHDQ$í%3DSS 
To assess potential oral bioavailability, TL-77 was next subjected to 
pharmacokinetic (PK) analysis in mice following a single intravenous (IV) 
dose of 2 mg/kg or an oral (PO) dose of 10 mg/kg. ON01910.Na was included 
in the study as a comparator. The PK analysis was carried out by Cyprotex 
Discovery Ltd. (Macclesfield, UK). Blood samples were collected at 0.030, 
0.080, 0.25, 0.50, 1.0, 2.0, 4.0, 6.0, and 8.0 h. Pharmacokinetic parameters 
calculated included the total area under the plasma concentration-time curve 
(AUC0-t), elimination half-life (t1/2), volume of distribution (Vd), systemic 
clearance (Cl), and oral bioavailability (F). The peak plasma concentrations 
(Cmax) were obtained by visual inspection of the plasma concentration-time 
curves. The PK parameters are shown in Table 4.5. 
A plot of the compounds plasma concentrations versus time is provided in 
Figure 4.7. After PO dosing, plasma concentration-time profiles of TL-77 
displayed a higher plasma concentration than ON01910.Na, which exhibited a 
rapid distribution phase (t  30min) with a relatively slow terminal elimination 
phase. As shown in the figure, eliminations of both compounds included a 
prolonged terminal phase, where low plasma concentrations are sustained.  
TL-77 was shown to have excellent oral bioavailability with F = 56%, good 
half-life (t1/2 = 3.02 h) and AUC (7.2·h PM following PO administration). In 
contrast, ON01910.Na exhibited low oral bioavailability with an F = 9%; the 
half-life was shorter (~ 2.6 h) and low drug exposure in plasma (AUC = 1.0 
ȝ0āK following PO administration). Compared with the GI50s achieved from 
MTT assays (Table 4.2 and Table 5.1), the plasma concentrations of TL-77 at 
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both IV and PO administration reached to high doses (Cmax > 6.3 PM). 
Although the plasma concentration of ON01910.Na is high via IV 
administration (Cmax = 11.7 PM), it only kept at 0.4 PM when being taken 
orally, indicating ON01910.Na was not utilized effectively in vivo. In short, 
TL-77 possesses superior oral bioavailability in single-dose pharmacokinetic 
studies in mice. 
7DEOH3DUDPHWHUVLQSKDUPDFRNLQHWLFVWXGLHVRI7/-LQPLFH 
Variables TL-77 ON01910.Na 
Parameter (Unit) 2mg/kg IV 10mg/kg PO 2mg/kg IV 10mg/kg PO 
Exposure 
Cmax(PM) 9.4 6.3 11.7 0.4 
AUC0-t(PM·h) 2.6 7.2 2.06 1.0 
Elimination t1/2(h) 3.22 3.02 2.53 2.66 
Volume of Distribution Vd(ml/kg) 7699 - 7482 - 
Clearance Cl(ml/min/kg) 27.6 - 33.9 - 
Oral Bioavailability F 56% 9% 
 
)LJXUH3ORWRIPHDQ7/-DQG211DSODVPDFRQFHQWUDWLRQVYHUVXVWLPH
IROORZLQJVKRUWWHUP,9DQG32LQIXVLRQVWRPLFH 
7LPHFRXUVHVRIPHDQSODVPDFRQFHQWUDWLRQVRIFRPSRXQGVIROORZLQJFRQWLQXRXV,9LQIXVLRQV
RIPJNJDQG32 LQIXVLRQVRIPJNJ7/-DQG211D WRKHDOWK\DWK\PLFPLFH
Q ± 
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 Conclusion 
In this chapter, SAR of novel series of (E)-3-((styrylsulfonyl)methyl)pyridine 
derivatives was discussed. Several compounds exhibited potent anti-
proliferative activity in cancer cell lines. Lead compounds TL-68 and AH-123, 
containing an amino group at the respective 2C- and 3C-positions of 
styrylsulfonyl methylpyridine, were the most effective anti-proliferative agents 
in the series. Both of them were potent tumour suppressors (GI50 = 6-8 nM) 
and were >10-fold more potent than ON01910.Na.  
In cellular mode of action studies, TL-68, TL-77 and AH-123 exhibited similar 
cell cycle effect to ON01910.Na in HCT-116 cancer cells, inducing cell cycle 
arrest at the G2/M phase. Cell morphology observation and annexinV/PI 
double staining proved that all the compounds cause the cell death by inducing 
apoptosis in cancer cells. Importantly, despite other three compounds have 
little selectivity between cancer and normal cells, TL-77 exhibited 4-fold 
greater potency against HCT-116 compared with untransformed HMEC-1 cell 
line. TL-68, AH-123, especially TL-77 possess desirable physicochemical 
properties, including favourable lipophilicity (pKa and logD7.4) and metabolic 
stability. In the following pharmacokinetic studies performed in mice, TL-77 
exhibited desirable pharmacokinetic properties (56% bioavailability, good half-
life) in comparison with ON01910.Na, (9% bioavailability). 
These data suggest that TL-77 and analogues represent promising orally 
bioavailable anticancer agents worthy of further evaluation. 
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5 Cellular mechanisms of action of TL-77 
as mitotic kinase inhibitor 
 Introduction 
Identification of the primary target(s) of designed anti-cancer kinase inhibitors 
in cancer cells plays a key role in kinase drug development. In a programme to 
identify a novel chemical series of molecules possessing similar modes of 
action, but improved pharmaceutical properties compared to ON01910.Na, I 
designed and synthesized a novel class of (E)-styrylsulfonyl methylpyridines. 
TL-77, as one of the lead compounds, has shown potent in vitro anti-tumour 
activities and improved oral bioavailability (Figure 5.1). I wished to 
investigated its cellular mechanism of action, as well as determine similarities 
and/or differences in mechanisms of action between TL-77 and ON01910.Na. 
 
)LJXUH&KHPLFDOVWUXFWXUHRI7/-(-1--PHWKR[\---
WULPHWKR[\VW\U\OVXOIRQ\OPHWK\OS\ULGLQ--\OPHWKDQHVXOIRQDPLGH 
 TL-77 is a potent, time-dependent anti-
proliferative agent 
Anti-proliferative activities of TL-77 were first assessed against a panel of 10 
tumour cell lines and 3 untransformed cell lines using a 96 h MTT cytotoxicity 
assay in comparison with ON01910.Na. Tumour cell lines from different organ 
origins were utillized, such as colon, breast, melanoma, ovary, cervix and 
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pancreas. To investigate tumour suppressor expression status sensitivity to the 
compounds, HCT-116 colon carcinoma (HCT-116 p53 (+/+) and HCT-116 p53 
(-/-)), MDA-MB 468 breast (mutant p53, Rb negative) and MDA-MB 435 
melanoma (mutant p53, Rb positive) were included. To test the toxicity of both 
compounds on normal cell lines, microvascular endothelial cells HMEC-1 and 
HUVEC as well as diploid MRC-5 fibroblasts were included. These three cell 
lines are well characterized and commonly used as non-cancerous cell lines for 
in vitro cytotoxicity testing.162-164 The results are presented in Table 5.1. In 
addition, to further identify the sensitivity and selectivity of compounds 
towards cancer cells and non-transformed cells, a mean graph plots of GI50 
values for both compounds are displayed as Figure 5.2. 
As shown in Table 5.1, in general, similar sensitivity was observed for cells 
with different p53 and Rb status for both compounds, indicating their p53 and 
Rb independent anti-proliferative activity. TL-77 displayed potent anti-
proliferative activity against a wide variety of tumour cell lines irrespective of 
tissue origin. It suppressed cancer cell proliferation with GI50 values ranging 
between 317 and 860 nM, but was less potent than ON01910.Na in the same 
cell lines. TL-77 exhibited modest selectivity: as illustrated in Table 5.1 and 
Figure 5.2, TL-77 demonstrated 2-fold greater potency in cancer cell line over 
normal cells. Optimally, 10-fold greater selectivity was observed. (A2780 GI50 
= 317 nM; MRC-5 GI50 =3144 nM) Overall, ON01910.Na was a more potent 
suppressor of tumour cell proliferation in the same cell lines (GI50 = 7-62 nM). 
A safety profile of ON01910.Na on several normal human cell lines (HUVEC 
GI50 !  ȝ0 KDV EHHQ UHSRUWHG61 However, in this study, ON01910.Na 
showed little to no selectivity against non-transformed human cells (GI50 = 30-
51 nM). 
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7DEOH$QWL-SUROLIHUDWLYHDFWLYLW\RI7/-DQG211DDJDLQVWDSDQHORIFHOO
OLQHV 
* Data expressed as the mean ± standard deviation of three independent experiments. ER, 
estrogen receptor; Rb, retinoblastoma protein; PDT, population doubling time. 
Among 10 tested cancer cell lines (Figure 5.2), both compounds showed 
superior toxic effect towards HCT-116 (Colon), MDA-MB-435 (Melanoma) 
and Miapaca-II (Pancreatic) cells, while MCF-7 (Breast), MDA-MB-231 
(Breast) and PANC-1 (Pancreatic) cells were less sensitive to both compounds. 
In general, the anti-proliferative activity responses of most cancer cell lines are 
related to their population doubling time. (Table 5.1) In contrast, although 
possessing the equivalent population doubling levels to some of cancer cells 
(MDA-MB-468 and PANC-1, PDT~ 50 h), non-transformed cells (HMEC-1 
and HUVEC, PDT~ 50 h) showed apparent less sensitive to the compounds. 
Human cell lines 96h-MTT,* GI50 (nM) ± SD 
Origin Destination PDT ON01910.Na TL-77 
Colon carcinoma 
HCT-116 (p53+, Rb+) 18 ± 3 h154 21 ± 5 570 ± 23 
HCT-116 (p53-, Rb+) 20 h165 17 ± 2 860 ± 86 
Breast carcinoma 
MCF-7 (p53+,ER+) 30.2 ± 0.7 h153 50 ± 10 780 ± 25 
MDA-MB 231(p53-,ER-) 27.8 ± 5 h166 55 ± 15 671 ± 56 
Melanoma 
MDA-MB 468 ( p53-,Rb±) 47 h167 39 ± 15 509 ± 130 
MDA-MB 435 ( p53-,Rb+) 25.8 h154 12 ± 2 592 ± 128 
Ovarian carcinoma A2780 13.5 ± 3 h152 62 ± 4 317 ± 179 
Cervical carcinoma Hela 24 h 12 ± 1 682 ± 112 
Pancreatic carcinoma 
Mia-paca II 40 h168, 169 7 ± 2 463 ± 208 
PANC-1 52 h168 39 ± 6 875 ± 274 
Microvascular 
endothelial 
HMEC-1 55 h170 51 ± 2 1681 ± 270 
Umbilical vein 
endothelial 
HUVEC 48 h171 30 ± 1 1110 ± 270 
Lung Fibroblast MRC-5 32.7 ± 6 h172 49 ± 25 3144 ± 832 
  Cellular mechanisms of TL-77 
 87 
 
)LJXUH0HDQJUDSKSORWVRI*,YDOXHVIRU7/-$DQG211D%DJDLQVWD
SDQHORIFHOOOLQHVLQK077DVVD\ 
The mean GI50 for TL-77 and ON01910.Na across cancer cell lines was calculated. Cell lines 
that were more sensitive are displayed as bars to the right of the mean. Cell lines that were less 
sensitive are displayed with bars to the left. Cancer cell lines are represented in orange; non-
transformed cell lines are shown in green.  
Time-dependent anti-proliferative effects were further observed for both 
compounds as exemplified in two well-characterized cancer cell lines, HCT-
116 and A2780 (Figure 5.3). In previous results (Table 5.1), ON01910.Na 
showed ~30-fold more potent anti-proliferative activity than TL-77. To 
improve the accuracy of screening data, 6 testing concentrations ranging from 
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HCT-116
HCT-116 (p53-/-)
MCF-7
MDA-MB 231
MDA-MB 468
MDA-MB 435
A2780
Hela
Mia-paca II
PANC-1
HMEC-1
HUVEC
MRC-5
GI50(nM)
Anti-proliferative activity of ON01910.Na (96 h MTT)B
0 500 1000 1500 2000 2500 3000
HCT-116
HCT-116 (p53-/-)
MCF-7
MDA-MB 231
MDA-MB 468
MDA-MB 435
A2780
Hela
Mia-paca II
PANC-1
HMEC-1
HUVEC
MRC-5
GI50(nM)
Anti-proliferative activity of TL-77 (96 h MTT)A
Mean GI50=632 nM 
Mean GI50=31.4 nM 
  Cellular mechanisms of TL-77 
 88 
ȝ0WRȝ0ZHUHXVHGIor ON01910.Na, which are one tenth of those 
for TL-77 (0.016-ȝM) in time-course MTT assays. 
As displayed in Figure 5.3, after 24 h treatment, TL-77 started to suppress 
tumour cell proliferation from 0.4 ȝM in both HCT 116 and A2780 cells. At 48, 
72 and 96 h time points in both cell lines, TL-77-treated cell numbers 
GHFUHDVHG VKDUSO\ EHWZHHQ  ȝ0 DQG  ȝ0 WUHDWPHQWV Meanwhile, 
remarkable time-dependent growth inhibitions induced by ON01910.Na were 
observed from 0.008 ȝM in both cell lines at tested time points, excepted that a 
moderate cytotoxicity in A2780 cells was observed as early as 24 h 
ON01910.Na exposure. 
Following 24 h exposure to TL-77 or ON01910.Na, GI50 values of 4 ȝM and 
0.06 ȝM respectively in HCT 116 cells, and 2 ȝM and 0.25 ȝM respectively in 
A2780 cells were observed and adopted as agent concentrations used in 
subsequent assays. 
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)LJXUH7LPH-FRXUVHJURZWKLQKLELWLRQFXUYHVRI7/-DQG211D 
+&7-DQG$FHOOVZHUHWUHDWHGZLWKFRPSRXQGVIRUDUDQJHRIFRQFHQWUDWLRQVDWK
KKRUKUHVSHFWLYHO\7KHUDQJHRIFRQFHQWUDWLRQV7/-
ȝ0211Dȝ07KHGDWDJLYHQDUHPHDQYDOXHVGHULYHG
IURPDWOHDVWWKUHHUHSOLFDWHV6' 
 TL-77 inhibits cell cycle progression 
One of the major abnormalities caused by ON01910.Na is the mitotic arrest in 
many tumour cell lines.53 TL-77 has displayed potent anti-proliferative 
activities. Thus, whether this effect was a consequence of inhibition of cell 
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cycle progression that caused activation of the cellular apoptosis programme 
was investigated. 
 Cell cycle analysis of TL-77 and ON01910.Na 
The effects of the two compounds on tumour cell cycle progression were firstly 
assessed by flow cytometry in HCT-116 and A2780 cells. The cells were 
treated with compounds for 6, 12, 18 and 24 h at the concentrations shown in 
Figure 5.4. Analyses by flow cytometry exposed stark time-dependent G2/M 
cell cycle block and enhanced numbers of cells with 4N DNA content after 
treatment of cells with both compounds at GI50 values. 
Particularly in HCT-116 cells (Figure 5.4 A), TL-77 caused accumulation of a 
significant G2/M cells population (>50%) as early as 6 h, while ON01910.Na 
FDXVHGWKHVDPHHIIHFWa*0DUUHVWDIWHUD ORQJHUH[SRVXUHSHULRG
12 K)ROORZLQJWUHDWPHQWRIȝ07/-RUȝ0211DIRUK
55.4% or 70.3% cells respectively arrested in the G2/M phase. Similar cell 
cycle profiles with TL-77 and ON01910.Na were observed in A2780 cells 
(Figure 5.4 %7UHDWPHQWZLWKȝ07/-RUȝ0211DUHVXOWHG
in accumulation of 56% or 29.7% G2/M cells respectively. No such mitotic 
abnormalities were observed in untreated cells. 
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)LJXUH&HOOF\FOHDQDO\VLVRI7/-DQG211DRQFDQFHUFHOOV 
+&7- $ DQG $ % FHOOV ZHUH WUHDWHG ZLWK *, FRQFHQWUDWLRQV RI 7/- RU
211DK&HOOVZHUHIL[HGVWDLQHGZLWKSURSLGLXPLRGLGHDQG'1$FRQWHQWZDV
DQDO\VHGE\IORZF\WRPHWU\ 
Treatment of both cell lines for > 18 h caused accumulation of events 
containing substantial subG1 DNA content, which is an indication of cell death, 
suggesting that the induction of apoptosis might be a consequence of cell cycle 
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arrest. Cell cycle arrest was induced more rapidly when concentrations 
increased to 2xGI50 for both compounds (data not shown).  
As TL-77 was significantly less active in proliferation assays carried out on 
untransformed cells, its cell-cycle effects on HMEC-1 cells was also 
investigated. The cells were treated with TL-77 or ON01910.Na for 6, 12, 18 
and 24 h at the concentrations shown in Figure 5.5. Little or no disturbance of 
cell cycle distribution was observed with TL-77 (in contrast ± 24 h 
ON01910.Na ± substantial preG1). 
 
)LJXUH&HOOF\FOHDQDO\VLVRI7/-DQG211DRQXQWUDQVIRUPHGFHOOV 
+0(&-FHOOVZHUH WUHDWHGZLWK*,FRQFHQWUDWLRQVRI7/-RU211DK&HOOV
ZHUHIL[HGVWDLQHGZLWKSURSLGLXPLRGLGHDQG'1$FRQWHQWZDVDQDO\VHGE\IORZF\WRPHWU\ 
 TL-77 evoked a notable mitotic block 
DNA content analysis alone cannot resolve whether cells are delayed in G2 
phase, entry into mitosis, and/or progression through mitosis. Phosphorylation 
of histone H3 is generally accepted as mitotic marker.173 Therefore, the extent 
of histone H3 phosphorylation and the percentage of cells with condensed 
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mitotic chromosomes was analysed by fluorescence staining (mitotic index 
assay). 
Effects of TL-77 on phospho-histone H3 in HCT-116 cells was analysed by 
Western blot analysis (Figure 5.6). As expected, treatment of ON01910.Na 
after 8 h led to a significant dose-dependent increase in the phospho-histone H3 
content in HCT-116 cells peaking at 0.24 ȝ0. Meanwhile, intense bands of 
phospho-histone H3 were observed in HCT-116 cells exposed to TL-77 at all 
tested concentrations (4-16 ȝ0. This result revealed that TL-77 as well as 
211DLQGXFHGPLWRWLFDFFXPXODWLRQDVDQHDUO\HYHQWKLQFDQFHU
cells.  
 
)LJXUH(IIHFWRI7/-RQSKRVSKRU\ODWHGKLVWRQH+ 
+&7-FHOOVZHUHLQFXEDWHGZLWKLQGLFDWHGFRQFHQWUDWLRQVRI7/-RU211DIRUK
E-$FWLQZDVXVHGDVDQLQWHUQDOFRQWUROIRUSURWHLQORDGLQJ 
The mitotic accumulation induced by both compounds was then quantitatively 
analysed by mitotic index assay. Mitotic index indicates the ratio between the 
number of cells in mitosis and the total number of cells. It is calculated by 
measuring cell nuclei stained with the positive mitosis-specific antibody (anti-
phospho-histone H3) versus total cell nuclei stained with Hoechst. 
HCT-116 cells were treated with TL-77 or ON01910.Na for a period of 6 h or 
12 h and the mitotic index was measured. As displayed in Figure 5.7 A, TL-77 
increased mitotic index in a time- and dose-dependent manner. Following 6 h 
exposure to TL-77 (0.5-2xGI50), a 15% of cells resided in mitosis compared 
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with 2% in control samples. An increased mitotic index (25%) was further 
observed in cells exposed to 4xGI50 TL-77 of (16 ȝ0. After 12 h treatment 
with TL-77, a dramatic dose-dependent increase in mitotic index was observed 
(> 35%; 4 ȝ0-16 ȝ07/-77). ON01910.Na caused less dramatic mitotic arrest. 
At concentrations > 0.06 ȝ0, a gentle dose-dependent increase in mitotic index 
was observed at both 6 h and 12 h (Figure 5.7 B). Only at 4xGI50 value (0.24 
ȝ0 211D ZDV D WLPH-dependent divergence observed (mitotic index 
17% and 27% after 6 h and 12 h respectively). 
 
)LJXUH&HOOF\FOHVWDWXVRI7/-DQG211DGHWHFWHGE\PLWRWLFLQGH[LQ+&7-
FHOOV 
+&7- FHOOV ZHUH WUHDWHG ZLWK FRQFHQWUDWLRQV RI 7/- $ RU 211D % DQG
LQFXEDWHGIRUKDQGK$IWHUIL[DWLRQLQSDUDIRUPDOGHK\GHFHOOVZHUHWUHDWHGZLWK3-
KLVWRQH + DQWLERG\ DQG +RHFKVW 7KH FHOOV ZHUH DQDO\VHG E\ FRQIRFDO ODVHU PLFURVFRS\
9HUWLFDO EDUV UHSUHVHQW WKH PHDQV  6' RI DW OHDVW  LQGHSHQGHQW H[SHULPHQWV Q    SHU
H[SHULPHQW9DOXHVVLJQLILFDQWO\SGLIIHUHQWIURP'062YHKLFOHFRQWUROZHUHPDUNHG
ZLWKDQDVWHULVN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)LJXUH&HOOF\FOHVWDWXVRI7/-DQG211DSORWWHGEDVHGRQPLWRWLFLQGH[DQG
FHOOF\FOHLQ+&7-FHOOV 
$ SORW RI PLWRWLF LQGH[ FRPSDUHG ZLWK WKH GDWD IURP FHOO F\FOH DQDO\VLV 7/- $ RU
211D%7KHSRSXODWLRQPHDQRIFHOOVLQ*SKDVHZDVREWDLQHGE\VXEWUDFWLQJPHDQ
RI PLWRWLF LQGLFHV IURP PHDQRI*0YDOXHV DW FRUUHVSRQGLQJ FRQFHQWUDWLRQV P*  P*0-
P0LWRVLV 7KH SRSXODWLRQ RI FHOOV LQ *0 SKDVH DQG PLWRVLV ZHUH FRQVLGHUHG DV WZR UDQGRP
YDULDEOHV7KH VWDQGDUGGHYLDWLRQ LVDGRSWHGDVܵܦ ? ?ൌ ඥV ? ?Ȁ ?൅ V ? ?Ȁ ?V DQGV DUH
WKH SRSXODWLRQ YDULDQFHV IRU WKH SRSXODWLRQ RI FHOOV LQ *0 DQG PLWRWLF UHVSHFWLYHO\ P
SRSXODWLRQRIFHOOV 
Plots of mitotic index (detailing % mitotic cells in a given population) 
compared with data from cell cycle analyses (detailing G2/M events) are 
provided in Figure 5.8. By subtracting mitotic indices from G2/M values, the 
population of cells in G2 phase could be obtained. Data in Figure 5.8 A 
demonstrate that TL-77 evoked a notable mitotic block (6 h-12 h exposure). 
Whereas, numbers of TL-77 (1-2 GI50) -treated cells in G2 phase remained 
stable at 6 h. In addition, ~20% increased G2 events was noticed when TL-77 
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exposure extended to 12 h at 2xGI50 (8 ȝ0). In contrast, ON01910.Na-treated 
cells revealed a less significant but dose-dependent mitotic block (Figure 5.8 
B). At 6 h, ON01910-treated cells started to arrest in G2 phase (~10%) at 
2xGI50. Furthermore, after 12 h treatment ON01910.Na sharply increased the 
numbers of cells in G2 phase (~20%-25%) at both GI50 and 2xGI50. These 
results are consistent with cell cycle observations (Figure 5.4 A), where more 
rapid cell cycle arrest was observed in cells exposed to TL-77. 
 TL-77 induces spindle abnormalities 
 TL-77 inhibits microtubule polymerization 
In view of the remarkable effects of the compounds on cell cycle progression, a 
biochemical assay was adopted to then examine whether either compound 
affected tubulin polymerization. Two known compounds, paclitaxel and 
nocodazole were set as the positive and negative controls, respectively. 
Paclitaxel binds to tubulin to suppress dissociation of microtubules175, and 
promotes polymerization of purified tubulin. In contrast, nocodazole inhibits 
PLFURWXEXOHSRO\PHUL]DWLRQE\ELQGLQJ WRȕ-tubulin and preventing formation 
of one of the two interchain disulfide linkages between tubulins.176, 177  
The two compounds¶ effects on microtubule polymerization were compared at 
0.5xGI50, GI50 and 1.5xGI50 for TL-77, GI50 and 2xGI50 for ON01910.Na. 
During preparation of the tubulin polymerization assay, slight precipitation of 
TL-77 at 8 ȝ0 (2xGI50 value) in H2O solution was observed. Consequently, a 
concentration of ȝ01.5xGI50) was applied instead. The results are shown in 
representative traces in Figure 5.9. TL-77 displayed a dose-dependent effect on 
microtubule formation (Figure 5.9 A). Similar to DMSO control (0.2% v/v), no 
influence on microtubule polymerization was observed after incubation of 2 
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ȝ07/-77. As the concentrations increased to 4 ȝ0DQG6 ȝ0 TL-77 acted as 
a microtubule suppressor in a similar manner to nocodazole. Similar results 
were obtained with ON01910.Na DW  ȝ0 DQG  ȝ0 (Figure 5.9 B). 
These data indicate that both compounds potently suppress microtubule 
polymerization in a manner similar to nocodazole at tested concentrations. 
 
)LJXUH7/-DQG211DLQKLELWHGWXEXOLQSRO\PHUL]DWLRQ 
7XEXOLQ SRO\PHUL]DWLRQ ZDV PHDVXUHG DFFRUGLQJ WR WKH DVVD\ FRQGLWLRQV GHVFULEHG LQ
([SHULPHQWDO3URFHGXUHV3DFOLWD[HODQGQRFRGD]ROHZHUHXVHGDVDGGLWLRQDOFRQWUROVNQRZQWR
HQKDQFHRUSUHYHQW WXEXOLQSRO\PHUL]DWLRQUHVSHFWLYHO\$7/-DQG%211DDUH
FRPSDUHGZLWKFRQWURO 
% 
0.00
0.05
0.10
0.15
0.20
0 20 40 60
Ab
so
rp
tio
n 
(O
D 
at
 
34
0 
n
M
)
Time (minute)
DMSO
PAC
NOC
ON01910 0.06uM
ON01910 0.12uM
$ 
0.00
0.05
0.10
0.15
0.20
0 20 40 60
Ab
so
rp
tio
n 
(O
D 
at
 
34
0 
n
M
)
Time (minute)
DMSO
PAC
NOC
TL-77 2uM
TL-77 4uM
TL-77 6uM
  Cellular mechanisms of TL-77 
 99 
 TL-77 perturbs spindle assembly in HCT-116 cells 
To examine whether TL-77 could induce abnormal mitotic spindles in cancer 
cells, the spindle architecture was next examined using confocal microscopy. 
Immunofluorescent staining using anti-Į-tubulin antibody was performed.  
After 12 h DMSO treatment (0.2% v/v), interphase cells were observed with 
bipolar mitotic spindles (Figure 5.10 A). As depicted in Figure 5.10 B, both 4 
ȝ0 and 8 ȝ0TL-77 caused remarkable inhibition of microtubule assembly in 
treated cells. The phenotypes caused by TL-77 included abnormal mitotic 
spindle formation with tri- or multipolar spindles, chromosome misalignment, 
and complete loss of coordination in mitotic spindle assembly (red arrows). 
Monopolar spindles with circular chromosome arrangements, which are 
indicative of a centrosome separation failure, were also observed (white 
arrows). Meanwhile, abnormal mitotic spindle formation was also observed in 
cells after ON01910.Na treatment (Figure 5.10 C). Instead of generating 
multipolar spindles, cells exhibited fragmented microtubules following 
exposure to ON01910.Na, resulting in prevention of cell division. Paclitaxel 
and nocodazole were used in this study as positive and negative controls. Cells 
treated with paclitaxel displayed stabilized microtubules, accompanied by 
misaligned chromosomes (Figure 5.10 D). Microscopy of nocodazole-treated 
cells shows that they enter mitosis but cannot form metaphase spindles because 
microtubules cannot polymerize (Figure 5.10 E). 
  Cellular mechanisms of TL-77 
 100 
 
)LJXUH7/-LQGXFHGVSLQGOHDVVHPEO\DQGFKURPRVRPHDOLJQPHQWLQ+&7-FHOOV 
+&7- FHOOV ZHUH WUHDWHG ZLWK '062  YY 7/- 211D SDFOLWD[HO RU
QRFRGD]ROHIRUKIL[HGZLWKSDUDIRUPDOGHK\GHDQGWUHDWHGZLWKDQWL-Į-WXEXOLQDQWLERG\
JUHHQ ),7& FRQMXJDWHG DQG +RHFKVW EOXH 7KH FHOOV ZHUH DQDO\VHG E\ FRQIRFDO ODVHU
PLFURVFRS\$UURZVLQGLFDWHPLWRWLFVSLQGOHDEQRUPDOLWLHVDQGFKURPRVRPDOPLVDOLJQPHQW 
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 Discussion 
In cell-IUHHFRQGLWLRQV211Dȝ0DQGȝ0DVZHOODVTL-77 
(4 ȝ0DQG6 ȝ0VXSSUHVVHGPLFURWXEXOHformation, acting in a similar manner 
to nocodazole.  
However, minor inhibition or no effects of ON01910.Na on tubulin 
SRO\PHUL]DWLRQ DW  ȝ0 DQG  ȝ0 UHVSHFWLYHO\ KDV EHHQ UHSRUWHG53, 178 The 
apparent inconsistencies could be due to the differences in the experimental 
setup, such as testing buffer and compound concentrations. As mentioned by 
the manufacturer (refer to Material and Methods), glycerol (e.g. 10%) will 
result in enhanced polymerization. To sensitize the reaction, assay optimization 
of using G-PEM buffer minus glycerol is suggested. Therefore, I took this 
advice and glycerol was not included in this tubulin polymerization assay. 
According to published work, effect of ON01910.Na on tubulin polymerization 
were examined using G-PEM buffer in three glycerol concentrations (10%, 15% 
and 20%).119 No results of tests performed in glycerol-free buffer were reported 
and the quantitative influence of glycerol concentrations on this assay is not 
clear so far.  
But the consistency between the data sets in this study illustrated the 
reproducibility of tubulin polymerization results, Moreover, several reported 
experimental evidence have suggested that ON01910.Na is an inhibitor of 
tubulin polymerisation; cells with depolymerized microtubules were observed 
after treated with higher doses (2.5 PM) of ON01910.Na.97-99 Therefore, based 
on our observation, it is concluded that inhibition of tubulin polymerization is 
an important molecular mechanism of action of TL-77 as well as ON01910.Na.  
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The mitotic spindle is critical for segregation of chromosomes to two daughter 
cells during mitosis. Failure of sister chromatids to attach to microtubules 
results in prolonged cell cycle arrest and caspase-dependent apoptosis.179 
Several mitosis-specific protein kinases are required to organize the bipolar 
spindle assembly and chromosome bi-orientation, including Cdc2, Aurora B 
and Plk1.99 Plk1 has been identified to be a key player for G2/M transition and 
mitotic progression in both normal and tumour cells.24 In late G2 phase and 
mitosis, Plk1 is essential for centrosome maturation, separation and mitotic 
spindle assembly.84 Mutation of Polo leads to mitotic accumulation of cells that 
contain monopolar spindles, spindles with broad poles, or multipolar 
spindles.180 Immunofluorescence staining of D-tubulin revealed that TL-77 
promoted disassociation of microtubules, and inhibited mitotic spindle 
assembly, leading to formation of multipolar spindles and misalignment of 
chromosomes in vitro. This outcome is very similar to the phenotype observed 
with Plk1-depleted cells, which arrested in prometaphase with lack of spindle 
pole focusing and unstable attached chromosomes.180 Taken together with cell 
cycle data, these observations suggest TL-77 inhibits tubulin polymerization, 
induces spindle abnormalities and results mitotic block. 
 Effect of TL-77 on cell cycle regulators 
To explore the molecular consequences of TL-77 exposure, we then sought to 
assess factors that may indicate the degree of Plk1 and G2/M checkpoint 
inhibition. The cell cycle inhibition after exposure to TL-77 is correlated with 
Cdc25c activity (measuring total and phospho-Cdc25c) and cyclin B1 
expression levels. 
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In eukaryotic cells, initiation of mitosis is triggered by activation of the 
Cdc2/cyclin B1 complex, the µPLWRVLV-SURPRWLQJ IDFWRU¶ Cdc25c regulates 
Cdc2/cyclin B1 activity and controls entry into mitosis.181, 182 Cdc25c has been 
described to be phosphorylated by Plk1 at Ser198 and therefore represents a 
direct substrate of Plk1.24 Previous work reported that ON01910.Na inhibits 
activation of the phosphatase Cdc25c as one of its primary intracellular 
effects.53, 96 Cdc25c from interphase cells was found to migrate as a 54 to 57 
kDa doublet in SDS gels and exhibited basal phosphatase activity. In cultures 
enriched for mitotic cells, Cdc25c migrated at 66 kDa and exhibited elevated 
phosphatase activity.183 
HCT-116 and A2780 cells were treated with TL-77 and ON01910.Na for 8 h. 
Cell lysates were immune-blotted with antibodies against phospho-Cdc25c 
(Ser198), Cdc25c and cyclin B1. The results and quantification of western blot 
(presented as fold change compared to control) are displayed in Figure 5.11. 
Dramatically reduced phosphorylation of Cdc25c (Ser198) caused by both 
compounds were observed in both cell lines after 8 h treatment. 40-70% 
phosphorylation of Cdc25c (Ser198) compared to control were inhibited by 
TL-77 (1-4xGI50) in HCT-116 cells, while 50- 90% phosphorylation of Cdc25c 
(Ser198) were inhibited by TL-77 (1-4xGI50) in A2780 cells. Similarly, 
ON01910.Na treatment also caused equivalent reduced levels of phospho-
Cdc25c.  
Additionally, activity of Cdc25c was determined with total Cdc25c antibody 
(Figure 5.11 second lane). As expected, a significant electrophoretic shift of 
Cdc25c from 54- 57 kDa to 66 kDa was visualized in TL-77-treated cells 
compared with control, indicating the conversion of interphase to mitotic 
Cdc25c when cells enter mitosis. ON01910.Na treatment also resulted in 
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increase in the electrophoretic mobility of Cdc25c starting from 0.12 ȝ0 LQ
HCT-FHOOVDQGȝ0LQ$FHOOVUHVSHFWLYHO\,QDGGLWLRQit is noticed 
that the differential electrophoretic mobility of Cdc25c closely correlated to the 
abrogation of phospho-Cdc25c at Ser198. Therefore, it is highly likely that the 
differential electrophoretic mobility of Cdc25c in cells treated with both TL-77 
and ON01910.Na may be due to inhibition of phosphorylation at Ser198. 
Immunoblot analyses revealed that cyclin B1 accumulated in lysates of cells 
treated with TL-77 or ON01910.Na (8 h), indicating cells accumulated in a 
mitotic state. Suppression of cyclin B1 was detected in TL-77-treated cells (16 
ȝ0DVZHOODV21-WUHDWHGFHOOVȝ0DIWHU24 h treatment (Figure 
5.11).  
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)LJXUH(IIHFWRI7/-RQFHOO-F\FOHUHJXODWRUV 
+&7- DQG $ FHOOV ZHUH LQFXEDWHG ZLWK LQGLFDWHG FRQFHQWUDWLRQV RI 7/- DQG
211D IRU  K RU  K $UURZV GLIIHUHQW HOHFWURSKRUHWLF PRELOLWLHV RI &GFF (TXDO
ORDGLQJ RI O\VDWHV LQ HDFK LPPXQREORW ZDV FKHFNHG XVLQJ DQ DQWLERG\ DJDLQVW E-DFWLQ 7KH
:HVWHUQEORWUHVXOWVZHUHTXDQWLILHGDQGVWDWLVWLFDODQDO\VLVZDVSHUIRUPHG3$OORI
WKH DIRUHPHQWLRQHG H[SHULPHQWV ZHUH UHSHDWHG WKUHH WLPHV DQG D UHSUHVHQWDWLYH UHVXOW LV
VKRZQ 
We next examined the effect of TL-77 on expression of the major cell cycle 
regulator cyclin D1. HCT-116 and A2780 cells were treated with TL-77 in 
parallel with ON01910.Na. As shown in Figure 5.12Error! Reference source 
not found., after 8 h treatment, expression of cyclin D1 was significantly 
inhibited in ON01910.Na-treated cells at 0.24 ȝM (4xGI50) and TL-77-treated 
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cells from  ȝM (2xGI50) in HCT-116 cells, while only minor inhibition of 
cyclin D1 expression was observed for both compounds at 4xGI50 in A2780 
cells.  
 
)LJXUH(IIHFWRI7/-DQG211DRQF\FOLQ'H[SUHVVLRQ 
+&7- DQG $ FHOOV ZHUH LQFXEDWHG ZLWK LQGLFDWHG FRQFHQWUDWLRQV RI 7/-
211DIRUKE-$FWLQZDVXVHGDVDQLQWHUQDOFRQWUROIRUSURWHLQORDGLQJ7KH:HVWHUQ
EORW UHVXOWV ZHUH TXDQWLILHG DQG VWDWLVWLFDO DQDO\VLV ZDV SHUIRUPHG 3   $OO RI WKH
DIRUHPHQWLRQHGH[SHULPHQWVZHUHUHSHDWHGWKUHHWLPHVDQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
 Discussion 
Mitotic entry is triggered by a steep increase in cyclin B/Cdc2 activity.184 Plk1 
is suggested to regulate cyclin B/Cdc2 activity at several levels: it activates the 
phosphatase Cdc25c thereby triggering a dual positive amplification loop with 
cyclin B/Cdc2 - phosphorylating cyclin B1 and targeting it to the nucleus.185, 186 
The Xenopus Polo-like kinase Plx1 was shown to directly activate the 
phosphatase Cdc25c and depletion of Plx1 significantly delays both Cdc25c 
and cyclin B/Cdc2 activation.187 In mammalian cells, Plk1 phosphorylates 
Cdc25c on Ser198 and regulates nuclear translocation of Cdc25c.182 According 
to Schmidt et al., phosphorylation at Ser198 of Cdc25c has been suggested to 
serve as a reliable marker to track inhibition of Plk1 by small-molecule 
inhibitors in a cellular context.24  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1 2 4 1 2 4
cyclin D1 cyclin D1
HCT-116 A2780
re
la
ti
v
e
 i
n
te
n
si
ty
 (
fo
ld
 c
h
a
n
g
e
 c
o
m
p
a
re
 t
o
 c
o
n
tr
o
l)
ON01910
TL-77
* 
* 
* 
* 
* 
* 
  Cellular mechanisms of TL-77 
 107 
ON01910.Na is reported to inhibit Plk1 and decrease activity of Cdc25c.53, 96 
However, inconsistent effects of ON01910.Na on cyclin B/Cdc2 activity have 
been described.78, 96, 188 In this study, TL-77 effectively inhibited 
phosphorylation of Cdc25c at Ser198. Additionally, lack of phospho-Cdc25c at 
Ser198 could be correlated with the differential electrophoretic mobility from 
55-57 kDa to 66 kDa in total Cdc25c caused by TL-77 treatment.  
Minor effects on cyclin B1 were observed after 8 h treatment for both 
compounds in both cell lines. Besides, data from mitotic index analysis 
indicated that TL-77 evoked a notable mitotic block (6 h-12 h exposure). TL-
77 suppressed Cdc25c activity and the cyclin B1/Cdc2 complex still remained 
active. We therefore extrapolate that cells eventually entered mitosis during 
HDUO\ VWDJHV RI WUHDWPHQW   K ,W LV PRUH OLNHO\ WKDW TL-77 inhibits the 
tubulin polymerization; cells consequently become blocked at the mitosis 
checkpoint with the outcome of multipolar spindles and misaligned 
chromosomes. Moreover, the dramatic influence caused by TL-77 on 
phosphorylation of mitotic regulators, such as Cdc25c and histone H3, indicate 
this compound also interact with the activity of kinase(s) which mediate 
mitotic checkpoint, such as Plk1.29 Further investigations are still required. 
+RZHYHU OHVVHIILFLHQWO\*0DUUHVWV KZLWKPLOG mitotic blocks were 
observed after exposure to ON01910.Na, suggesting a defect in mitotic entry. 
Meanwhile, instead of generating multipolar spindles, cells exposed to 
ON01910.Na exhibited fragmented microtubules. This may be due to the 
multi-targeted nature of ON01910.Na in cancer cells, which still requires 
further exploration. 
After 24 h treatment, suppressed expression of cyclin B1 was observed in 
ON01910-WUHDWHG FHOOV  ȝ0 DV ZHOO DV 7/-77-WUHDWHG FHOOV  ȝ0
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Moreover, mitotic index analyses have shown increasing G2 arrest in cells after 
treatment of both ON01910.Na and TL-77 (2xGI50 only > 12 h). These data 
confirm the hypothesis that by inhibiting Cdc25c activity, both compounds 
maintain Cdc2 in its inactive state after longer exposure to compounds (12-24 
h). Consequently, cells fail to traverse mitosis and become blocked in the 
G2/M phase of the cell cycle. These observations indicate a multi-faceted 
mechanism culminating in mitotic inhibition in cancer cells for both 
compounds. 
 Inhibition of PI3K/Akt/mTOR signal 
transduction caused by TL-77 
ON01910.Na has been reported to inhibit PI3-K/Akt/mTOR signal 
transduction as the major target with suppression of cyclin D1, and activation 
of apoptosis.78 Cyclin D1 down-regulation was observed in both HCT-116 
(dramatically) and A2780 (mild) cell lines after TL-77 treatment. To determine 
whether TL-77 modulate PI3K/Akt/mTOR signalling, western blot expression 
of key effectors of the Akt/mTOR pathway was examined. Akt, a family of 
serine/threonine kinases, is the primary receptor of phosphoinositide 3-kinase 
(PI3K)-initiated signalling and controls essential cellular activities through 
phosphorylation of a number of downstream effectors.102, 107 Through 
phosphoinositide-dependent protein kinases (PDKs), PI3K activates Akt, 
which in turn phosphorylates (thereby activating) mTOR protein at Ser 2448. 
Western blot analysis detecting phosphorylated Akt Ser 473 revealed that TL-
77  4 ȝM) significantly inhibited Akt phosphorylation in HCT-116 cells, 
suggesting that TL-77 negatively regulates Akt in the same manner as 
ON01910.Na (Figure 5.13). To determine whether TL-77 inhibits effectors that 
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function upstream of Akt, we examined phosphorylation of PDK1, which is 
known to have a central function in Akt activation.189 Western blot analysis 
revealed that phosphorylation of PDK1 was down-regulated in a dose-
dependent manner by both compounds in HCT-116 cells. Complete inhibition 
of PDK1 phosphorylation was observed after 8 h exposure of cells to 4xGI50 
TL-77 (16 ȝM) and ON01910.Na (0.24 ȝM) (Figure 5.13). But the treatment 
with both compounds for 8 h minimally affected the phosphorylated Akt and 
PDK1 in A2780 cells (Figure 5.13). 
The impact of TL-77 on downstream effectors of Akt was further investigated. 
One known Akt substrate is a 40 kDa, proline-rich protein (PRAS40) that binds 
mTOR to transduce Akt signals to the mTOR complex. Phosphorylation of 
PRAS40 by Akt at Thr 246 helps to reduce PRAS40 inhibition of mTORC1. 
190
 Although ON01910.Na reduced phosphor-PRAS40 at 0.24 ȝ0, which is 
first reported here, only minor inhibition of PRAS40 phosphorylation was 
observed in TL-77-treated HCT-116 cells. This observation was confirmed in 
A2780 cells. (Figure 5.13) Subsequently, ON01910.Na treatment significantly 
reduced phosphorylation of mTOR in both cell lines. Although treatment with 
TL-77 for 8 h did not induce changes in the phosphorylation status of mTOR in 
HCT- FHOOV D GUDPDWLF LQKLELWLRQ ZDV VKRZQ DW  ȝM in A2780 cells. 
(Figure 5.13) In addition, it was observed that neither compound affected 
expression of PTEN in HCT-116 cells, the 3¶ phosphatase major tumour 
suppressor protein and inhibitory regulator of PI3K/Akt signalling. (Figure 
5.13) 
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)LJXUH(IIHFWRI7/-RQWKH$NWP725VLJQDOWUDQVGXFWLRQSDWKZD\ 
+&7- DQG $ FHOOV ZHUH LQFXEDWHG ZLWK LQGLFDWHG FRQFHQWUDWLRQV RI 7/-
211D IRU  K 7KH FHOOV ZHUH O\VHG DQG VXEMHFWHG WR :HVWHUQ EORW DQDO\VLV XVLQJ
LQGLFDWHGDQWLERGLHV(TXDOORDGLQJZDVFRQILUPHGLQHDFKODQHE\VWULSSLQJDQGUHSURELQJWKH
EORWV ZLWK HLWKHU DQWL-$NW DQWLERG\ VHFRQG SDQHO RU DQWL-P725 DQWLERG\ VL[WK SDQHO E-
$FWLQ ZDV XVHG DV DQ LQWHUQDO FRQWURO IRU SURWHLQ ORDGLQJ 7KH :HVWHUQ EORW UHVXOWV ZHUH
TXDQWLILHG DQG VWDWLVWLFDO DQDO\VLV ZDV SHUIRUPHG 3   $OO RI WKH DIRUHPHQWLRQHG
H[SHULPHQWVZHUHUHSHDWHGWKUHHWLPHVDQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
The PI3K/Akt pathway is a well-characterized cell survival signalling pathway 
that blocks apoptosis and promotes survival and growth in cancer cells.191 TL-
77, as well as ON01910.Na, inhibited the phosphorylation of Akt and PDK1. 
While ON01910.Na down regulated phosphor-mTOR in both cell lines, 
suppression of phosphor-mTOR is cell line specific following treatment with 
TL-77 (A2780 only). Also, the suppression of phosphor-PRAS40 were 
observed in ON01910.Na-treated cells at 4xGI50 for both cell lines, while only 
a moderate inhibition was detected at 16 ȝM (4xGI50) in HCT-116 cells after 
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treated with TL-77. Taken together, these results indicate that TL-77 inhibits 
PI3K/Akt/mTOR signal transduction; however, compared with ON01910.Na, 
arrest of PI3K/Akt/mTOR signalling by TL-77 appears to be less significant 
and cell line-specific. 
 Molecular mechanism of TL-77-induced 
apoptosis 
Apoptosis is a major form of cell death, characterized by a series of distinct 
morphological and biochemical alterations.192 A series of typical apoptotic 
morphological changes in cell structure after exposures to TL-77 as well as 
ON01910.Na were clearly detected (refer to Chapter Three). The molecular 
mechanisms of TL-77-mediated apoptosis in HCT-116 and A2780 cell lines 
were further explored. 
 AnnexinV/PI double staining 
One of the earlier events of apoptosis includes translocation of membrane 
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma 
membrane. AnnexinV is a Ca2+ dependent phospholipid-binding protein that 
binds tightly to PS. Fluorochrome-labeled Annexin V binds to cells with 
exposed PS, therefore, serves as a sensitive probe for flow cytometric analysis 
of cells in the early stages of apoptosis.193 
Propidium iodide (PI) is a fluorescent molecule that is used as a DNA stain to 
evaluate cell viability or DNA content in cells. Healthy cells with intact 
membranes exclude PI, whereas PI can penetrate the membranes of dead cells. 
Staining with FITC annexinV is usually used in conjunction with PI to 
differentiate necrotic, apoptotic and normal cells. Cells that are considered 
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viable are both Annexin V and PI negative; while early apoptotic cells are 
FITC annexin V positive and PI negative, and cells in late apoptosis or already 
dead are both Annexin V and PI positive. Progression through these three 
stages can be used to confirm cell apoptosis. 
Induction of apoptosis by TL-77 or ON01910.Na was analysed by Annexin 
V/PI double staining in HCT-116 and A2780 cancer cells following treatments 
for 24 h and 48 h. As illustrated in Figure 5.14, both TL-77 and ON01910.Na 
induced apoptosis in dose- and time-dependent manners in both cancer cell 
lines. TL-77 induced HCT-116 apoptosis at GI50 and 2xGI50 YDOXHVȝ0DQG
ȝ0UHVSHFWLYHO\KH[SRVXUH with maximal effect after 48 h treatment, 
whereas ON01910.Na triggered apoptosis more slowly than TL-77 (minor 
effect at 24 h, clear effect at 48 h) (Figure 5.14 A). A2780 cells appeared more 
sensitive to ON01910.Na and TL-77; both TL-77 and ON01910.Na at GI50 
effectively
 
induced apoptosis with > 30% (24 h) and > 60% (48 h) cells 
undergoing through early apoptosis (Figure 5.14 B). These time-dependent 
observations are consistent with cell cycle effects. 
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)LJXUH,QGXFWLRQRIDSRSWRVLVE\7/-DQG211DLQFDQFHUFHOOV 
$ +&7- DQG % $ FHOOV ZHUH H[SRVHG WR GLIIHUHQW FRQFHQWUDWLRQV RI 7/- RU
211D  K RU  K DQG VWDLQHG XVLQJ ),7&-FRQMXJDWHG $QQH[LQ 9 DQG SURSLGLXP
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LRGLGHFHOOVSHUVDPSOHZHUHVXEMHFWHGWRIORZF\WRPHWULFDQDO\VHVDVGHVFULEHGLQWKH
H[SHULPHQWDOSURFHGXUHV$$QQH[LQ-QHJDWLYHDQG3,-SRVLWLYHGHDGFHOOV$GRXEOH-SRVLWLYH
ODWHDSRSWRWLFFHOOV$GRXEOHQHJDWLYHOLYHFHOOV$$QQH[LQ9-SRVLWLYH3,-QHJDWLYHHDUO\
DSRSWRWLFFHOOV$OORI WKHDERYHH[SHULPHQWVZHUH UHSHDWHG WKUHH WLPHV DQGD UHSUHVHQWDWLYH
UHVXOWLVVKRZQ 
Induction of apoptosis was also tested in untransformed HMEC-1 cells after 
exposure to TL-77 or ON01910.Na for 24 h and 48 h (Figure 5.15). 
Importantly, HMEC-1 cells were less sensitive to TL-77 treatment compared to 
the cancer cell lines. Only ~ 13% - 18% apoptotic cells were detected 
following treatment with TL-77, which were 2 fold lower than apoptotic HCT-
116 cells (~ 26% - 36%) at same concentration (4PM in Figure 5.14 A). In 
contrast, ON01910.Na induced detectable apoptosis (~ 21% - 36%) in HMEC-
 FHOOV DW  ȝ0 VKRZLQJ PLQLPDO VHOHFWLYLW\ WRZDUGV FDQFHU RYHU QRUPDO
cells. These results are consistent with corresponding activities in the growth 
inhibition assays. 
 
)LJXUH,QGXFWLRQRIDSRSWRVLVE\7/-DQG211DLQQRQ-WUDQVIRUPHGFHOOV 
+0(&-FHOOVZHUHH[SRVHGWRGLIIHUHQWFRQFHQWUDWLRQVRI7/-RU211DKRUK
DQGVWDLQHGXVLQJ),7&-FRQMXJDWHG$QQH[LQ9DQG3,FHOOVSHUVDPSOHZHUHVXEMHFWHG
WRIORZF\WRPHWULFDQDO\VHVDVGHVFULEHGLQWKHH[SHULPHQWDOSURFHGXUHV$$QQH[LQ-QHJDWLYH
DQG3,-SRVLWLYHGHDG FHOOV$ GRXEOH-SRVLWLYH ODWH DSRSWRWLF FHOOV$ GRXEOHQHJDWLYH OLYH
FHOOV$$QQH[LQ9-SRVLWLYH3,-QHJDWLYHHDUO\DSRSWRWLFFHOOV$OORIWKHDERYHH[SHULPHQWV
ZHUHUHSHDWHGWKUHHWLPHVDQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
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 TL-77 induces caspase-dependent apoptosis 
Apoptotic signalling mainly converges in the activation of caspases, which 
propagate death signalling by cleaving key cellular proteins.117 Induction of 
caspase 3/7 activity therefore was examined in HCT-116 and HMEC-1 cells 
after 24 h treatment either with TL-77 or ON01910.Na. Results in Figure 5.16 
demonstrate that TL-77 dose-dependently enhanced caspase 3/7 activities in 
HCT-116 cells compared with DMSO control (0.2% v/v) at FRQFHQWUDWLRQV
ȝ0 (0.5xGI50), confirming an active apoptotic process during this period. But 
no such activity was detected in HMEC- FHOOV  16 ȝ0 (4xGI50). On the 
contrary, ON01910.Na significantly DFWLYDWHGFDVSDVH!ȝ0 (GI50) in 
cancer cells and at  ȝ0 (2xGI50) in normal cells. These results revealed 
that TL-77 as well as ON01910.Na induced caspase-dependent apoptosis in 
cancer cells, and further demonstrated the selective nature of TL-77-induced 
apoptosis. 
 
)LJXUH  7/- DQG 211D LQGXFH FDVSDVH  DFWLYLW\ LQ FDQFHU DQG QRQ-
WUDQVIRUPHGFHOOOLQHV 
+&7-DQG+0(&-ZHUHWUHDWHGZLWKLQGLFDWHGFRQFHQWUDWLRQVRI7/-DQG211D
IRU  K &DVSDVH  DFWLYLW\ ZDV PHDVXUHG DFFRUGLQJ WR WKH DVVD\ FRQGLWLRQV GHVFULEHG LQ
([SHULPHQWDO3URFHGXUHV9HUWLFDOEDUVUHSUHVHQWWKHPHDQ6'RIWKUHHUHSOLFDWHVQ SHU
H[SHULPHQW9DOXHVVLJQLILFDQWO\SGLIIHUHQWIURP'062YHKLFOHFRQWUROZHUHPDUNHG
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ZLWKDQDVWHULVN 
Effector caspases (Caspase-3, -6, -7) directly cleave a variety of substrates 
resulting in proteolysis of cellular proteins and apoptosis. The best 
characterized caspase substrate is poly-(ADP-ribose) polymerase (PARP), a 
family of proteins involved in DNA repair and is a key mediator of 
programmed cell death.117 During apoptosis, PARP is inactivated by caspase-3 
cleavage and converted from 116 kDa to fragments of 89 and 24 kDa.194 
Cleavage of PARP has been used extensively as a marker of cells undergoing 
apoptosis.195 Western blot assays (Figure 5.17) revealed that both compounds 
inactivated PARP by causing caspase cleavage after 24 h treatments. TL-77 
induced dose-dependent PARP cleavage in A2780 cells, while significant 
PARP cleavage was observed at all WHVWHGFRQFHQWUDWLRQVȝ0LQ+&7-116 
cells.  Consistent with delayed apoptosis observed (in the Annexin V/PI dual 
staining assay; Figure 5.14 A), PARP cleavage in cells exposed to 
ON01910.Na was not detected below ȝ0xGI50) treatments in HCT-116 
cells.  
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)LJXUH7/-LQDFWLYDWHG3$53E\FDXVLQJFDVSDVHFOHDYDJH 
:HVWHUQ EORW DQDO\VHV LQ +&7- FHOOV DQG $ FHOOV &HOOV ZHUH WUHDWHG ZLWK LQGLFDWHG
FRQFHQWUDWLRQVRI7/-RU211DIRUK&HOOO\VDWHVZHUHVXEMHFWHGWR:HVWHUQEORW
DQDO\VHVE\XVLQJDQWL-3$53DQWLERGLHVWRDVVHVVWKHFOHDYDJHRI3$53E-$FWLQZDVXVHGDVDQ
LQWHUQDO FRQWURO IRU SURWHLQ ORDGLQJ$OO RI WKH DERYH H[SHULPHQWV ZHUH UHSHDWHG WKUHH WLPHV
DQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
 TL-77 down-regulates expression of Bcl family proteins  
Caspases and Bcl family proteins comprise the mediators of apoptosis. 
Apoptosis is affected by the stoichiometry between pro- (Bax, Bid) and anti-
apoptotic (Bcl-xl, Mcl-1) molecules196, the expression levels of Bcl-2 family 
members in HCT-116 cells after 24 h treatment was tested. 
Bid plays the key role in releasing cytochrome c from mitochondria.116 As an 
inactive precursor localized within the cytosol of cells, Bid is activated 
following cleavage by caspase-8; it subsequently translocates to the 
mitochondria and induces cytochrome c release, followed by mitochondrial 
damage.117 As shown in Figure 5.18, expression levels of Bid were 
significantly reduced in TL-77-treated cells compared to controls, while 
ON01910.Na showed only a minor effect. Total protein levels of Bax in HCT-
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116 cells following treatment with these compounds were then examined; we 
observed that the expression of these molecules was essentially unchanged. 
Expression of Bcl-xl and Mcl-1 however were significantly reduced in TL-77-
treated cells compared to controls. Treatment with TL-77 at 16 ȝ0 IRU K
resulted in the complete inhibition of Bcl-xl protein expression. Mcl-1 is highly 
expressed in myeloid leukemia cell lines and its translation is regulated by the 
PI-3K/Akt pathway. 
 
 
 
 
 
 
)LJXUH(IIHFWVRI7/-RQ%FOIDPLO\SURWHLQV 
+&7-FHOOVZHUHWUHDWHGZLWKLQGLFDWHGFRQFHQWUDWLRQVRI7/-RU211DIRUK
&HOOO\VDWHVZHUHSUHSDUHGDQGVXEMHFWHGWR:HVWHUQEORWDQDO\VHVE\XVLQJDQWL-%,'DQWL-%D[
DQWL-%FO-[ODQG0FO-DQWLERGLHVE-$FWLQZDVXVHGDVDQLQWHUQDOFRQWUROIRUSURWHLQORDGLQJ
$OORIWKHDERYHH[SHULPHQWVZHUHUHSHDWHGWKUHHWLPHVDQGDUHSUHVHQWDWLYHUHVXOWLVVKRZQ 
 Discussion 
Anticancer drug-induced apoptosis is mainly controlled by two major pathways:  
the membrane death receptor (extrinsic) pathway and the mitochondrial 
(intrinsic) pathway.117 The mitochondria-dependent pathway involves cleavage 
of a pro-apoptotic protein, Bid, resulting in the production of truncated Bid 
(tBid). Subsequent BID cleavage participates in cytochrome-c mediated 
apoptosis and activates caspase 3.197 Bcl-xL prevents the release of cytochrome 
c by inhibiting the VDAC (Voltage-dependent anion channels)-mediated 
permeability transition pore.197 
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From our observations, dose- and time-dependent apoptosis induced by both 
compounds, detected by Annexin-V binding, is closely associated with 
induction of caspase 3/7 activity and PARP cleavage. In HCT-116 cells, TL-77 
induced rapid apoptosis, whereas ON01910.Na only triggered apoptosis after a 
longer exposure period, an observation consistent with cell cycle effects, 
indicating that cell-cycle arrest may be the apoptotic trigger. 
Analysis of Bcl-2 family proteins after treatment of cells with TL-77 and 
ON01910.Na revealed that neither compound altered expression levels of the 
pro-apoptotic molecule Bax. However, expression of Bid was significantly 
reduced in cells following TL-77 treatment. This may indicate that the 
precursor form of Bid translocates to mitochondria, where it induces 
cytochrome c release116, suggesting the involvement of the mitochondrial 
pathway in TL-77-mediated apoptosis. Among the pro-survival molecules, 
expression of Bcl-xL and Mcl-1 was significantly inhibited by both compounds. 
Taken together, these data show that TL-77 and ON01910.Na selectively 
induce G2/M cell cycle block with ensuing induction of apoptosis through the 
mitochondrial pathway in tumour cells. 
 TL-77 induces DNA double-strand breaks 
Cell cycle checkpoints are cellular responses to DNA damage by delaying 
progression of the cell cycle until DNA is repaired. Many anti-cancer drugs 
exert their effect through DNA damage and subsequent induction of apoptosis 
in cancer cells. H2AX is a variant of histone H2A required to maintain 
genomic stability.198 Phosphorylation of Ser-139 of the histone variant H2AX, 
forming Ȗ-H2AX, is an early cellular response to the induction of DNA double-
strand breaks.199 Detection of this phosphorylation event has emerged as a 
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highly specific and sensitive molecular marker for DNA double strand breaks 
induced by DNA-damaging agents.200 
&HOOXODUH[SUHVVLRQRIȖ-H2AX was detected following treatment of cells with 
TL-77 or ON01910.Na for 8 h and 24 h, indicative of DNA damage. Western 
blot analysis of HCT-116 cells after treatment with TL-77 and ON01910.Na 
for 8 h showed significant dose-dependent HOHYDWLRQRIȖ-H2AX (Figure 5.19). 
Following treatment of cells with either compound for 24 h, intense bands 
revealed high OHYHOV RI Ȗ-H2AX. These data reveal that early and prolonged 
phosphorylation of Histone H2AX has occurred after treatment with TL-77 or 
ON01910.Na. This observation illuminated that TL-77 induces rapid DNA-
damage in cancer cells. 
 
)LJXUH,QGXFWLRQRIȖ-+$;E\7/-DQG211D 
:HVWHUQ EORW DQDO\VLV ZDV SHUIRUPHG LQ +&7- FHOO &HOOV ZHUH WUHDWHG ZLWK LQGLFDWHG
FRQFHQWUDWLRQVRI7/-RU211DIRURUKE-$FWLQZDVXVHGDVDQLQWHUQDOFRQWURO
IRU SURWHLQ ORDGLQJ $OO RI WKH DERYH H[SHULPHQWV ZHUH UHSHDWHG WKUHH WLPHV DQG D
UHSUHVHQWDWLYHUHVXOWLVVKRZQ 
 Conclusion 
,QWKLVVHFWLRQSUHOLPLQDU\FHOOXODUPHFKDQLVPVRIDFWLRQRI7/-KDYHEHHQ
LQYHVWLJDWHG DQG FRPSDUHG ZLWK 211D 7/- H[KLELWV H[FHOOHQW DQWL-
SUROLIHUDWLYH DFWLYLW\ DJDLQVW D ZLGH UDQJH RI KXPDQ WXPRXU FHOO OLQHV ,W
GHPRQVWUDWHVGHPRQVWUDWHG! IROG JUHDWHUSRWHQF\ LQ FDQFHU FHOO OLQHV RYHU
QRUPDOFHOOV&HOOF\FOHDQDO\VHVUHYHDOWKDW7/-HYRNHVSURIRXQG*0FHOO
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F\FOHDUUHVWDWKLQFDQFHUFHOOVIROORZHGE\WKHRQVHWRIDSRSWRVLV 
In cell-free conditions, TL-77 as well as ON01910.Na potently inhibits tubulin 
polymerization. Mitotically arrested cells display multipolar spindles and 
misalignment of chromosomes, indicating that TL-77 interferes with mitotic 
spindle assembly in cancer cells. The TL-77-treated cell phenotypic change is 
similar to that observed in Plk1-depleted cells. The underlying mechanism of 
G2/M arrest showed a strong inhibitory effect of Cdc25c phosphorylation and 
cyclin B1 protein expression: TL-77 inhibits phosphorylation of Cdc25c 
(Ser198), which is indicative Plk1 inhibition. Subsequent down-regulation of 
cyclin B induced by TL-77 block the mitotic entry. Thus, it is proposed that 
TL-77 arrests the DNA damage checkpoint, induces DNA damage, inhibits 
spindle assembly and induces mitotic block. Analysis of apoptotic signalling 
pathways reveals that TL-77 down-regulates expression of Bcl-2 family 
proteins (Bid, Bcl-xl and Mcl-1) and stimulates caspase activation (caspase 
3,7), indicating TL-77 induces apoptosis through the mitochondrial pathway in 
tumour cells. These effects are comparable to those elicited by ON01910.Na. 
Unlike ON01910.Na, however, TL-77 elicits lower toxicity in non-transformed 
cells and mediates rapid mitotic inhibitory effects. Moreover, non-significant 
effects on PI3K/AKT signal transduction are observed after TL-77 treatment. 
These observations indicate a multi-faceted mechanism of TL-77 culminating 
in mitotic inhibition in cancer cells. Therefore, further evaluation of this 
promising anti-tumour agent is justified. 
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6 Conclusion and future directions 
 General conclusion 
The major goal of this project was to identify ON01910.Na mimetic 
compounds with superior drug properties, and to validate the mechanism of 
action. To achieve this goal, a novel series of (E)-3-
((styrylsulfonyl)methyl)pyridines has been designed and synthesised. The lead 
compounds were identified through cellular and pharmacological screening. 
Preliminary cellular mechanisms of action of TL-77 have been investigated. 
Our data suggest that lead compounds exhibit high potency and selectively 
cytotoxicity (2-10 folds) to cancer cells over untransformed cells. These 
compounds arrested cancer cells in the G2/M phase of cell cycle and induced 
apoptosis effectively. Importantly TL-77 possesses significantly improved 
pharmacological properties, with high oral bioavailability when compared to 
ON01910.Na. Therefore, the objectives of this study have been met. This work 
validates the novel (E)-styrylsulfonyl methylpyridines as anti-cancer agents 
and presents a strong rationale for further optimizing derivatives iteratively 
through chemical synthesis and biological evaluation. As a mitotic inhibitor, 
TL-77 represents a promising anti-cancer agent worthy of further evaluation. 
 Future directions 
The hit-to-lead and optimization processes are iterative cycles of chemical 
synthesis and biological evaluation. Based on the study of TL-77 and other 
lead compounds, primary understandings of this analogue have been developed 
and structure modification is still required. Although TL-77 exhibited some 
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favourable physicochemical properties, the pharmaceutical assessment 
revealed a relatively high efflux ratio of TL-77 (ER= 5.29) indicating this 
compound may undergo active efflux. Therefore, the structural modification to 
improve permeability should be considered. 
Cell cycle is a dynamics process. Among the protein complexes that vary 
during the cell cycle, almost all of complexes contain both periodically 
expressed (dynamic) and constitutively expressed (static) components. In 
Chapter four, TL-77 alters the expression of several checkpoint proteins, 
including Cdc25c, cyclin B1 and phospho-histone H3 have been discussed. In 
view of the dynamic expression of these markers during cell cycle, the 
activities of mitotic proteins are suggested to be correlated with the 
proportional changes, rather than absolute baseline levels. This could be 
achieved in the future evaluation by cell synchronization and addition of 
testing time points (reducing testing time interval). In this way, it is easier to 
monitor the expression changes of cell cycle proteins after in vitro and in vivo 
drug exposure. 
In our study, multistep recognition was investigated for the molecular 
mechanism of TL-77 effecting cell cycle protein kinases. In attempt to direct 
recognizing precise kinase inhibition, a kinase screen DVVD\0HUFN0LOOLSRUH¶V
.LQDVH3URILOHU was conducted for both TL-77 and ON01910.Na 
(ON01910.Na as the positive control) on six potential target proteins. 
(Appendix I) However, neither compounds showed inhibitory effect on tested 
proteins. According to reported work, kinase inhibitory effects of ON01910.Na 
were identified by kinase assays using recombinant protein kinases, such as PI3 
Kinases and Plk1, isolated from insect cells or Sf9 cells and incubating with 
compounds, [J-32P] ATP and substates.53, 78 Therefore, the poor reproducibility 
  Conclusion and future directions  
 124 
is a big concern. Yet, in cell-based assays in this study, clear down-regulation 
of phosphorylated Cdc25c protein was observed, indicating inhibition of Plk1 
activity. Detailed possible explanations have been discussed in Chapter four 
(4.2.2.1).Therefore, developing reliable biochemical assays to validate the 
target(s) of this analogue is urgent and essential, and this will become a 
challenge and main goal for the future understanding of mechanisms of action. 
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7 Experimental section 
 General chemical procedure 
Chemicals and solvents were purchased from commercial standard suppliers 
and used as received. Reactions were monitored by analytical thin-layer 
chromatography (TLC) using Merck silica gel 60 GF254 pre-coated (0.2 mm). 
TLC plates were visualised under UV light (254 nm). Purification by column 
chromatography and flash chromatography was performed using Merck silica 
gel 60 (0.040-0.063 mm). Flash chromatography was performed using 
Biotage® FlashMaster Personal Plus flash chromatography.  
1H and 13C Nuclear magnetic resonance (NMR) spectra were recorded on a 
Bruker-AV 400 spectrometer (1H at 400 MHz and 13C NMR at 100 MHz). 
NMR spectra were processed using the Bruker Topspin 3.2 software. 
Deuterated solvents used were CDCl3 (Cambridge Isotope Laboratories Inc.) 
and CD3OD (Sigma-Aldrich). 1H NMR signals are reported with chemical shift 
values į (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet and br = broad), relative integral, coupling constants J (Hz) and 
assignments. Mass spectra were recorded on a High Resolution Time of Flight 
(TOF) electrospray ionisation (ES) system comprising of a Waters 2795 
Separations module and Micromass LCT Platform, data was processed using 
0DVV/\Q[VRIWZDUH0HOWLQJSRLQWVZHUHUHFRUGHGRQDQ(OHFWURWKermal IA 
9100 digital melting point apparatus. 
The purity of compounds used for biological tests was determined by analytic 
high performance liquid chromatography (HPLC), and is greater than 95%. 
Analytical HPLC was carried out on Waters automated LC system (Waters 
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2525 binary gradient pump coupled to Waters 2767 sample manager and to 
:DWHUV  GXDO Ȝ DEVRUEDQFH GHWHFWRU with phenomenex Gemini-NX 5u 
C18 110A 250 × 4.60 mm column, UV detector at Ȝ 254 nm. The systems 
used were: 
z Method A: 10% MeOH containing 0.1% TFA for 4 min, followed by 
linear gradient 10% to 100% MeOH over 12 min at a flow rate of 1 ml/min; 
z Method B: 10% MeCN containing 0.1% TFA for 4 min, followed by linear 
gradient 10% to 100% MeCN over 12 min at a flow rate of 1 ml/min. 
2-Methoxy-5-methyl-3-nitropyridine (2). 
 
To anhydrous MeOH (100 ml) was added Na (2.31 g, 100 mmol), and the 
resulting solution went clear over the course of 30 min. Compound 1 (17.2 g, 
99.7 mmol) was added at room temperature. The reaction mixture was heated 
at reflux for 4 h under N2, cooled down to room temperature and concentrated 
under reduced pressure. The residue was diluted with H2O (100 ml) and 
extracted with CH2Cl2 (2 × 50 ml). The organic extracts were combined, 
washed with brine (30 ml), dried over MgSO4 and concentrated under reduced 
pressure. The residue was crystallized (EtOH:H2O = 1:15, 320 ml) to give 2 as 
a pale orange solid (15.4 g, 92%). m.p. 76-78 °C. 1H NMR (400 MHz, DMSO-
d6) į 2.31 (s, 3H, pyridine-CH3), 3.98 (s, 3H, OCH3), 8.30 (d, 1H, J 2.0, 
pyridine-H), 8.35 (d, 1H, J 2.0, pyridine-H). 13C NMR (100 MHz, DMSO-d6) į 
16.8, 54.9, 127.4, 133.7, 135.9, 152.0, 154.3. HRMS (ESI) m/z 169.0570 
[M+H]+; calcd. for C7H9N2O3 [M+H]+ 169.0608. 
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5-(Bromomethyl)-2-methoxy-3-nitropyridine (3).  
 
To a solution of compound 2 (8.40 g, 50.0 mmol) in carbon tetrachloride (100 
ml) were added benzoyl peroxide (3.50 g, 14.4 mmol) and N-
bromosuccinimide (17.8 g, 100 mmol). The reaction mixture was heated at 
reflux for 48 h under N2, cooled down to room temperature and concentrated 
under reduced pressure. The residue was diluted with saturated Na2CO3 (200 
ml) and extracted with CH2Cl2 (3 × 50 ml). The organic extracts were 
combined, washed with brine (50 ml), dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, petroleum ether ramping to EtOAc:petroleum ether 
= 1:99) to give 3 as a pale yellow solid (4.10 g, 33%). m.p. 92-94 °C. 1H NMR 
(400 MHz, CDCl3) į 4.15 (s, 3H, OCH3), 4.51 (s, 2H, CH2), 8.34 (d, 1H, J 2.4, 
pyridine-H), 8.43 (d, 1H, J 2.0, pyridine-H). 13C NMR (100 MHz, CDCl3) į 
27.7, 55.2, 127.2, 133.7, 135.7, 151.4, 156.3. HRMS (ESI) m/z 246.9654 
[M(79Br)+H]+, 248.9631 [M(81Br)+H]+; calcd. for C7H8BrN2O3 [M(79Br)+H]+ 
246.9713, [M(81Br)+H]+ 248.9693. 
Methyl 2-(((6-methoxy-5-nitropyridin-3-yl)methyl)thio)acetate (4). 
 
To a solution of compound 3 (4.92 g, 19.9 mmol) in MeOH (50 ml) were 
added methyl thioglycolate (2.70 ml, 30.2 mmol) and Na2CO3 (2.12 g, 20.0 
mmol). The reaction mixture was stirred at room temperature for 1 h and 
concentrated under reduced pressure. The residue was dissolved in EtOAc (200 
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ml), and the solids were filtered and washed with EtOAc (2 × 25 ml). The 
filtrate and EtOAc washings were combined and concentrated under reduced 
pressure. The residue was crystallized with EtOH (50 ml) to give 4 as a pale 
green solid (3.99 g, 74%). m.p. 57-60 °C. 1H NMR (400 MHz, DMSO-d6) į 
3.32 (s, 2H, SCH2COOCH3), 3.59 (s, 3H, COOCH3), 3.90 (s, 2H, pyridine-
CH2S), 4.03 (s, 3H, pyridine-OCH3), 8.42 (d, 1H, J 2.0, pyridine-H), 8.44 (d, 
1H, J 2.0, pyridine-H). 13C NMR (100 MHz, DMSO-d6) į 31.6, 32.6, 52.5, 
55.2, 128.4, 133.8, 136.1, 152.1, 155.2, 170.7. HRMS (ESI) m/z 273.0573 
[M+H]+; calcd. for C10H13N2O5S [M+H]+ 273.0540. 
Methyl 2-(((6-methoxy-5-nitropyridin-3-yl)methyl)sulfonyl)acetate (5). 
 
To a solution of compound 4 (1.64 g, 6.02 mmol) in CH3COOH (40 ml) was 
added 30% H2O2 (2.60 ml, 22.9 mmol). The reaction mixture was stirred at 60 
°C for 6 h and concentrated under reduced pressure. The residue was 
crystallized with EtOH (50 ml), and the solid was filtered to give 5 as a pale 
yellow solid (1.80 g, 98%). m.p. 137-140 °C. 1H NMR (400 MHz, DMSO-d6) 
į 3.73 (s, 3H, COOCH3), 4.07 (s, 3H, pyridine-OCH3), 4.47 (s, 2H), 4.80 (s, 
2H) (total 4H, CH2SCH2), 8.48 (s, 1H, pyridine-H), 8.51 (s, 1H, pyridine-H). 
13C NMR (100 MHz, DMSO-d6) į 53.4, 55.2, 55.4, 56.7, 118.3, 133.7, 138.0, 
154.3, 156.3, 163.9. HRMS (ESI) m/z 305.0519 [M+H]+; calcd. for 
C10H13N2O7S [M+H]+ 305.0438. 
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2-(((6-Methoxy-5-nitropyridin-3-yl)methyl)sulfonyl)acetic acid (6). 
 
To a solution of compound 5 (1.83 g, 6.01 mmol) in MeOH/H2O (1:1, 20 ml) 
was added Na2CO3 (1.80 g, 17.0 mmol). The reaction mixture was stirred at 
room temperature for 4 h and concentrated under reduced pressure. The residue 
was acidified to pH 2 with 1 M HCl, and the precipitate was filtered to give 6 
as a white solid (1.72 g, 99%). m.p. 183-186 °C. 1H NMR (500 MHz, DMSO-
d6) į4.06 (s, 3H, OCH3), 4.29 (s, 2H), 4.77 (s, 2H) (total 4H, CH2SCH2), 8.47 
(d, 1H, J 2.5, pyridine-H), 8.50 (d, 1H, J 2.0, pyridine-H), 13.57 (br s, 1H, 
COOH). 13C NMR (125 MHz, DMSO-d6) į 55.1, 55.4, 57.2, 118.5, 133.7, 
138.0, 154.3, 156.2, 164.9. HRMS (ESI) m/z 289.0064 [M-H]Ø; calcd. for 
C9H9N2O7S [M-H]Ø 289.0136. 
(E)-2-Methoxy-3-nitro-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridine (7). 
 
To a solution of compound 6 (14.5 g, 50.0 mmol) in toluene (750 ml) were 
added 2,4,6-trimethoxybenzaldehyde (10.8 g, 55.0 mmol), benzoic acid (0.915 
g, 7.49 mmol) and piperidine (642 ȝO, 6.50 mmol). The reaction mixture was 
heated at reflux for 3 h under N2, and the water generated was removed using a 
Dean-Stark apparatus. The reaction mixture was cooled down to room 
temperature and concentrated under reduced pressure. The residue was washed 
with MeOH (100 ml) and CH3CO2H (200 ml) to give 7 as a pale brown solid 
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(8.70 g, 41%). m.p. 187-189 °C. 1H NMR (400 MHz, CDCl3) į 3.87 (s, 6H), 
3.88 (s, 3H), 4.12 (s, 3H), (total 12H, 4 × OCH3), 4.26 (s, 2H, CH2), 6.11 (s, 
2H, benzene-H), 7.06 (d, 1H, J 15.6, SO2CH=CH), 7.80 (d, 1H, J 15.6, 
SO2CH=CH), 8.34 (d, 1H, J 2.4, pyridine-H), 8.40 (d, 1H, J 2.0, pyridine-H). 
13C NMR (100 MHz, DMSO-d6) į 55.3, 56.1, 56.5, 91.2, 91.4, 102.8, 120.0, 
122.7, 133.3, 135.3, 137.0, 154.1, 156.0, 161.5, 164.5 (three carbon signals 
overlapping or obscured). HRMS (ESI) m/z 425.1146 [M+H]+; calcd. for 
C18H21N2O8S [M+H]+ 425.1013. Anal. RP-HPLC: tR 13.24 min, purity > 97% 
(method A); tR 11.18 min, purity > 98% (method B). 
(E)-2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-
amine (8). 
 
To a solution of compound 7 (5.00 g, 11.8 mmol) in MeOH/CH3COOH (3:4, 
350 ml) was added iron powder (5.24 g, 93.8 mmol). The reaction mixture was 
heated at 50 °C for 3 h under N2 and concentrated under reduced pressure. The 
residue was dissolved in CH2Cl2 (200 ml), and 1 M NaOH (100 ml) was added. 
The precipitate was removed by centrifugation. The aqueous layer was 
separated and extracted with CH2Cl2 (2 × 100 ml). The organic layer and 
extracts were combined, dried over MgSO4 and concentrated under reduced 
pressure. The residue was washed with EtOAc (200 ml) to give 8 as a white 
solid (3.15 g, 68%). m.p. 170-172 °C. 1H NMR (500 MHz, DMSO-d6) į 3.84 
(s, 3H), 3.85 (s, 3H), 3.86 (s, 6H) (total 12H, 4 × OCH3), 4.27 (s, 2H, CH2), 
5.04 (s, 2H, NH2) 6.30 (s, 2H, benzene-H), 6.88 (s, 1H, pyridine-H), 7.09 (d, 
1H, J 15.5, SO2CH=CH), 7.28 (s, 1H, pyridine-H), 7.57 (d, 1H, J 15.5, 
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SO2CH=CH). 13C NMR (125 MHz, DMSO-d6) į 53.4, 56.1, 56.6, 57.8, 91.4, 
103.0, 119.0, 121.2, 123.9, 132.5, 133.5, 134.8, 152.3, 161.4, 164.1 (three 
carbon signals overlapping or obscured). HRMS (ESI) m/z 395.1250 [M+H]+; 
calcd. for C18H23N2O6S [M+H]+ 395.1271. Anal. RP-HPLC: tR 12.69 min, 
purity > 98% (method A); tR 10.35 min, purity > 98% (method B). 
(E)-N-(2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-
yl)methanesulfonamide (9a). 
 
To a solution of compound 8 (1.00 g, 2.54 mmol) in anhydrous pyridine (25 
PODW&ZDVDGGHGGURSZLVHPHWKDQHVXOIRQ\OFKORULGHȝOPPRO
The reaction mixture was stirred at room temperature for 13 h and concentrated 
under reduced pressure. The residue was dissolved in CH2Cl2 (150 ml) and 
washed with H2O (3 × 30 ml). The organic phase was concentrated under 
reduced pressure, and the residue was purified by an Isolera Four automated 
flash chromatography system using a 50 g KP-SIL SNAP flash cartridge (silica 
gel, EtOAc:hexane = 0:100 ramping to 100:0) to give 9a as a white solid 
(0.914 g, 76%). m.p. 211-212 °C. 1H NMR (500 MHz, DMSO-d6) į2.96 (s, 
3H, SO2CH3), 3.85 (s, 3H), 3.86 (s, 6H), 3.90 (s, 3H) (total 12H, 4 × OCH3), 
4.47 (s, 2H, CH2), 6.29 (s, 2H, benzene-H), 7.12 (d, 1H, J 15.5, SO2CH=CH), 
7.54 (d, 1H, J 15.5, SO2CH=CH), 7.65 (d, 1H, J 2.5, pyridine-H), 7.91 (d, 1H, 
J 2.0, pyridine-H), 9.25 (s, 1H, NHSO2). 13C NMR (100 MHz, acetone-d6) į 
38.8, 53.3, 55.1, 55.5, 57.4, 90.7, 103.2, 119.4, 121.7, 123.2, 130.2, 134.7, 
143.7, 154.1, 161.5, 164.3 (three carbon signals overlapping or obscured). 
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HRMS (ESI) m/z 473.1115 [M+H]+; calcd. for C19H25N2O8S2 [M+H]+ 
473.1047. Anal. RP-HPLC: tR 12.74 min, purity > 98% (method A); tR 10.16 
min, purity > 97% (method B). 
(E)-N-(2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-
yl)acetamide (9b).  
 
To a solution of compound 8 (240 mg, 0.608 mmol) in anhydrous pyridine (10 
ml) at 0 ºC was added dropwise acetyl chloride (110 ȝO 1.55 mmol). The 
reaction mixture was stirred at room temperature for 12 h and concentrated 
under reduced pressure. The residue was acidified to pH ~ 6-7 with 2 M HCl 
and extracted with CH2Cl2 (2 × 10 ml). The organic extracts were combined, 
washed with saturated Na2CO3 (10 ml) and brine (10 ml), dried over MgSO4 
and concnetrated under reduced pressure. The residue was purified by flash 
column chromatography (silica gel, EtOAc:petroleum ether = 3:1) to give 9b 
as a white solid (114 mg, 43%). m.p. 190-192 °C. 1H NMR (400 MHz, CDCl3) 
į2.21 (s, 3H, NHCOCH3), 3.86 (s, 6H), 3.87 (s, 3H), 4.03 (s, 3H) (total 12H, 4 
× OCH3), 4.21 (s, 2H, CH2), 6.11 (s, 2H, benzene-H), 7.13 (d, 1H, J 15.6, 
SO2CH=CH), 7.61 (s, 1H, NHCO), 7.88 (d, 1H, J 15.6, SO2CH=CH), 7.89 (d, 
1H, J 2.0, pyridine-H), 8.65 (d, 1H, J 2.0, pyridine-H). 13C NMR (100 MHz, 
CDCl3) į 24.8, 54.0, 55.5, 55.8, 58.8, 90.3, 103.8, 118.3, 122.3, 122.5, 128.8, 
136.1, 142.0, 152.9, 161.6, 163.9, 168.6 (three carbon signals overlapping or 
obscured). HRMS (ESI) m/z 437.1460 [M+H]+; calcd. for C20H25N2O7S 
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[M+H]+ 437.1377. Anal. RP-HPLC: tR 12.53 min, purity > 99% (method C); tR 
13.52 min, purity > 96% (method D). 
(E)-N-Ethyl-N-(2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)acetamide (9c). 
 
To a solution of compound 9b (50 mg, 0.11 mmol) in anhydrous DMF (10 ml) 
was added NaH (0.60 mg, 0.025 mmol). The reaction mixture was stirred at 
room temperature for 45 min. Iodoethane (60 µL, 0.75 mmol) was added 
dropwise. The reaction mixture was stirred at room temperature for 3.5 h, 
dilute with H2O (10 ml) and extracted with CH2Cl2 (2 × 20 ml). The organic 
extracts was combined, washed with brine (10 ml), dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, EtOAc:petroleum ether = 1:1) to give 9c as a white 
solid (37 mg, 70 %). m.p. 168-171 °C. 1H NMR (400 MHz, CDCl3) į 0.99 (t, 
3H, J 7.2, CH2CH3), 1.71 (s, 3H, COCH3), 3.39 (m,1H, CH2CH3), 3.80 (m,1H, 
CH2CH3), 3.81 (s, 6H), 3.84 (s, 3H), 3.96 (s, 3H) (total 12H, 4 × OCH3), 4.20 
(s, 2H, pyridine-CH2SO2), 6.07 (s, 2H, benzene-H), 7.04 (d, 1H, J 15.6, 
SO2CH=CH), 7.48 (d, 1H, J 2.0, pyridine-H), 7.74 (d, 1H, J 15.6, 
SO2CH=CH), 8.13 (d, 1H, J 2.0, pyridine-H). 13C NMR (100 MHz, CDCl3) į 
12.9, 22.2, 42.5, 54.1, 55.5, 55.8, 57.9, 90.4, 103.6, 118.6, 121.4, 125.6, 136.9, 
140.4, 148.2, 160.2, 161.6, 164.2, 170.4 (three carbon signals overlapping). 
HRMS (ESI) m/z 465.1393 [M+H]+; calcd. for C22H29N2O7S [M+H]+ 
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465.1690. Anal. RP-HPLC: tR 12.80 min, purity > 99% (method C); tR 15.47 
min, purity > 97% (method D). 
(E)-Ethyl 2-((2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)amino)acetate (9d). 
 
To a solution of compound 8 (140 mg, 0.355 mmol) in DMF (10 ml) were 
DGGHG HWK\O EURPRDFHWDWH  ȝO  PPRO DQG .2CO3 (138 mg, 0.999 
mmol). The reaction mixture was heated at 60 °C overnight, diluted with H2O 
(20 ml) and extracted with EtOAc (2 × 20 ml). The organic extracts were 
combined, washed with brine (10 ml), dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, EtOAc:petroleum ether = 3:2) to give 9d as a white 
solid (124 mg, 73%). m.p. 151-153 °C. 1H NMR (400 MHz, CDCl3) į 1.33 (t, 
3H, J 7.0, CH2CH3), 3.85 (s, 6H), 3.87 (s, 3H) (total 9H, 3 × OCH3), 3.90 (d, 
2H, J 2.8, NHCH2), 4.00 (s, 3H, OCH3), 4.15 (s, 2H, pyridine-CH2SO2), 4.27 
(q, 2H, J 7.2, CH2CH3), 4.83 (d, 1H, J 5.8, NHCH2), 6.10 (s, 2H, benzene-H), 
6.74 (d, 1H, J 2.0, pyridine-H), 7.04 (d, 1H, J 15.6, SO2CH=CH), 7.44 (d, 1H, 
J 2.0, pyridine-H), 7.81 (d, 1H, J 15.6, SO2CH=CH). 13C NMR (100 MHz, 
CDCl3) į 14.2, 44.9, 55.4, 55.7, 59.2, 61.5, 90.4, 103.8, 116.8, 118.5, 122.3, 
131.8, 135.1, 136.0, 152.7, 161.5, 163.9, 170.4 (four carbon signals 
overlapping or obscured). HRMS (ESI) m/z 481.1364 [M+H]+; calcd. for 
C22H29N2O8S [M+H]+ 481.1639. Anal. RP-HPLC: tR 13.09 min, purity > 95% 
(method C); tR 14.80 min, purity > 95% (method D). 
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(E)-2-((2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-
yl)amino)acetic acid (9e). 
 
To a solution of compound 9d (114 mg, 0.237 mmol) in THF (10 ml) was 
added a solution of NaOH (10.0 mg, 0.250 mmol) in H2O (10 ml). The reaction 
mixture was stirred at room temperature for 1 h, acidified to pH = 1 - 2 with 2 
M HCl and extracted with EtOAc (3 × 10 ml). The organic extracts were 
combined, washed with brine (10 ml), dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, EtOAc:petroleum ether = 3:2 to EtOAc:MeOH = 
5:1) . The resulting solid was further washed with Acetone and dried to give 9e 
as a white solid (74.5 mg, 69.5%). m.p. 79-81 °C. 1H NMR (400 MHz, DMSO-
d6) į 3.72 (s, 2H, NHCH2), 3.84 (s, 3H), 3.85 (s, 6H), 3.88 (s, 3H) (total 12H, 4 
× OCH3), 4.31 (s, 2H, pyridine-CH2SO2), 5.33 (br s, 1H, NHCH2), 6.29 (s, 2H, 
benzene-H), 6.65 (d, 1H, J 1.6, pyridine-H), 7.11 (d, 1H, J 15.6, SO2CH=CH), 
7.34 (d, 1H, J 1.6, pyridine-H), 7.54 (d, 1H, J 15.6, SO2CH=CH). 13C NMR 
(100 MHz, DMSO-d6) į 44.4, 53.6, 55.4, 56.1, 56.5, 91.4, 103.0, 117.2, 119.2, 
123.8, 132.2, 133.8, 134.6, 152.1, 161.4, 164.2, 172.2 (three carbon signals 
overlapping or obscured). HRMS (ESI) m/z 451.1245 [M-+@Ø FDOFG IRU
C20H23N2O8S [M-+@Ø$QDO53-HPLC: tR 12.52 min, purity > 98% 
(method C); tR 13.30 min, purity > 98% (method D). 
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(E)-2-((2-Methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-
yl)amino)acetamide (9f). 
 
To a solution of compound 9d (118 mg, 0.246 mmol) in H2O (5 ml) was added 
ammonia (7 M in MeOH, 8.00 ml, 56.0 mmol). The reaction mixture was 
heated at 60 °C overnight and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, 
EtOAc:petroleum ether = 1:1) to give 9f as a brown solid (115 mg, 97%). m.p. 
211-213 °C. 1H NMR (400 MHz, DMSO-d6) į 3.56 (d, 2H, J 5.6, NHCH2), 
3.84 (s, 3H), 3.85 (s, 6H), 3.87 (s, 3H) (total 12H, 4 × OCH3), 4.32 (s, 2H, 
pyridine-CH2SO2), 5.38 (t, 1H, J 5.4, NHCH2), 6.29 (s, 2H, benzene-H), 6.61 
(d, 1H, J 2.0, pyridne-H), 7.10 (d, 1H, J 15.6, SO2CH=CH), 7.31 (m, 2H, 
NH2), 7.34 (d, 1H, J 2.0, pyridine-H), 7.55 (d, 1H, J 15.6, SO2CH=CH). 13C 
NMR (100 MHz, DMSO-d6) į 45.8, 53.6, 56.1, 56.5, 57.9, 91.4, 103.0, 117.1, 
119.2, 123.7, 132.4, 133.8, 134.6, 152.3, 161.4, 164.2, 171.5 (three carbon 
signals overlapping or obscured). HRMS (ESI) m/z 452.1560 [M+H]+; calcd. 
for C20H26N3O7S [M+H]+ 452.1486. Anal. RP-HPLC: tR 12.19 min, purity > 
98%(method C); tR 12.67 min, purity > 97% (method D). 
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2-Methoxy-5-(1-(methylsulfonyl)-2-(piperidin-1-yl)-2-(2,4,6-
trimethoxyphenyl)ethyl)-3-nitropyridine (10). 
 
To a solution of compound 6 (2.03 g, 6.99 mmol) in anhydrous pyridine (20 
ml) were added 2,4,6-trimethoxybenzaldehyde (1.37 g, 6.98 mmol) and 
piperidine (500 ȝOPPRO7KHUHDFWLRQPL[WXUHZDVKHDWHGDWUHIOX[IRU
h under N2, cooled to room temperature and concentrated under reduced 
pressure. The residue was acidified to pH ~ 7 with 2 M HCl and extracted with 
CH2Cl2 (2 × 50 ml). The organic extracts were combined, washed with 
saturated Na2CO3 (30 ml) and brine (30 ml), dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, EtOAc:CH2Cl2:petroleum ether = 1:2:8) to give 10 
as a white solid (1.02 g, 29%). m.p. 198-200 °C. 1H NMR (400 MHz, CDCl3) į 
1.30 (s, 2H, piperidine-H), 1.48-1.57 (m, 5H, piperidine-H), 2.55 (br d, 3H, J 
96.0, piperidine-H), 3.45 (s, 3H, SO2CH3), 3.61 (s, 3H), 3.70 (s, 3H), 3.83 (s, 
3H), 3.98 (s, 3H) (total 12H, 4 × OCH3), 5.10 (d, 1H, J 12.0) , 5.37 (d, 1H, J 
12.0) (total 2H, pyridine-CHCH-benzene), 5.78 (d, 1H, J 2.0, benzene-H), 6.03 
(d, 1H, J 2.0, benzene-H), 8.11 (d, 1H, J 2.4, pyridine-H), 8.15 (d, 1H, J 2.4, 
pyridine-H). 13C NMR (100 MHz, DMSO-d6) į 24.3, 26.5, 44.6, 55.0, 55.1, 
55.2, 56.0, 59.4, 102.7, 120.9, 156.4, 159.2, 159.8, 161.0 (nine carbon signals 
overlapping or obscured). HRMS (ESI) m/z 510.1417 [M+H]+; calcd. for 
C23H32N3O8S [M+H]+ 510.1905. Anal. RP-HPLC: tR 11.62 min, purity > 95% 
(method C); tR 12.22 min, purity > 99% (method D). 
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 General biology procedures 
 Materials 
MTT assay 
MTT Sigma-aldrich (cat: M2128-1G); DMSO Sigma-aldrich (cat: D5879-1L). 
Cell cycle analysis 
Buffers and Solutions: Hypotonic Fluorochrome solution (0.1% sodium citrate; 
0.1% Triton X-ȝJPOSURSLGLXPLRGLGHXJPO51AseA in dH2O) 
Annexin V/PI staining assay 
Reagents: FITC Annexin V (BD Biosciences, cat: 556420); propidium iodide 
(Sigma, cat: P4170) 
Buffers and Solutions: 10 × binding buffer (0.1 M HEPES, Ph 7.4; 1.3 M NaCl; 
25 mM CaCl2); propidium iodide solution (50 ȝJPOLQ3%6 
Western blot analysis 
Reagents: PageRuler Plus Prestained Protein Ladder (Thermo, cat: #26619); 
Immun-Blot PVDF Membrane (Bio-Rad, cat: #162-0177); Empty Gel 
Cassettes, mini, 1.5 mm (Invitrogen, cat: NC2015); Albumin from bovine 
serum (BSA) (Sigma, cat: A4503); DC3URWHLQ$VVD\5HDJHQW$%6%LR-
Rad, cat: 500-0113/0114/0115); Acrylamide/Bis-acrylamide, 30% solution 
(Sigma, cat: A3699); Triton-X 100 (Sigma, cat: X100); Ammonium persulfate 
(AMPS); N,N,N',N'-Tetramethylethylenediamine (TEMED); Complete Mini 
protease inhibitor cocktail tablet (Roche, cat: 04693159001); PhosSTOP 
Phosphatase Inhibitor Cocktail Tablets (Roche, cat: 04906845001); Amersham 
ECL Western Blotting Detection Reagents (GE Healthcare, cat: RPN2106); 
Amersham Hyperfilm ECL (GE Healthcare, cat: 28906837). 
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7DEOH%XIIHUVDQG6ROXWLRQV 
*HO )RUDPOVHSDUDWLQJJHO 
)RUDPO
VWDFNLQJ
JHO 
$FU\ODPLGH
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
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
ȝO ȝO 
DPPRQLXP
SHUVXOIDWH$36 

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
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ȝO 

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7(0(' ȝO ȝO ȝO ȝO ȝO ȝO 
Running buffer 1L (3.03g Trizma Base, 14.4 g glycine, 1 g SDS); Transfer 
buffer 1L (3.03 g Trizma Base, 14.4 g glycine, 0.375 g SDS, 200 ml methanol, 
pH 7.6); TBST 1L (8 g NaCl, 2.42 g Trizma Base pH 7.6, 0.05% Tween 20); 4 
× Loading buffer 10 ml (4 ml 100% glycerol, 2.4 ml 1 M Tris-HCl pH 6.8, 0.8 
g SDS, 4 mg bromophenol blue, 0.5 ml ß-mercaptoethanol, 3.1 ml water); 
NP40 Cell Lysis Buffer (150 mM NaCl, 1.0% Triton X-100, 0.1% SDS, 50 
mM  Tris-HCl pH 8.0, a tablet of Protease Inhibitor and Phosphatase Inhibitor); 
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6WULSSLQJ EXIIHU  PO  J 7UL]PD EDVH  J 6'6  PO ȕ-
mercaptoethanol). 
7DEOH$QWLERGLHV 
$QWLERG\ 'LOXWLRQ 6WRUDJH &RPSDQ\ &DW 
3KRVSKR-$NW3DWKZD\
$QWLERG\6DPSOHU.LW  -& &HOOVLJQDOLQJ  
P7256XEVWUDWHV
$QWLERG\6DPSOHU.LW  -& &HOOVLJQDOLQJ  
%FO-[O  -& 6LJPD % 
%D[  -& &HOOVLJQDOLQJ  
%LG  -& &HOOVLJQDOLQJ  
&GFF  -& &HOOVLJQDOLQJ  
3KRVSKR-&GFF6  -& &HOOVLJQDOLQJ  
F\FOLQ%  -& &HOOVLJQDOLQJ  
F\FOLQ'  -& &HOOVLJQDOLQJ  
0FO-  -& &HOOVLJQDOLQJ  
J-+$;  & 0LOOLSRUH - 
3$53  -& &HOOVLJQDOLQJ  
E-DFWLQ  -& &HOOVLJQDOLQJ  
JRDWDQWL-PRXVH,J*  & 'DNR 3 
JRDWDQWL-UDEELW,J*  & 'DNR 3 
Tubulin polymerization assay 
Tubulin Polymerization HTS Assay Kit (Cytoskeleton, cat: BK004P) 
Immunofluorescence microscopy 
Reagents: phosphate buffered saline (PBS) (Sigma, cat: P4417); Formaldehyde 
solution, 37% in H2O (Sigma, cat: F8775); Monoclonal Anti-Į-7XEXOLQí),7&
antibody produced in mouse (Sigma, cat: F2168); Alexa Fluor® 488 Goat 
Anti-Mouse IgG (H+L) Antibody (Invitrogen, cat: #A-11029). 
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Buffers and Solutions: 1 × Wash Buffer 100 ml (10 ml 10 × Wash Buffer, 90 
ml dH2O); Fixation Solution 12 ml (1.2 ml 37% formaldehyde, 10.8 ml 1 × 
Wash Buffer); 1 × Blocking Buffer 100 ml (10 ml 10 × Blocking Buffer, 90 ml 
dH2O); 1 × Permeabilization Buffer 20 ml (2 ml 10 × Permeabilization buffer, 
18 ml dH2O); Primary Antibody Solution 6 ml (15 µl Mitotic Index Primary 
Antibody, 6 ml 1 × Blocking Buffer); Staining Solution 6 ml (12 µl Secondary 
Antibody, 0.3 µl Hoechst Dye, 6 ml 1 × Blocking Buffer).  
Caspase 3/7 assay 
Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega G7790) 
 Methods 
 General cell culture 
All cell lines were obtained from the American Type Tissue Culture Collection 
(ATCC), expanded and stored in the liquid nitrogen cell bank at the Centre for 
Biomolecular Sciences, University of Nottingham, UK. All cancer cell lines 
were maintained in RPMI-1640 medium with 10% foetal bovine serum (FBS). 
The FBS was inactivated by heating at 56 °C for 60 min to denature 
complement proteins which would evoke cellular immune responses. MRC-5 
cell lines were cultured in minimum essential medium with 10% FBS, 1% of 
7.5% sodium bicarbonate, 1% 0.1 mM non-essential amino acids, 1% 1 M 
HEPES, 1% 200 mM L-glutamine and 1% penicillin. Human dermal 
microvascular endothelial cells (HMEC-1) were maintained in EBM-2 medium 
with 10% FBS. Human umbilical cord vein endothelial cells (HUVECs) were 
maintained in EBM-2 medium with 10% FBS and EGM-2. Cells were 
incubated in a humidified incubator at 37 °C with 5% CO2. 
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 Preparation of compounds solution 
The tested compounds were weighed using mini gram scales and were 
dissolved in DMSO to make up a 10 mM concentration stock solutions which 
were stored at -20 oC.  
 MTT cytotoxicity assay (96 h) 
MTT assay is a quantitative colorimetric method to determine viable cell 
number in proliferation and cytotoxicity studies. 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), a yellow tetrazole, is reduced by 
mitochondrial succinate dehydrogenase in living cells to its insoluble purple 
formazan, which could be dissolve by DMSO to produce a colored solution. 
The absorbance which reflects the amount of living cells can be measured 
spectrophotometrically. 
Day 1: Cells were seeded at 3 x 103 per well in a 96 well plates in a volume of 
ȝOFHOOFXOWXUHPHGLXPadditional columns of cells were plated in the T0 
plate for each cell line. All plates were incubated at 37 oC with 5% CO2 
overnight.  
Day 2: T0 SODWHZDVWUHDWHGZLWKȝO077VROXWLRQPJPOLQ3%6SHUZHOO
and then incubated for a further 2-4 h at 37 oC with 5% CO2. Following 
asSLUDWLRQRIPHGLD077PL[WXUHDQGDGGLWLRQRIȝ/'062SHUZHOOWKH
T0 plate was shaken for 5 min. Absorbance of each well was quantified at 550 
nm using a Perkin Elmer plate reader and data were transferred to Microsoft 
Excel. At the same time, test compounds in 10 mM DMSO stock solution were 
GLOXWHGWRDFRQFHQWUDWLRQUDQJHEHWZHHQȝ0DQGȝ0ZLWKmedium. 
)RUHDFKFRQFHQWUDWLRQȝOGLOXWLRQZDVDGGHGSHUZHOOLQWULSOLFDWHIRUHDFK
FHOOOLQHUHVXOWLQJLQDGLOXWLRQUDQJHIURPȝ0WR ȝ0 
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Day 6: After 96 hours exposure to test agent, to all wells were added  ȝO
MTT solution. Plates were analysed in the same manner as the T0 plate. Each 
assay was performed at least 2 times for candidate screening and at least 3 
times for mechanism studies of lead compounds. All data were transferred to 
Microsoft Excel. To determine GI50 values of test agents (concentration 
required to 50% growth inhibition), dose-response curves were constructed 
using nonlinear regression analysis. The mean value and standard deviation of 
each compound was calculated by Excel. 
 Cell cycle analysis 
The analysis of cell cycle distribution was performed by flow cytometric 
measurement of cellular DNA contents. HCT-116, A2780 and HMEC-1 cells 
were seeded in 6-well plates at a density of 5 × 105 cells/well and incubated at 
37 °C 5% CO2 overnight. Following incubation with compounds at appropriate 
concentrations and time points, the cells were collected with the medium in a 
FACS tube and centrifuged at 1200 rpm for 5 min at 4 °C. The supernatants 
were discarded. Cells were washed twice with cold PBS and gently re-
suspended in 400 ȝl of fluorochrome solution. Then, cells were protected from 
light and stored at 4 °C overnight. Prior to flow cytometric analysis, the cell 
suspension was syringed to obtain a single cell suspension. DNA content was 
measured by a Beckman Coulter EPICS-;/0&/IORZF\WRPHWHUDQGGDWD
was analysed using the (;32VRIWZDUH 
 Annexin V/PI staining assay 
AnnexinV/propidium iodide (PI) staining was a commonly used quantitatively 
method for studying apoptotic cells. HCT-116, A2780 and HMEC-1 cells were 
seeded in 6-well plates at a density of 4 × 105 per well and incubated at 37 °C 5% 
  Experimental section  
 144 
CO2 overnight. After the appropriate incubation time, cells were collected with 
the medium in a FACS tube and centrifuged at 1200 rpm for 5 min at 4 °C. The 
cells were gently re-suspended with 1 ml fresh medium. Then 1 x 105 of cells 
were transferred into a fresh FACS tube. After washing (1 ml PBS), cells were 
re-VXVSHQGHGLQȝOELQGLQJEXIIHUDQGȝO$QQH[LQ9-FITC. After 15 min 
incuEDWLRQ LQ WKHGDUNDW URRP WHPSHUDWXUH VDPSOHVZHUH DGGHGZLWKȝO
binding buffer, together with 5 ȝO3,6DPSOHVZHUHNHSWRQLFHDQGSURWHFWHG
from light for a further 10 min and analysed using FACS after vortex within 1 
h. 
 Mitotic index assay 
Mitotic index is a measure of the proliferation status of a cell population. It is 
defined as the ratio between the number of cells in mitosis and the total number 
of cells. HCT-116 cells were seeded at the density of 1 × 104 cells/well in 
Packard ViewPlate black clear bottom 96-well microtitre plates. After the 
appropriate incubation time with compounds at 37 °C and 5% CO2, the 
PHGLXP ZDV UHPRYHG )ROORZHG E\  PLQ IL[DWLRQ LQ  ȝO RI IL[DWLRQ
solution at 37 °C, cells were ZDVKHG RQFH ZLWK  ȝOZHOO RI  î EORFNLQJ
EXIIHUDQGVXEVHTXHQWO\SHUPHDELOL]HGLQȝORIîSHUPHDELOL]DWLRQEXIIHU
IRU  PLQ $IWHU ZDVKLQJ FHOOV ZHUH LQFXEDWHG ZLWK  ȝOZHOO SULPDU\
antibody solution for 1 h, and then with staining solution for another 1 h. 
Fluorescence was measured at 460 nm at room temperature using a Leica 
DMIRE2 fluorescence microscope to calculate the mitotic index which is the 
percentage of cell nuclei stained with the mitosis-specific antibody (anti-
phospho-Histone H3) versus total cell nuclei stained with Hoechst. Vinblastine 
 ȝ0 ZDV XVHG DV D SRVLWLYH FRQWURO DQG '062  ZDV XVHG DV D
negative control. Assays were carried out using duplicate plates.  
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 Caspase-3/7 assay 
Caspase activity was determined using the Apo-ONE® Homogeneous 
Caspase- $VVD\ 3URPHJD * IROORZLQJ WKH PDQXIDFWXUHU¶V
instructions. Fluorescence was measured at 460 nm at room temperature using 
an EnVision multilabel plate reader (PerkinElmer). 
 Western blot analysis 
Western Blot analyses were performed in a standard manner. Following 
separation by polyacrylamide gel electrophoresis, the proteins were electro 
transferred to membranes and detected with specific antibodies.  
7.2.2.8.1 Cell lysate preparation 
Cells were seeded at a density of 106 on a 10 cm tissue culture plate and 
incubated at 37 °C 5% CO2 overnight. After treatment with compounds at 
appropriate concentrations and time points, the cells were collected with the 
medium and centrifuged at 1200 rpm for 5 min, 4 °C. The pellet was washed 
with ice-cold PBS and re-suspended in lysis buffer (containing Protease 
Inhibitor and Phosphatase Inhibitor) for 30 min at 4 °C. Cell lysates were 
centrifuged (13000 rpm, 4 °C, 10 min) to remove insoluble proteins and cell 
debris.  
7.2.2.8.2 Protein determination 
A Bradford assay was performed to determine the protein content in the lysates 
using the Bio-Rad DC protein assay. Firstly, the protein was diluted 1:10 in 
water and left on ice. Cell lysates were then stored at -20 °C temporarily for 
later use. BSA protein standards were prepared at a concentration range of 10, 
5, 2.5, 2, 1.5, 1, 0.75, 0 mg/ml BSA with RIPA buffer. 5 Pl of each of the BSA 
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standards or protein was pipetted in a 96-well plate with 3 replicates of each 
sample. Then 200 Pl of Bradford reagent was added to each well and mixed 
gently to avoid any bubbles. After 15-20 min incubation at room temperature, 
absorbance of each well was quantified at 595 nm using a Perkin Elmer plate 
reader and data was transferred to Microsoft Excel. A standard curve was 
plotted to determine the protein concentrations.  
7.2.2.8.3 Gel electrophoresis 
Proteins were separated using gel electrophoresis. SDS denatures proteins by 
negatively charging the polypeptides in proportion to their length once they 
have been treated with strong reducing agents. In denaturing SDS-PAGE (SDS 
polyacrylamide gel electrophoresis), therefore, proteins are separated according 
to their molecular weight. Depending on the molecular weight of the protein of 
interest, different concentrations of acrylamide were used in the gels (6-15%). 
In a gel cassette, polymerization was initiated when AMPS and TEMED were 
added to the separating buffer. Once the separating gel had polymerized, 
stacking gel buffer with AMPS and TEMED was added. Simultaneously, a 
comb was placed on the top of the cassette to create sample wells.  
Cell lysate samples were prepared containing 50- ȝJ total protein 
depending on cell lines. Along with loading buffer, samples were denatured at 
95 °C for 5-10 min and subsequently loaded into narrow wells using special gel 
loading tips. PageRuler Plus Prestained Protein Ladder ȝOZDVDGGHGWRWKH
first well for determination of the protein size and also to monitor the progress 
of the electrophoretic run. Protein samples were separated at a voltage between 
60-180 V in running buffer until the migration front reaches the bottom of the 
gel. The gel was then removed from cassettes. 
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7.2.2.8.4 Transfer of proteins and staining (Western blotting)  
Proteins separated by SDS-PAGE in gels were electro-transferred onto PVDF 
membranes using transfer buffer in semi-dry conditions (at 25 V for 1.5 h). The 
membranes were washed using 20 ml of 1x PBS and then blocked with either 5% 
BSA or 10% dried non-fat milk (dependant on primary antibodies) in TBST for 
1 h at room temperature with gentle shaking. All primary and secondary 
antibodies used are shown in Table 7.2 with corresponding concentrations used 
for the Western blot. Membranes were incubated with primary antibody 
overnight at 4 °C with agitation. To remove residual primary antibody, the 
membranes were washed 3 times in TBST while shaking, 5-10 min per wash. 
Membranes were next incubated with appropriate HRP-conjugated secondary 
antibodies for 1 h at room temperature, and rinsed again with TBST. 
7.2.2.8.5 Detection 
All blots were visualized using enhanced chemiluminescence according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQ )ROORZLQJ WKH SURFHGXUHV LQ WKH PDQXIDFWXUHU¶V
instruction of AmershamTM ECLTM Western Blotting Detection Reagents, 
membranes were exposed to X-ray films in the dark for appropriate exposure 
times. Films were developed manually. 
 Tubulin polymerization assay  
The Tubulin Polymerization HTS Assay Kit from Cytoskeleton was used 
according to the PDQXIDFWXUHU¶VSURWRFRO7KHNLW-based assay is an adaptation 
of a method202, where polymerization is monitored by optical density 
enhancement as it occurs. Briefly, test compounds and their corresponding 
vehicles were pipetted into a 96-well microtiter plate, then tubulin reaction 
mixture was quickly added to the wells, and tubulin polymerization was 
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initiated and monitored at 37 °C for 1 h by recording fluorescence absorbance 
at 340 nm. The tubulin reaction mixture was composed of 80 mM PIPES (pH 
6.9), 1 mM MgCl2, 1 mM EGTA, 1.0 mM GTP and 2 mg/ml of highly purified 
porcine brain tubulin heterodimer. 
 Immunofluorescence microscopy 
HCT-116 cells were cultured at a density of 2 × 103 cells/well to the 6 cell-
plates containing gelatin-coated coverslips. After appropriate concentrations 
and time points of treatments, the coverslips were washed twice with PBS and 
transferred into a petri dish with two sheets of moistened filter pater. Cells 
were fixed in 3.7% formaldehyde for 15 min and washed briefly in PBS. 
Excess PBS was removed by touching to dry filter paper. Then, cells were 
permeabilized with 0.3% Triton-X 100 in PBS for 5 min. To block non-specific 
binding sites, cells were incubated with blocking buffer for 45 min at room 
temperature. Fixed cells were incubated with anti-mouse Į-tubulin antibody (1: 
50 dilution) for 2 h at room temperature, and then exposed to the secondary 
antibody (FITC-conjugated goat anti-mouse IgG at 1:100 dilution) for 2 h at 
room temperature in the dark, followed by DNA staining with Hoechst. 
Photomicrographs were obtained using a Leica TCS SP2 Confocal Spectral 
Microscope. 
 Statistical analysis 
All experiments were performed in triplicate and repeated at least twice. 
Similar results were obtained and representative experiments were selected for 
ILJXUHV 6WXGHQW¶V W-test for paired sample was used to determine statistical 
VLJQLILFDQFH3ZDVFRQVLGHUHGWR be statistically significant. 
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Appendix I 
Kinase inhibitory activity of TL-77 and ON01910.Na 
Experimental procedure 
Kinases of interest (Aurora-A, Aurora-B, CDK1/cyclinB and Plk1) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, proper substrate, 10 mM 
0J$FHWDWH DQG >Ȗ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the 
MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid VROXWLRQȝ/RIWKH
reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and 
scintillation counting. ATP concentration is used within 15 PM of the Km value for each kinase. 
[Non-radioactive assay] PI3 Kinase LV LQFXEDWHG LQ DVVD\ EXIIHU FRQWDLQLQJ  ȝ0 SKRVSKDWLG\OLQRVLWRO -bisphosphate (PIP2) and MgATP 
(concentration as required). The reaction is initiated by the addition of the proper substrate. After incubation for 30 minutes at room temperature, the 
reaction is stopped by the addition of stop solution containing EDTA and biotinylated phosphatidylinositol- 3,4,5-trisphosphate. Finally, detection 
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buffer is added, which contains europium-labelled anti-GST monoclonal antibody, GST-tagged GRP1 PH domain and streptavidin allophycocyanin. 
The plate is then read in timeresolved fluorescence mode and the homogenous time-resolved fluorescence (HTRF) signal is determined according to 
the formula HTRF = 10000 x (Em665nm/Em620nm). 
$SSHQGL[7DEOH.LQDVHVDVVD\LQIRUPDWLRQ 
Kinase Construct 
Enzyme final 
concentration (µM) Substrate Substrate concentration ATP concentration 
Aurora-A(h) Full length; I31F 0.0064 LRRASLG 200 µM 15 µM 
Aurora-B(h) Full length 0.0323 AKRRRLSSLRA 30 µM 10 µM 
CDK1/cyclinB(h) Full length 0.000662 Histone H1 0.1 mg/ml 45 µM 
PI3 Kinase (p110a/p85a)(h) Full length 0.000242 PIP2 10 µM 200 µM 
PI3 Kinase (p110b/p85a)(h) Full length 0.000333 PIP2 10 µM 200 µM 
Plk1(h) Full length 0.0974 Casein 1.25 mg/ml 70 µM 
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Results 
$SSHQGL[7DEOH.LQDVHLQKLELWRU\DFWLYLW\RI7/-DQG211D 
 
Activity±SD (% Control) 
Sample Aurora-A(h) Aurora-B(h) CDK1/cyclinB(h) Plk1(h) PI 3-Ka(h) PI 3-Kb(h) 
Control (Plus Enzyme) 100 100 100 100 100 100 
Control(Blank) / / / / 0 0 
TL-77 2µM 93±4 104±2 108 105±0 98±1 95±2 
TL-77 4µM 95±6 106±7 111 105±3 98±1 94±1 
TL-77 8µM 96±7 98±1 110 112±4 98±3 95±2 
TL-77 16µM 112±3 94±6 103 101±7 98±2 95±1 
ON01910.Na 0.03µM 104±0 100±4 111 100±4 99±0 96±0 
ON01910.Na 0.06µM 108±1 103±4 110 107±4 98±0 97±1 
ON01910.Na 0.12µM 98±4 102±2 109 104±2 98±0 99±0 
ON01910.Na 0.24µM 105±5 99±2 102 100±2 97±2 98±1 
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Plk1 kinase inhibitory profile of ON01910.Na reported by Gumireddy et al 
Plk1 expressed in the Sf9 cell line was purified. 10 ng of recombinant Plk1 was incubated with different concentrations of ON01910 in a 15 µl reaction 
mixture (50 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 2 mM Dithiothreitol, 0.01% NP-40 [pH 7.5]) for 30 min at room temperature. Kinase reactions 
were performed for 20 min at 30°C in a volume of 20 µl (15 µl HQ]\PH  LQKLELWRU  O  P0 $73  O RI Ȗ 32PATP (40 µci), and 1 µl of 
recombinant Cdc25C (100 ng) or casein (1 µg) substrates. Reactions were terminated by boiling for 2 min in 20 µl of 2× Laemmli buffer. 
Phosphorylated substrates were separated by 18% SDS-PAGE. The gels were dried and exposed to X-ray film for 3±10 min.53 
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Appendix II 
Awards: 
Feb. 2013 Graduate School Travel Prize 
The University of Nottingham 
Dec.2012 EORTC-PAMM fellowship to attend the EORTC-
PAMM-BACR conference 
EORTC-PAMM group 
Publications, patents and proceedings: 
z Lu, T. et al. Discovery of (E)-3-((Styrylsulfonyl)methyl)pyridine and (E)-
2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: 
Synthesis, Structure-Activity Relationships, and Biological Activities. J 
Med Chem 57, 2275-2291 (2014).  
z Lu T., Laughton C. A., Wang S., Bradshaw D T. In vitro anti-tumour 
mechanism of (E)-N-(2-methoxy-5-(((2,4,6-
trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide. 
Molecular Pharmacology, Accepted on October 14, 2014 
z Lu T., Wang S., Laughton C. A., Bradshaw D T. Abstract 3406: 
Evaluation of (E)-Styrylsulfonyl methylpyridine: A novel kinase inhibitor 
targeting mitotic pathways. AACR 104th Annual Meeting 2013; 
Washington, DC. Cancer Research: April 15, 2013; Volume 73, Issue 8, 
Supplement 1. 
z Wang, S.; Chahrour, O.; Lu, T.; Hu, A. Compounds for treating 
proliferative disorders, International patent, WO2011161446. 21 June, 
2011.  
z Lu Tiangong. Review and prospect of Gecko anti-tumor action and its 
pharmacological mechanism, Chinese Journal of Medicine, Volume 9, 
periodical 6, 2009, ISSN1680-077X, CN98-0333/R 
Conference presentations: 
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z Synthesis and evaluation of (E)-Styrylsulfonyl Methylpyridine: a novel 
mitotic kinase inhibitor 
Podium presentation 
7th Biological and medicinal chemistry symposium 
13 Dec. 2013. Cambridge, UK 
z Evaluation of (E)-Styrylsulfonyl methylpyridine: a novel kinase inhibitor 
targeting mitotic pathways 
Poster presentation 
AACR conference 2013 (Abstract Number: 3406) 
6-10 Apr. 2013. Washington DC, US 
z Evaluation of (E)-Styrylsulfonyl Methylpyridine: a novel mitotic kinase 
inhibitor 
Podium 
34th EORTC-PAMM-BACR Winter conference 
23-26 Jan. 2013. Cardiff, UK 
z Discovery and Evaluation of (E)-Styrylsulfonyl methylpyridines as Novel 
Anti-cancer Agents 
Podium &Poster presentation 
UK-PharmSci 2012 
12-14 Sep. 2012. Nottingham, UK 
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Appendix III 
In: Proceedings of the 104th Annual Meeting of the American 
Association for Cancer Research 
2013 Apr 6-10; Washington, DC. Philadelphia (PA) 
AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3406. doi:10.1158/1538-
7445.AM2013-3406 
Abstract 3406: Evaluation of (E)-Styrylsulfonyl methylpyridine: 
A novel kinase inhibitor targeting mitotic pathways. 
Tiangong Lu, Shudong Wang, Charles Laughton, and Tracey Bradshaw. 
University of Nottingham, Nottingham, United Kingdom. 
ON01910.Na, a styryl benzylsulfone, is a Phase III stage, non-ATP competitive 
anti-cancer agent. It is multi-targeted, promoting selective mitotic arrest and 
apoptosis in cancer cells. Extensive Phase II/III trials conducted in patients 
with solid tumors and hematological cancers have proved its excellent efficacy 
and impressive safety profile. However, incomplete understanding of 
mechanisms of action and relatively low drug oral bioavailability remain 
obstacles to development. By modifying the structure of ON01910.Na, a novel 
class of (E)-Styrylsulfonyl methylpyridines was designed and synthesized. I 
report herein the evaluation of a selected compound, TL-77, (E)-N-(2-
methoxy-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)pyridin-3-
yl)methanesulfonamide, as a potent small molecule inhibitor targeting mitotic 
pathways. 
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MTT assays were performed to assess in vitro anti-proliferative effects. In a 
panel of 10 tumor and 2 non-transformed human cell lines following 96 h 
exposure, TL-77 gave consistent GI50 values in the sub-micromolar range in 
tumor cells, whereas, it was non-toxic to non-transformed human mammary 
endothelial cells (HMECs). Cell cycle was analyzed by flow cytometry. TL-77 
caused significant G2/M arrest ı 6 h, whereas ON01910.Na caused the same 
effect after longer exposure periods (ı  12 h). An OD-based tubulin 
polymerization assay allowed us to explain obstruction of cell division caused 
by TL-77. TL- UHWDUGHG WXEXOLQ SRO\PHUL]DWLRQ EHWZHHQ ȝ0 DQG ȝ0
intriguingly, microtubules were stabilizes at TL- FRQFHQWUDWLRQV ! ȝ0
Western blot analyses of cell lysates following treatment of cells with TL-77 
revealed dose-dependent reduction of phosphorylated Cdc25c, a known 
substrate of Plk1 and/or Chk1/2, indicating Plk1 and/or Chk1/2 inhibition. 
Finally, dose- and time-dependent apoptosis triggered by TL-77, detected by 
Annexin-V assays, was closely associated with induction of caspase 3/7 
activity. Importantly, pharmacokinetics studies in mice revealed that the oral 
bioavailability of TL-77 was optimized to 56% compared with 9% for 
ON01910.Na. 
In summary, TL-77 is a potent anti-cancer agent. It disturbs tubulin during cell 
division, resulting in G2/M cell cycle arrest, followed by caspase-dependent 
apoptosis. TL-77 appears to share an analogous mechanism of action with 
ON01910.Na, but exhibits greater selectivity towards cancer cells and 
possesses superior oral bioavailability. Therefore, further evaluation of TL-77 
as a promising anti-tumor agent is justified. 
